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ABSTRACT
Protein phosphorylation is a major regulator of cellular signaling. It functions 
when a kinase joins a phosphate group to a protein, or when a phosphatase strips 
off a phosphate group from serine, threonine, or tyrosine residue of the protein. 
Protein phosphorylation is a major regulator of cellular signaling, and offers fast, 
dynamic, and reversible means of regulation.
Intermediate filaments (IFs) are a protein family with about 70 members, 
which are part of the cytoskeleton – a filamentous 3D meshwork inside the cells 
that engages in support, transport, and several other functions. IFs play a role in 
establishing and maintaining cellular organization and tissue integrity through 
forming cytoplasmic and nuclear filamentous structures. IFs provide structural 
support and assist in mechanical cellular functions. In addition, IFs work as sig-
naling scaffolds. Through these activities, IFs regulate cellular functions such as 
motility, stress and apoptosis, cell growth and division, cellular differentiation, and 
homeostasis. Intermediate filament structure consists of conserved central rod do-
main and more variable N-terminal head and C-terminal tail domains. A multi-
tude of post-translational modification (PTM) sites resides mostly in the head and 
tail domains. The most important of these PTMs is likely phosphorylation. Phos-
phorylation is known to regulate IF assembly and disassembly, and in many cases 
allows IFs to function as a dynamically adjustable signaling scaffold.
Vimentin is the most abundant IF, and it shows the highest expression in cells 
originating from mesenchyme. Vimentin is a canonical marker, and one of the 
causative factors of epithelial-mesenchymal transition (EMT), in which epithelial 
cells become more migratory and invasive, typically during development or can-
cerogenesis.
Our research group previously identified all the interphase in vivo serine/thre-
onine phosphorylation sites. In our first study (I), by using phosphorylation on/
off status mimicking mutagenesis, we demonstrate that from multiple sites, only 
phosphorylation of vimentin serines 7, 8 and/or 9 are critical to vimentin filamen-
tous structure, and S6 and S71 and/or 72 have a lesser effect. Some phosphoryla-
tion of S7, 8 and/or 9 may be needed to stabilize or generate vimentin structure. 
Our results show that phosphorylation of serines 6, 7, 8 and/or 9 may affect cy-
toskeletal interactions, and has a major effect in increasing the tetrameric soluble 
pool of vimentin incrementally based on phosphorylation amount. Based on the 
previous research also, solubility increase is most likely caused by breakage of vi-
mentin head-rod helix 2B interaction and warrants further investigation.
S1P and SPC are sphingolipids, which regulate processes like cellular migra-
tion, for example. In our second study (II), we demonstrate how S1P and SPC 
cause a restructuring of vimentin and regulate thyroid and breast cancer cell che-
motactic migration via vimentin serine 71 phosphorylation. S1P receptor 2 and 
Rho-associated protein kinase (ROCK) appear to mediate these effects.
In the third study (III), we demonstrate how vimentin balances Notch signal-
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ing pathway by causing an increase in Jagged 1-Notch signaling at the expense of 
Delta-like 4-Notch signaling in angiogenesis. When vimentin is absent, Jagged 1 
accumulates at the cell membrane and loses its transactivation capability. Vimen-
tin aminoterminal PCK-regulated phosphorylation sites have a role in this. We 
demonstrate that this signaling effect causes weaker vasculature in the chorion 
allantois membrane (CAM) model, in the human umbilical vascular endothelial 
cell (HUVEC) angiogenesis assay, in aortic ring sprouting angiogenesis assay, and 
finally in vimentin knockout mouse embryos.
Par-4, CK2, AATF, and c-Jun are important regulators of cellular apoptosis and 
survival machinery. These proteins regulate others or are regulated by phosphor-
ylation – CK2 being a kinase. Par-4 and CK2 function especially prominently in 
prostate cancer. AATF is an important component in DNA damage response.
In the fourth study (IV), we demonstrate how CK2-mediated phosphorylation 
of Par-4 impairs pro-apoptotic functions of Par-4. This effect involves prevention 
of caspase cleavage of Par-4 by Par-4 S124 phosphorylation in rats, or effects in-
dependently of cleavage by Par-4 S231 phosphorylation in humans. We also show 
that this phosphorylation has relevance in prostate cancer cells.
In the fifth study (V), we demonstrate previously unknown pro-apoptotic func-
tion of AATF after UV stress. We show that this mechanism requires AATF trans-
location from the nucleolus to nucleoplasm and interaction with transcription fac-
tor c-Jun, as well as activation of the pro-apoptotic function of c-Jun.
These studies reveal new phosphorylation-mediated mechanisms in the regu-
lation of vimentin structure via phosphorylation of the N-terminal serine cluster, 
and separately via a sphingolipid-mediated pathway that also inhibits chemotactic 
cancer cell migration through vimentin phosphorylation. Only little studied vi-
mentin effect on angiogenesis is described further including previously unknown 
effect of vimentin on Notch signaling possibly via PKC phosphorylation sites on 
vimentin. Our results strengthen the view of vimentin as a multifunctional cellular 
scaffold, and provide information about vimentin function especially in the con-
text of cancer. Two separate studies on apoptosis describe phosphorylation-con-
trolled CK2-Par-4-connection as potentially important in prostate cancer survival 
and AATF behaving pro-apoptotically after UV stress by controlling c-Jun activa-
tion by phosphorylation. Together, the results demonstrate the operational modal-
ities of some phosphorylation-dependent switches and how these types of switches 
may regulate cellular fate and function in different ways.
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SAMMANFATTNING
Proteinfosforylering är en viktig regulator av cellulär signalering. Det fungerar 
när ett kinas ansluter en fosfatgrupp till ett protein eller när ett fosfatas frigör en 
fosfatgrupp från protein serin, treonin eller tyrosin-rest. Proteinfosforylering är 
en viktig regulator av cellsignalering och utgör ett snabbt, dynamiskt och revers-
ibelt sätt att ändra en signalmekanism från en funktion till en fullständing annan 
funktion.
Intermediära filament (IF) är en proteinfamilj med cirka 70 medlemmar som 
utgör en del av cytoskelettet. IF har roller i att upprätta och upprätthålla cellulär 
organisation och vävnadsintegritet genom att de bildar cytoplasmiska och nuk-
leära filamentära eller trådlika strukturer. Intermediära filament ger strukturellt 
stöd och bistår cellers mekaniska funktioner. Dessutom kan IF fungera som 
byggställningar för signalering. Via dessa roller reglerar IF cellfunktioner som 
rörlighet, stress och apoptos, celltillväxt och delning, cellulär differentiering och 
homeostas. IF har en struktur med en konserverad central domän och mer variab-
la N-terminala och C-terminala domäner. De N- och C-terminala domänerna har 
ett stort antal ställen för posttranslationella modifieringar av vilka fosforylering 
utgör den viktigase. Fosforylering är känd för att reglera IF polymerisering och de-
polymerisering och ger i många fall möjlighet för IF att fungera som en dynamiskt 
omformbar byggställning för signalering .
Vimentin är mest allmänt förekommande IF-protein som uttrycks i de flesta 
celler av mesenkymal härstamning. Vimentin är en kanonisk markör och en av or-
saksfaktorer för den s.k. epitel-mesenkymala transitionen (EMT), där epitelceller 
blir övergår till att bli mer rörliga och invasiva i samband med differentiering och 
cancer.
Vårt labb har tidigare karakteriserat alla interfasspecifika in vivo serin / treonin 
fosforyleringsställen. Vi kunde visa att genom specifik mutagenes att som imiterar 
fosforylerat och defosforylerat tillstånd att utav alla vimentinets otaliga fosfory-
leringsställen är det endast fosforylering av vimentinet seriner 7, 8 och 9 som är 
av helt avgörande betydelse för att uppnå den fintrådiga struktur som vimentin 
normalt uppvisar. S6 och S71 och samt 72 uppvisade mindre effekt. Fosforylering 
av S7, 8 och / eller 9 kan behövas för att stabilisera eller bilda vimentin struktur. 
Fosforylering av seriner 7, 8 och / eller 9 kan även påverka cytoskeletala interak-
tioner och initiera depolymerisering av vimentin.
S1P och SPC är sfingolipider, som reglerar t.ex. cellulär migration. I en annan 
studie visar vi hur S1P och SPC via en ny signalväg kan omstrukturera vimentin 
och reglera kemotaktisk migration hos sköldkörtel- och bröstcancerceller via vi-
mentinets serin-71-fosforylering. Dessa effekter förmedlas av S1P-receptor 2 och 
Rho-associerat proteinkinas (ROCK).
I den tredje studien visar vi hur vimentin balanserar Notch signalvägen gen-
om att orsaka ökning av Jagged 1-Notch-signalering på bekostnad av Delta-like 
4-Notch signalering i angiogenes. När vimentin är frånvarande, ackumuleras 
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Jagged 1 i cellmembranet och förlorar sin trans-kapacitet. Vi visar att denna sig-
naleffekt ger upphov till defekta och svagare kärl i fyra modeller: en modell där 
celler får växa på den inre ägghinnan, d.v.s. chorionallantois membranet (CAM), 
i en modell där vaskulära endotelceller från människans navelsträng (HUVEC) 
genomgår angiogenes och den spirande angiogenes analyseras, i analys av aortar-
ingar och slutligen analys av vasulaturen i vimentin knockout musembryon.
Par-4 och CK2 är båda viktiga regulatorer av prostatacancer apoptos och 
överlevnad. I den fjärde studien visar vi hur CK2-medierad fosforylering av Par-
4 försämrar Par-4 proapoptotiska funktioner. Denna effekt beror på att CK2 
specifikt inhiberar kaspasberoende klyvning av Par-4 eller verkningar oberoende 
av klyvning. Vi visar också att denna fosforylering har relevans i prostatacancer.
I den femte studien visar vi en proapoptotisk funktion av AATF efter UV-stress. 
Vi visar att denna mekanism kräver att AATF utlokaliseras från nukleolerna till 
nukleoplasman samt en interaktion med transkriptionsfaktorn c-Jun som i sin tur 
aktiverar c-Juns proapoptotisk funktion.
Tillsammans har dessa studier visat nya fosforylering-medierade mekanismer 
för reglering av vimentinets struktur, för reglering av en sfingolipid-medierad up-
pströms signalväg som i sin tur reglerar vimentinets struktur och därmed dess 
effekter på kemotaktisk migration, samt för att reglera de effekter vi demonstrerat 
gällande vimentinets förmåga att påverka angiogenes i musembryo och cellmod-
eller via reglering av Notch-ligander. Våra resultat stärker synen på vimentin som 
en multifunktionell cellulär byggnadsställning för signalering och ger information 
om vimentin funktion speciellt i samband med cancer. Vi har också utforskat en 
annan fosforyleringsberoende räcka där CK2hämmar apoptos i prostatacancer via 
fosforylering och hämning av pro-apoptotiska Par-4 och . En liknande omkopplare 
mellan överlevnad och apoptos i prostatacancer upptäckte vi i i samband med att 
nukleolärt AATF efter UV-strålning påverkade aktiveringen och fosforyleringen 
av c-Jun genom en tillsvidare oupptäckt translokation av AATF från nukleoler till 
nukleoplasman. Sammantaget belyser våra resultat ett antal olika sätt med vilka 
fosforyleringsberoende omkopplare kan reglera cellens ödesbeslut. 
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INTRODUCTION
For an organism to develop correctly, survive, and reproduce, the building 
blocks of organisms, cells, need to respond correctly to extra- and intracellular 
cues. These responses are regulated by a multitude of signaling networks, and lead 
to cellular responses such as changes in cell shape, cellular and tissue organization, 
cell motility, cell division and death, maintaining of homeostasis, and further sig-
naling events. Many cellular signaling events are dependent on the addition or re-
moval of post-translational modifications to/from specific amino acids in proteins. 
The most studied and perhaps the most important of these is phosphorylation.
Entire cells can move by swimming through aqueous solution with the help of 
beating cilia, flagella, etc. Another form of cell motility is crawling motility. Crawl-
ing motility is divided into amoeboid motility and cell migration with lamellipo-
dia. The cytoskeleton, including intermediate filaments, is a crucial part of cell 
migration. Crawling motility is important in various steps of both development 
and wound healing, and when misregulated, it can, for example, cause cancer pro-
gression by allowing cancer cells to spread to surrounding tissues and to form 
metastases.
Blood vessels are formed either by vasculogenesis or angiogenesis. Angiogen-
esis occurs when new blood vessels form from pre-existing ones. Angiogenesis is 
one of the crucial processes in growth, development, and wound healing. When 
angiogenesis activates in tumors, oxygen can reach the inside of tumors. This event 
allows tumors to grow much larger and potentially become malignant. Cell-to-
cell-contact-based Notch signaling is a critical regulator of angiogenesis.
Apoptosis is an intracellular death program. It is used by an organism to elim-
inate unneeded or severely damaged cells. Casein kinase 2 (CK2), Par-4, AATF, 
and c-Jun are proteins that can, depending on the context, induce apoptosis (Par-
4, c-Jun, AATF) or protect from apoptosis (CK2, c-Jun, AATF) through apoptotic 
signaling circuitry.
When cells harbor specific mutations, their growth becomes uncontrollable. 
Such uncontrolled growth can cause cancer. There are many barriers, including 
angiogenesis, metastasis, and apoptosis avoidance, which cancer cells must over-
come to become lethal.
One of the important regulators of cellular signaling and mechanics are the 
third and least studied part of the cellular cytoskeleton: intermediate filaments. 
Intermediate filaments (IFs) consist of ~70 members of network-forming proteins 
that express and function in a tissue-specific manner.
Vimentin is the most abundant of the IFs. Its expression occurs in cells origi-
nating from mesenchyme. Although vimentin knockout mice created in the 1990s 
had a very mild phenotype, new interest in vimentin has arisen recently due to 
vimentin representing a potential target for cancer metastasis treatment, and as 
influential for organisms under stress. Vimentin is a well-known marker of epithe-
lial-mesenchymal transition (EMT), in which cells lose their epithelial phenotype 
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and become more migratory and invasive. EMT is thought to be an important 
mechanism in cancer. Vimentin forms filaments inside cells and also has a more 
freely-moving soluble pool. Vimentin network structure affects cell mechanics, 
and acts as a signaling scaffold. Soluble subunits of vimentin have several signal-
ing functions. In this thesis, we examine mechanisms of how vimentin affects cell 
migration downstream of sphingolipids sphingosine-1-phosphate and sphingo-
sylphosphorylcholine, how it affects angiogenesis via Notch signaling, and how 
vimentin structure is affected by specific phosphorylation sites. Also, the antiapop-
totic effect of CK2 via Par-4 phosphorylation and the apoptotic effect of AATF via 
c-Jun after UV stress are demonstrated.
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REVIEW OF THE LITERATURE
1. Post-translational modifications
Post-translational modifications (PTMs) occur in protein biosynthesis after 
translation during the lifetime of the protein. Post-translational modifications in-
crease the diversity of the proteome by covalent addition of functional groups or 
proteins, by cleaving regulatory subunits proteolytically, or by degrading entire 
proteins. Estimates show that 5% of the proteome consists of enzymes that can 
perform approximately 400 types of post-translational modifications (Khoury et 
al., 2011; Snider and Omary, 2014a; Walsh, 2006). Some of the typical modifica-
tions are: phosphorylation, ubiquitination, glycosylation, methylation, nitrosyla-
tion, lipidation, acetylation, and proteolysis (Khoury et al., 2011). Post-transla-
tional modifications are crucial components of all cell signaling pathways, often 
affecting protein structure and interactions in a critical way. They affect almost 
all aspects of normal cell biology and pathogenesis, including processes relevant 
to this thesis: cell migration, differentiation, and death. Often post-translation-
al modifications offer a fast, dynamic, and usually reversible way to alter protein 
function (Walsh, 2006). 
1.1. Mechanisms of post-translational modifications
Post-translational modifications can be added or removed in any step during 
the life cycle of a protein with the help of a specific enzyme. For example, many 
proteins are modified after translation completes. Modification may mediate prop-
er protein folding or stability, or guide the new protein to a distinct cellular com-
partment (Bauer et al., 2015; Braakman and Bulleid, 2011; Nalivaeva and Turner, 
2001). After folding and proper localization, the protein can be modified by PTMs, 
which, for example, may regulate protein enzymatic activities, target proteins for 
degradation, or cleave the protein. Sometimes, post-translational modifications 
occur in a step-wise fashion to mature or activate a protein. Some modifications, 
such as phosphorylation and acetylation, are reversible, and some, such as proteo-
lytic cleavage and sulfation, are not. A single protein can have a multitude of dif-
ferent modifications, which act in a variety of ways (Dai and Gu, 2010; Nalivaeva 
and Turner, 2001; Walsh, 2006).
1.2. Protein phosphorylation and dephosphorylation
All the articles in this thesis examine the effects of protein phosphorylation. 
Reversible phosphorylation is the most abundant post-translational modification 
in cellular proteins. At least one third of proteins go through reversible phosphor-
ylation by phosphorylating kinases and dephosphorylating phosphatases. Protein 
kinases are one of the largest gene families in living organisms. In humans, there 
are 518 different kinases and 106 inactive pseudogenes (Roskoski, 2015). There are 
two large kinase families: histidine autokinases and eukaryotic protein kinases. 
Eukaryotic kinases catalyze the phosphorylation of serine, threonine, or tyrosine 
residues, or in some cases all of the listed amino acids (Marks et al., 2009; Roskos-
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ki, 2015). The number of protein phosphatases is close to 200 (Almo et al., 2007). 
Recently, it has been found that arginine, histidine, and lysine residues may also be 
phosphorylated yielding acid-labile phosphoramidates (Cieśla et al., 2011).
The phosphate group carries two negative charges in a neutral medium and 
can form four hydrogen bonds via its four oxygen atoms. Adding this structure 
to an amino acid may cause substantial changes in protein structure. Phosphory-
lation yields highly substrate-specific effects. It can activate or deactivate protein 
function, provide new interaction interfaces, or affect protein stability or localiza-
tion (Nishi et al., 2014). Many factors, including cellular stresses, nutrition status, 
or activation of signaling pathways, can influence the activity of a kinase. Also, 
tissue-specific expression of kinases or subcellular localization of them, and the 
specificity to particular substrate sequences, allows control over when and where 
specific substrates become phosphorylated (Marks et al., 2009).
2. Cell migration
Cell migration is important both during the development and maintenance of 
the homeostasis of multicellular organisms. Immune responses, tissue formation 
in embryonic development, and wound healing require organized cell movement 
to certain locations (Alberts et al., 2007; Weinberg, 2013). Aberrantly regulated 
cell migration can produce a progression of cancer, e.g. during metastasis (Yilmaz 
and Christofori, 2010). Cell migration can occur as mesenchymal or amoeboid mi-
gration (Bear and Haugh, 2014; Guck et al., 2010; Lämmermann and Sixt, 2009). 
Typical in amoeboid migration is the formation of blebs, which are produced by 
actomyosin contractility (Lämmermann and Sixt, 2009). Mesenchymal migration 
is characterized by the formation of lamellipodia at the front leading edge of the 
cell, and filopodia extending beyond lamellipodia. All the components of the cyto-
skeleton have important roles in regulating cell migration (Bear and Haugh, 2014; 
Bisi et al., 2013; Machesky, 2008; Mattila and Lappalainen, 2008).
The main processes included in cell migration are the formation of cell po-
larity, protrusion formation, cell adhesion, translocation of the cell body, and the 
retraction of the rear end, all of which are accompanied by signal integration and 
regulation (Vicente-Manzanares and Horwitz, 2011). Cell polarity forms through 
molecular and functional differences between the front and rear of the migrating 
cell (Macara and McCaffrey, 2013). Protrusion formation involves the extension 
of cellular membranes. Leading protrusion usually points in the direction of cell 
movement. Protrusions usually form in response to chemoattractive signals and 
their gradients, which cause cells to move in the correct direction. However, some 
cells extend protrusions in an exploratory manner without directional stimulation. 
Formation of protrusions requires several cellular processes. Actin cytoskeleton 
polymerization pushes the cell membrane facing towards movement forward, and 
the cell membrane expands under tension when endocytosed vesicles fuse to the 
cell front. Protrusions must also adhere to the surrounding substrate to allow the 
rest of the cell to be pulled toward protrusion (McNiven, 2013; Petrie and Yamada, 
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2012; Ridley, 2011). Cell adhesion occurs between adjacent cells or between the 
cell and the extracellular matrix (ECM). Cell-matrix adhesion is the most thor-
oughly-studied form of adhesion mediating cell migration. Cell-matrix adhesions 
are sites of convergence between the actin cytoskeleton and ECM fibrils. There are 
several types of adhesions: nascent adhesions, focal complexes, focal adhesions, 
podosomes and invadopodia with different distributions, molecular compositions, 
and roles in migrating cells (Parsons et al., 2010; Ridley, 2011). Cell body translo-
cation immediately follows protrusion. This movement is caused by coordinated 
contraction of the actomyosin cytoskeleton, and depends on myosin II. Translo-
cation of the nucleus is controlled by actin-myosin contraction and microtubule 
motors. Cell rear retraction is accomplished by coordinated contraction of the ac-
tin cytoskeleton and disassembly of the adhesions at the trailing edge (Cramer, 
2013). Multiple intertwined signaling networks control cell migration. Signaling 
can be initiated through G-protein-coupled receptors (GPCRs), integrins, growth 
factors, and other receptors, and continues to propagate along one or more sig-
naling branches of complex interconnected networks. Small Rho (Ras-homology) 
GTPases are important regulators of migration. Migration-related signaling often 
converges to small Rho GTPases. One of them is RhoA, which can relay signals 
downstream (among others) to Rho-associated protein kinases (ROCKs). Small 
Rho GTPase signaling results in relatively few varieties of cellular response, in-
cluding the aforementioned processes (Alberts et al., 2007; Bear and Haugh, 2014; 
Devreotes and Horwitz, 2015; Hasan and Siekmann, 2015; Weinberg, 2013).
Intermediate filaments vimentin and sphingolipids S1P and SPC are non-es-
sential regulators of cell migration. In this thesis, we examine how the effects of 
sphingolipids S1P and SPC on migration are connected to IF vimentin effect on 
migration through S1P receptor 2 (S1PR2) and ROCK.
3. Angiogenesis
Angiogenesis is a process in which new vasculature forms from pre-existing 
blood vessels. The process is crucial to organism development and growth, wound 
healing and granulation tissue formation, but it is also critical to the formation of 
larger, malignant, tumors. Early embryonic mesoderm gives rise to blood vessels 
and lymphatic vessels, for example. Blood supply depends on endothelial cells, 
which form the lining of blood vessels. During tissue growth and repair, endothe-
lial cells extend and remodel existing vasculature. There are two forms of angio-
genesis: sprouting and intussusceptive. In intussusceptive (splitting) angiogenesis 
a new blood vessel is formed when an existing blood vessel splits in two. This study 
mainly concerns sprouting angiogenesis. In the sprouting angiogenic process, an 
endothelial cell starts to extend and proliferate toward the surrounding matrix 
from the wall of an existing blood vessel. An endothelial tip cell, with many filopo-
dia, leads the advance of each capillary sprout by invading surrounding tissue. Be-
hind the tip cell, endothelial stalk cells form and divide, and start to form a hollow 
capillary sprout that becomes a new blood vessel tube. Notch signaling is essential 
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to the decision of which cells become tip or stalk cells. Angiogenesis has many 
similarities and signaling mechanisms in common with lymphangiogenesis and 
neuronal growth (Alberts et al., 2007; Krishna Priya et al., 2016; Weinberg, 2013).
Figure 1: Basic mechanisms of angiogenic sprouting. Adapted from (Alberts et 
al., 2007).
Angiogenesis is controlled by the production of hypoxia-inducible factor 1 
α (HIF1α) when tissues face low oxygen levels. HIF1α stimulates transcription 
of vascular endothelial growth factor (VEGF) (Ahluwalia and Tarnawski, 2012). 
VEGF secretes from cells and stimulates nearby endothelial cells to proliferate, 
invade through basal lamina of the parent capillary or venule, and form sprouts. 
The tip cells of the sprouts detect the VEGF gradient and move toward it. When 
the oxygen concentration in the tissue becomes normal, expression of HIF1α and 
VEGF is downregulated ending the angiogenic response (Alberts et al., 2007; Car-
meliet, 2005; Cébe-Suarez et al., 2006; Kiselyov et al., 2007; Weinberg, 2013).
Notch signaling mediates angiogenesis by regulating one of the main process-
es of angiogenesis: endothelial cells signaling to each other and the decision of 
which endothelial cells become tip cells and which become stalk cells. This effect 
is regulated by specific Notch ligand, Delta-like 4, which is expressed in tip cells 
and signals to neighboring stalk cells, activating their Notch signaling. This causes 
neighboring cells to downregulate their VEGF receptors causing them to become 
unresponsive to VEGF, and thus preventing the formation of too many sprouts 
(Alberts et al., 2007; Benedito and Hellström, 2013; Bridges et al., 2011; Garcia 
and Kandel, 2012; Kangsamaksin et al., 2014a; Liu et al., 2014; Weinberg, 2013). 
In this thesis we further examine the newly found connection between vimentin 
cytoskeleton and angiogenesis, and specifically focus on how vimentin affects the 
signaling from the Notch ligands Jagged1 and Delta-like.
4. Apoptosis
Multicellular organisms require tight control of their cell populations, since 
overall cell numbers and cell types, as well as cell locations, need to be correct in 
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order to produce a healthy and functional organism. Cell numbers are controlled 
by their rate of proliferation, but also by cell death. This ratio must be balanced to 
keep an organism the correct size. Cells can undergo apoptosis or necrosis. Cells 
that die as a result of acute injury typically undergo necrosis: they swell and burst. 
Unnecessary or sufficiently damaged cells are removed by programmed cell death, 
the most common form of which is apoptosis (Edinger and Thompson, 2004; Nic-
otera et al., 1999; Nikoletopoulou et al., 2013). Apoptosis is apparent during devel-
opment. For example, in order to form separate and correctly shaped digits, nu-
merous cells between the digits must be removed. During neuronal development, 
many neurons die in order to match the number of target cells that require inner-
vation. Also, in adult humans, billions of cells in the bone marrow and intestines 
die each day. Apoptosis also occurs during DNA damage and other stresses, if the 
damage incurred is substantial enough. Apoptosis allows the organism to elimi-
nate nonfunctioning cells, and prevents the development of cancer by removing 
cells with potentially cancer-promoting mutations (Alberts et al., 2007; Krishna 
Priya et al., 2016).
In apoptosis, cells die without bursting or causing inflammatory reactions. 
Cells undergoing apoptosis shrink and condense; the cytoskeleton collapses, the 
nuclear envelope disassembles, and the nuclear DNA breaks into fragments. The 
cell surface also changes, sending signals to nearby cells or macrophages to phago-
cytose the apoptotic cell (Alberts et al., 2007; Moffitt et al., 2010).
Apoptosis is carried out primarily by an intracellular proteolytic cascade, medi-
ated by caspases. During apoptosis, inactive procaspases are activated to caspases, 
often initially in distinct activation complexes: DISC or apoptosome. Cells have at 
least two distinct pathways for apoptosis. The extrinsic pathway activates by extra-
cellular ligands binding to death receptors. The intrinsic pathway is activated by 
intracellular signals in response to stresses. Extracellular signal proteins and Bcl2 
and IAP proteins are major regulators of apoptosis, only allowing apoptosis to oc-
cur when it is beneficial for the organism (Alberts et al., 2007; Moffitt et al., 2010).
In this thesis, we examine how protein casein kinase 2 (CK2), a pro-survival 
factor, inhibits pro-apoptotic effects of prostate apoptosis response-4 (Par-4) via 
direct phosphorylation that is likely functioning in prostate cancer.
5. Cytoskeleton
The cytoskeleton is a scaffolding structure in the cellular cytoplasm. The cy-
toskeleton provides structure and shape for the cell. The cytoskeleton consists of 
three different protein families: microfilaments, microtubules, and intermedi-
ate filaments (IFs) (Huber et al., 2013). Microfilaments, consisting of actin, are 
around 6 nm thick, and are flexible and relatively strong filaments. Microfilaments 
are highly versatile, and function in cytokinesis, cell motility, and changes in cell 
shape. Actin filaments can provide force for a cell with actin-attaching myosin 
molecular motors, which can be applied for pushing the cell membrane or mov-
ing vesicles inside the cell, for example (Sackmann, 2015). Actomyosin-driven 
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contractile molecular motors also drive muscle contraction (Chalovich, 1992). 
Microtubules form from α- and β-tubulin with an average width of 24 nm. Mi-
crotubules can form cilia and flagella, and also form platforms for intracellular 
transport. Microtubules participate in movements of secretory vesicles, organelles, 
and intracellular substances. Dynein and kinesin motor proteins move along mi-
crotubules. During mitosis, microtubules form mitotic spindles, which are crucial 
for pulling apart eukaryotic chromosomes. Microtubule networks protrude from 
central locations called microtubule organizing centers (MTOC) (Alberts et al., 
2007; Vasiliev and Samoylov, 2013; Wade, 2009).
6. Intermediate filament protein family
Intermediate filaments are a protein family consisting of about 70 members, 
and the third member of the cytoskeleton. They are found in metazoan cells. In-
termediate filaments form flexible filamentous networks inside the cell. Most of 
IFs are mainly cytoplasmic, except the lamins, which reside mainly in the nucleus 
(Eriksson et al., 2009).
Intermediate filaments get their name from being “intermediate” in width 
(about 10 nm), as compared to other cytoskeletal components, namely microtu-
bules and actin. The IF networks are flexible and give mechanical strength to the 
cell. Intermediate filament networks protect cells from mechanical stress, provide 
cells with much of their shape, and some IFs are significant for cell motility (Eriks-
son et al., 2009; Goldman et al., 2008; Herrmann et al., 2007). Intermediate fila-
ments are expressed tissue-specifically and also at certain times, such as during 
wound healing or embryonic development (Pallari and Eriksson, 2006).
Intermediate filaments are divided into six distinct subcategories based on their 
sequences. Type I and II IFs are formed by acidic and basic keratins – mixing in a 
1:1 ratio. Keratins are expressed in epithelial cells and consist of 54 members in hu-
mans (Moll et al., 2008; Oshima, 2007; Toivola et al., 2015). Group III IF proteins 
consist of vimentin, desmin, glial fibrillary acidic protein (GFAP), and peripherin, 
of which vimentin is the subject of three articles presented in this thesis. These 
proteins can form homo- or heteropolymeric filaments. Type IV IFs consist of 
neurofilaments (NFs) NF-L, NF-M, and NF-H, synemin, α-internexin, nestin, and 
syncoilin (Moorwood, 2008; Omary, 2009; Xie et al., 2015; Yuan et al., 2012). Type 
V IFs consist of lamins. They reside mostly on the nuclear membrane (Gruenbaum 
and Foisner, 2015; Omary, 2009; Osmanagic-Myers et al., 2015; Yoon et al., 2012). 
Intermediate filament type VI consists of two proteins: beaded filaments Bfsp1 and 
Bfsp2. They are expressed in eye lenses (FitzGerald, 2009; Omary, 2009). A sum-
mary of the IFs and the tissues they are expressed in is shown in Table 1.
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Tissue Intermediate filaments expressed
Lens Bfsp1 (VI); Bfsp2 (VI); Vimentin (III)
Nervous system Neurofilaments NFH, NFM, NFL (IV); α-internexin (IV); Nestin (IV); Peripherin (III); GFAP (III)
Skin Epidermal keratins K1, K2, K5, K6 (II), K9, K10, K14-K17, K19 (I)
Lungs, Liver, 
Intestine, Gut Simple epithelial keratins K7, K8 (II), K18-K20, K23 (I)
Muscle (cardiac, 
skeletal, smooth) Desmin (III); Syncoilin (III); Synemin (IV)
Blood vessel/oth-
er mesenchyme Vimentin (III)
Nucleus Lamin A/C (V); Lamin B1, B2 (V)
Table 1: Intermediate filament tissue distribution. The group of the IF is shown in 
brackets (I-VI). Adapted from (Omary, 2009).
6.1. Intermediate filament structure
All IFs share a similar structure. In the center of the amino acid sequence there 
is a conserved rod domain, which is crucial for filament assembly and forms α-he-
lixes. In the ends of an IF, there is an N-terminal head domain and a C-terminal 
tail domain. These domains are more variable in sequence, and contain multiple 
post-translational (most importantly phosphorylation) modification sites that af-
fect IF structure and function (Hyder et al., 2008a). The N- and the C-termini 
likely cause the unique characteristics of each IF protein (Parry, 2005). The rod 
domain forms the core of the filament. The N- and the C-termini reside on the 
filament surface. Type I and II epidermal keratins, and type III IF N-terminal head 
domains exhibit a flexible structure, which can interact with the rod domain (Block 
et al., 2015; Godsel et al., 2008; Lowery et al., 2015). In both cases, head domain is 
needed for in vitro filament assembly (Herrmann et al., 1996; Wilson et al., 1992). 
C-terminus is not required for filament assembly but produces an increase in the 
mass-per-length ratio (Herrmann et al., 1996). Exposure of N- and C-termini on 
the filament surface leaves them free to associate with other filaments and cellular 
structures in vivo, and affect filament structure or assembly through these associa-
tions (Block et al., 2015; Godsel et al., 2008; Lowery et al., 2015).
Intermediate filaments are long and flexible structures. Therefore, it is challeng-
ing to produce crystal from them to use for structural analysis with X-ray diffrac-
tion. By crystallizing partial filaments, an almost complete structure of IF vimentin 
rod domain (which has a relatively stable structure) dimer has now become known 
(Chernyatina et al., 2012, 2015). However, ascertaining how the much more freely 
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mobile head and tail domains, and their post-translational modifications, contrib-
ute to the overall IF structure cannot be determined by crystallization and X-ray 
diffraction analysis. As a result, there is a need for alternative approaches.
6.2. Intermediate filament assembly
Intermediate filament assembly starts with the formation of dimers. In dimers, 
α-helical rod domains of two proteins are wound together in a coiled-coil form in 
a parallel fashion. After dimer formation, dimers assemble into tetramers. Tetram-
ers form when two dimers associate in an antiparallel form (Mücke et al., 2004; 
Sokolova et al., 2006). This tetrameric subunit is a form of filament, in which most 
of the soluble non-filamentous vimentin resides in a cell. This form is apolar, and 
complete filaments are apolar as well. This stands in contrast to actin and micro-
tubules, which form filaments with distinct plus and minus ends (Cooper, 2000).
Tetramers associate into higher-order oligomers to form unit-length filaments 
(ULFs). ULFs are around 60 nm long. In these polymers, filaments can associate 
in antiparallel formations in a number of ways. ULFs elongate longitudinally to 
form immature IFs. Immature 16 nm-wide filaments radially shrink into a more 
compact, 10-12 nm-wide structure in order to form mature filaments. This step 
has been suggested as occurring via lateral arrangements of filaments so that the 
mass or the filament length does not change (Godsel et al., 2008; Herrmann et al., 
1996, 2007; Parry et al., 2007; Sokolova et al., 2006). 
Figure 2 (next page): Structure and assembly of IFs. Vimentin as an example. 
A) The molecular structure of vimentin dimer. Intermediate filament structural do-
mains and their lengths in amino acids. Intermediate filaments consist of a variable 
head and tail domains and a more conserved rod domain. The rod domain consists 
of α-helical, more rigid, coils A1, B1, A2 and B2 and more flexible linkers L1, L12, 
and L2 (present knowledge identifies A2 and L2 as structurally paired). B) Different 
assembly stages of IFs. C) Full vimentin network in MEF cells. Adapted from (Minin 
and Moldaver, 2008a; Parry et al., 2007).
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IF networks are stable under normal conditions. Their half-time of recovery 
is typically in the order of minutes (e.g. for vimentin t½ this is about six min-
utes) (Yoon et al., 1998). When cells migrate, divide, or spread, or when stresses 
such as shear flow or stretching affect cells, IFs undergo structural rearrangements. 
During these events, largely unknown post-translational modifications and inter-
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acting proteins regulate IF assembly states (Snider and Omary, 2014a). Intermedi-
ate filaments elongate from the filament ends, and they are capable of exchanging 
subunits along their length (Colakoğlu and Brown, 2009).
Lateral association of protofibrils into protofilaments is likely regulated by the 
IF head domain. The termination of filaments after they have grown to approxi-
mately 10 nm is regulated by the tail domain (Heins et al., 1993). Phosphorylation 
is a critical effector of these events. Vimentin and desmin in vitro phosphorylation, 
which is caused by protein kinase A or C, disassemble pre-existing filaments and 
block subunit polymerization (Eriksson et al., 2004a; Geisler and Weber, 1988; 
Inagaki et al., 1987). This observation suggests that site-specific phosphorylation 
of the amino-terminal head domain of IF proteins induces the disassembly of IFs 
(Sihag et al., 2007a). Phosphorylation of vimentin head domain drives specific 
head domain regions away from each other (Aziz et al., 2010). Phosphorylation of 
some of the vimentin head domain amino acids 35-75 has been hypothesized to 
be active in the assembly and breakdown of vimentin filaments. This hypothesis 
derives from studies that show filament assembly requires some parts of the head 
domain (Gill et al., 1990; Heins et al., 1993; Sihag et al., 2007a). It is also known 
that the large middle part of the vimentin N-terminus (amino acids 40-95 or 25-
38) and the entire C-terminus are not essential for vimentin filament formation (K 
R Rogers, 1995; Shoeman et al., 2002). Nonapeptide motif near the N-terminus of 
vimentin head is essential for filament formation (Beuttenmüller et al., 1994; Herr-
mann et al., 1992). Vimentin disassembly by phosphorylation produces tetrameric 
subunits with specific functional significance as a soluble vimentin pool in cells. 
Therefore, the critical step of filament assembly that is regulated by phosphoryla-
tion may be protofilament assembly from tetramers (Eriksson et al., 2004a). The IF 
assembly stage has a critical effect on the signaling events it regulates (in addition 
to mechanical properties) and therefore on the cellular functions of IFs.
6.3. Phosphorylation and other post-translational modifications of 
intermediate filaments
Intermediate filaments go through a multitude of post-translational modifi-
cations, including phosphorylation, farnesylation, ubiquitylation, sumoylation, 
glycosylation, acetylation, transamidation, and ADP-ribosylation. It is important 
to characterize post-translational modifications’ on-off mechanisms, crosstalk, 
and utility as biomarkers for IF-related diseases (Snider and Omary, 2014a). IF 
PTMs have a multitude of different cellular functions. Often, the effects are based 
on PTMs affecting which molecules can interact with IF surfaces, or by affecting 
IF networks or their assembly itself. Most PTMs reside in the tail and head do-
mains, which have better access for interacting with the surrounding molecules 
and which are also the least conserved parts of IFs, likely contributing the most to 
unique functions of different IFs.
IFs have similar structures and variably conserved sequences. Therefore, spe-
cific PTM in one IF may have similar PTM site and corresponding effects in other 
IFs also. The most well-known PTM of IFs is phosphorylation. Phosphorylation 
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was first observed to regulate IF reorganization, increase dynamic subunit ex-
change by ser/thr-kinases, and to promote IF solubility (Sivaramakrishnan et al., 
2009a; Snider and Omary, 2014a; Woll et al., 2007a). Effects of tyrosine phosphor-
ylation are less known, but keratin 8 rod domain Y267 phosphorylation is known 
to promote keratin insolubility (Snider et al., 2013). Several sites, mostly in the IF 
head and tail domains, regulate IF reorganization. IF subunits can dynamically 
join IF filaments anywhere along the length of IF structures. This subunit exchange 
is heavily regulated by phosphorylation. Usually, when affecting solubility, serine 
or threonine phosphorylation increases IF solubility. Other PTMs are also likely 
to affect solubility, and rod domain PTMs are likely increased by some head and 
tail domain PTMs when the rod domain becomes more accessible to modifying 
enzymes (Hyder et al., 2008b; Sihag et al., 2007b; Sivaramakrishnan et al., 2009b; 
Woll et al., 2007b).
Neurofilaments NF-M and NF-H have high phosphorylation of their tail do-
main lys-ser-pro (KSP) repeat motifs. This phosphorylation is caused by proline-di-
rected kinases. KSP-phosphorylation regulates axonal caliber by cross-bridging 
NF sidearms, and also affects axonal stability and transport (Ackerley et al., 2003; 
Nixon et al., 1994; Snider and Omary, 2014a). NF tail domain is typically highly 
phosphorylated in the axons. On the other hand, phosphorylation of the head do-
main is relatively low in the neuronal cell bodies. NF phosphorylation is deregulat-
ed in several neurodegenerative diseases (Binukumar et al., 2013).
Another important role of IF phosphorylation is the regulation of stress re-
sponse. Keratin phosphorylation may serve as a phosphate “sponge” in protecting 
hepatocytes during liver injury. Keratins act as phosphorylation targets that be-
come phosphorylated instead of the pro-apoptotic proteins, which are activated by 
phosphorylation (Ku and Omary, 2006; Snider and Omary, 2014a). Phosphoryla-
tion-preventing mutations of K8 S74 and K18 S54 are known to increase apoptosis 
and liver injury in mice (Ku and Omary, 2006; Ku et al., 1998). K4-K6 also become 
phosphorylated like K8 during various stresses and disease, indicating a possible 
similar role (Toivola et al., 2002). Since IFs are one of the most abundant proteins, 
this kind of functionality, which requires large quantities of protein to absorb extra 
phosphate groups or immobilize other molecules, is possible for them.
Lamin A/C disassembly during mitosis is regulated by its serine 22 phosphor-
ylation by Cdk1. This same pathway is used by cytomegalovirus (HCMV) by its 
kinase UL97, along with possibly PKC and Pin1 acting as mediators, in order to 
accomplish HCMV nuclear egress (Hamirally et al., 2009; Milbradt et al., 2010). 
This mechanism likely functions in a different context in the regulation of the 
transport of endogenous ribonucleoprotein particles to the cytoplasm. When this 
mechanism is disrupted by Lamin C muscle knockout in D. Melanogaster, neuro-
muscular junction (NMJ) defects are observed (Speese et al., 2012).
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Cell process IFs found to be involved Details
Axonal properties NF-H, NF-M Stability, caliber, and transport – KSP repeats
Cell growth K5, K17, K18, vimentin
Skin wound healing, liver 
regeneration, autophagy, inter-
action with 14-3-3
Cell migration K8, vimentin K8 inhibits, vimentin increases
Cell stress K8-K18 Inhibits hepatotoxicity and apoptosis
Disease states phospho-IF accu-mulation
pNF in neurons in axon and 
also in cell body, loss of pIF 
polarity
Muscle atrophy Desmin Ubiquitylation and breakdown of thin filaments
Neuromuscular junction 
development Nestin Disperses AchR cluster 
Nuclear egress Lamin A/C
Herpesvirus or ribonucleopro-
tein release from nucleus by 
disassembled lamina
Table 2: A list of cell processes where phosphorylation of different IFs plays an 
important role (Adapted from (Snider and Omary, 2014a))
Nestin phosphorylation is significant in NMJ (Yang et al., 2011). Cdk5 phos-
phorylates nestin T316 during myoblast differentiation causing nestin disassembly 
(Sahlgren et al., 2003). Nestin also has a scaffolding property for Cdk5 and p35 at 
NMJ synapses (Yang et al., 2011). Phosphorylation of nestin causes Cdk5 dissoci-
ation and activation, which affect acetylcholine-induced dispersal of acetylcholine 
receptor clusters (Lin et al., 2005). Without the aforementioned mechanism, nes-
tin-null mice exhibit impaired motor coordination. During muscle atrophy, de-
smin S28, 32, and 68 phosphorylation helps with the breakdown of thin filaments 
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and Z-band components via ubiquitin ligase Trim32 in mature myofibers (Cohen 
et al., 2012).
An important signaling function for IFs is associations with 14-3-3 proteins. 
For example, K18 S33 phosphorylation has been shown to regulate 14-3-3ζ bind-
ing. Adaptor protein 14-3-3 binds to some IF proteins, including K5, K17, K18, and 
vimentin, in a Ser/Thr-phosphorylation-mediated way. The interaction affects cell 
growth and tumorigenesis (Liao and Omary, 1996). K18 S34 and K17 T9 and S44 
phosphorylation create the 14-3-3 binding site. This interaction stimulates mTOR 
activation and cell growth during, for example, wound healing in skin epithelia 
(Kim et al., 2006; Ku et al., 2002). With K18, it also affects 14-3-3ζ availability in 
the nucleus to bind Cdc25, and aids mitotic progression (Pallari and Eriksson, 
2006). 14-3-3σ stabilizes a complex of soluble actin and cytokeratin, increasing 
breast tumor invasion. Stabilization is dependent on PKCξ-mediated phosphory-
lation (Boudreau et al., 2013).
Vimentin and many vimentin phosphorylation sites affect cell migration (pre-
sented in more detail later in this text). K8 S432 phosphorylation had a context-spe-
cific effect with increased migration of pancreatic and gastric cells and decreased 
migration of squamous carcinoma cells (Alam et al., 2011; Busch et al., 2012).
Intermediate filament phosphorylation occurs in many diseases. Advances in 
proteomic capabilities may allow pinpointing specific IF PTMs to indicate differ-
ent diseases, and IF PTMs may become a potential target for IF disease treatment 
(Omary et al., 2004; Snider and Omary, 2014a; Szeverenyi et al., 2008).
Other PTMs of IFs are less studied than phosphorylation and have a variety of 
effects. Sumoylation of IFs is known to regulate filament formation and solubility, 
and be modified in some IF mutant diseases and stresses, mainly in keratins and 
lamins. Vimentin354 sumoylation has been observed to affect migration. Acetyla-
tion of K8 K207 reduces solubility. K18 glycosylation can increase cell survival. 
Lamin A farnesylation affects its own association with the nuclear membrane and 
plays a role in the aging syndrome progeria. Lamin B farnesylation is crucial to 
neuronal development. Ubiquitination of keratins marks them for degradation. 
Transamidation of keratins is important for skin barrier function and formation 
of´MDBs. ADP-ribosylation inhibits at least desmin filament formation (Snider 
and Omary, 2014b).
Intermediate filament PTMs show complex crosstalk in modulating protein 
properties and cellular functions. For example, sumoylation of keratins is strong-
ly increased by keratin phosphorylation (Snider and Omary, 2014a; Snider et al., 
2011). Increase in sumoylation is partially dependent on keratin 8 S74 phosphor-
ylation and following sumoylation of keratin 8 K285 and K364 (Daub et al., 2008; 
Dephoure et al., 2008). In neurofilaments and keratins, there is an inverse correla-
tion of phosphorylation and glycosylation. This occurs, for example, when NF-H 
hyperphosphorylates, and has lower glycosylation during aging due to decreased 
PP2A activity. It also occurs in Alzheimer-diseased brains when NF-M has in-
creased phosphorylation and decreased glycosylation (Deng et al., 2008; Veeranna 
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et al., 2011). Keratins show similar behavior in a mouse liver injury model. Block-
ade of K18 glycosylation increases K8 S74 phosphorylation (Ku et al., 2010). K8 
lysine acetylation may function as a sensor to link metabolic status to K8 phos-
phorylation and filament reorganization. K8 K207 acetylation promotes insolubil-
ity and increases phosphorylation of K8 S74 and aggregation (Snider et al., 2013). 
Ubiquitination takes place when IFs are hyperphosphorylated (Ku and Omary, 
2000). Intermediate filament ubiquitination also occurs with proteasomal inhibi-
tion and formation of IF inclusions, such as Mallory-Denk Bodies (MDBs) found 
in liver cells during some diseases (Ku et al., 2007a; Tang et al., 2010). MDB forma-
tion is also associated with transamidation and stress-induced keratin phosphor-
ylation (Kwan et al., 2012). The mechanisms of IF crosstalk are largely unknown. 
Specific PTMs influence especially the immediate surroundings of the PTM and 
potentially (possibly by protein folding) regions further away in the IF molecule 
wherein the PTM is located. In addition, PTM can potentially block or free sites on 
nearby molecules in higher-order IF filamentous structures.
6.4. Intermediate filaments in cell mechanics, stress, and disease
Intermediate filaments can provide protection from many types of stresses. In-
termediate filaments have cytoprotective roles in the inhibition of apoptosis, or-
ganelle homeostasis, and scaffolding. The best known of the cytoprotective mech-
anisms is the protection from mechanical stress (Pekny and Lane, 2007; Toivola et 
al., 2010). Mechanical forces are absorbed by the flexible, crosslinked, filamentous 
structures formed by IFs.
Intermediate filaments have important functions in regulating cell mechanics. 
Cytoplasmic IFs, especially keratin, vimentin, and desmin, strongly affect cell stiff-
ness (Charrier and Janmey, 2016; Gruenbaum and Aebi, 2014; Kiss et al., 2006; 
Nolting et al., 2014; Schopferer et al., 2009; Wang and Stamenovic, 2002a). In the 
nucleus, lamins regulate nuclear mechanics and mechanotransduction (Davidson 
and Lammerding, 2014; Lammerding et al., 2006). Intermediate filaments are apo-
lar networks and are in constant interaction with other cytoskeletal networks: mi-
crotubules, microfilaments, and possibly other IFs (Gruenbaum and Aebi, 2014). 
Intermediate filaments connect to other cytoskeletal networks directly, and for 
example through plectin molecules. During cell contraction or externally applied 
stresses, plectins potentially transmit considerable quantities of forces among the 
three cytoskeletal filament systems (Castañón et al., 2013; Foisner et al., 1988).
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Figure 3: The involvement of IFs in human diseases. Adapted from (Omary et al., 
2009).
Specific mutations in most of the IFs can either cause or result in predisposal to 
disease states. To date, only a few IFs are not linked to diseases. Some IFs are also 
involved mutation-independently in human diseases, leading to the formation of 
characteristic cytoplasmic inclusions. The effect of these inclusions on the disease 
progression is not clear, but they are nevertheless histopathologic and diagnostic 
hallmarks of these diseases. IF-protein inclusions may be caused by overexpression 
of particular IFs in specific diseases (Omary, 2009). Mutation typically in keratins 
K5 and K14 can cause epidermolysis bullosa simplex (EBS) (Coulombe et al., 2009; 
Müller et al., 1998). Keratins K8, K18, and K19 can also be the causative agents in 
liver diseases. K8 and K18 are the major constituents and essential for the forma-
tion of MDBs, which are associated with several liver diseases (Ku et al., 2007b; 
Strnad et al., 2012; Zatloukal et al., 2007). Desmin mutations can cause skeletal 
and cardiac myopathies, of which there are over 20 different types (Goldfarb and 
Dalakas, 2009). Neuronal type III and IV IFs can be involved in several neurodege-
nerative disorders and in the formation of inclusions. Neurodegenerative Alexan-
der disease is almost always caused by dominantly acting mutations in GFAP gene, 
and initially defects in astrocytes expressing GFAP (Li et al., 2002; Quinlan et al., 
2007). In many neurodegenerative diseases, such as Alzheimer’s disease, Parkin-
son’s disease, and motor neuron diseases, there are large accumulations of neuro-
nal IFs in the neurons: neurofilaments, α-internexin, and peripherin. Mutations in 
NEFL gene (coding NF-L) are one cause of the inherited peripheral neuropathy 
Charcot-Marie-Tooth disease (Kazamel and Boes, 2015; Saporta, 2014). Mutations 
in NF-H, NF-M, and peripherin are weakly linked to amyotrophic lateral sclero-
sis (commonly known as ALS), that degrades motor neurons (Liem and Messing, 
2009; Riva et al., 2016). Mutations in nuclear lamins can cause laminopathies. 
Laminopathies range from muscular dystrophy and cardiomyopathy to partial li-
podystrophy and progeroid syndromes. Numerous mutations in lamin A and C 
(coded by LMNA gene), or less rarely in lamin B1 or B2, can cause these diseases 
(Maraldi et al., 2011; Worman, 2012). Beaded filament proteins Bfsp1 and Bfsp2 
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and vimentin mutations have also been found to cause cataracts by changing the 
optical properties of the eye lens (Song et al., 2009). Vimentin absence does not 
cause cataracts since vimentin knockout mice do not have cataracts. Vimentin 
with assembly disrupting-mutation R113C or phospho-deficient mutations in mi-
totic phosphorylation sites cause cataract formation in mouse models. In humans, 
one individual with E151K vimentin assembly-disrupting mutation had a cataract 
(Bornheim et al., 2008; Colucci-Guyon et al., 1994; Matsuyama et al., 2013; Müller 
et al., 2009).
In summary, the multitude of diseases associated with IFs highlights the im-
portant role of these abundant proteins in the main tissues they are expressed in. 
Many of the diseases in which abnormal IFs are causative agents relate to the sig-
nificant role of IFs in the protection from stress.
7. Vimentin
Vimentin belongs to group III IFs. Vimentin is expressed mainly in cells of 
mesenchymal origin. In murine development, vimentin expression is highest 
during the primitive streak stage starting from embryonic day 8.5 (Franke et al., 
1982). In adults, there is less vimentin expression, and it is localized to connective 
tissue mesenchymal cells, the central nervous system and muscle (Larsson et al., 
2004). Vimentin expresses in many cell types, including pancreatic precursor cells, 
neuronal precursor cells, sertoli cells, fibroblasts, trophoblastic giant cells, renal 
tubular cells, endothelial cells lining blood vessels, mesangial cells, macrophages, 
astrocytes, leukocytes, and renal stromal cells (Carter et al., 2005; Cochard and 
Paulin, 1984; Evans, 1998; Ko et al., 2004; Mahrle et al., 1983; Satelli and Li, 2011a; 
de Souza and Katz, 2001). Vimentin likely functions in many of these cell types in 
similar ways, such as by providing mechanical stability. However, vimentin also 
affects several physiological processes that are often specific to cell type. Still, spe-
cific functions of vimentin are known only in a few of the cell types in which 
vimentin is expressed. Vimentin, like all other IFs, is composed of central α-he-
lical rod domain, flanked by distal head and tail-regions (Parry, 2005). Vimentin 
functions in the cell’s biological and mechanical activities, including regulation of 
cell migration, adhesion, contractility, stiffness, stiffening, and proliferation (Wang 
and Stamenovic, 2002b). These processes concerning single, sometimes specific 
types of cells typically affect more expansive processes in the multicellular organ-
ism, such as wound healing, immune response, angiogenesis during implantation 
and embryonic development, lymphangiogenesis, etc. The effects vimentin has/
may have on these multicellular processes, possibly under stress, have not yet been 
completely determined.
Knockout models of vimentin did not reveal any apparent defects and showed 
virtually normal phenotypes. Therefore, vimentin is not critical for the survival of 
mice under normal physiological conditions (Colucci-Guyon et al., 1994). Still, 
further research has shown that vimentin functions as a regulator of fundamental 
physiological processes, and can have a major impact on the survival of an organ-
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ism during stress (Ivaska et al., 2007a). Later studies involving more detailed eval-
uation showed that vimentin knockout mice had impaired wound healing in both 
embryonic and adult stages due to weak and severely disabled fibroblasts incapable 
of migrating (Eckes et al., 2000). Vimentin knockout mice exhibit morphological 
changes in glia cells, decreased dilation of resistance arteries under flow, disturbed 
leukocyte homing to lymph nodes, and vascular endothelium with less integrity 
(Colucci-Guyon et al., 1999; Eckes et al., 1998; Henrion et al., 1997; Nieminen et 
al., 2006). Vimentin knockout mice also show impaired motor coordination and 
cerebellar defect (Colucci-Guyon et al., 1999).
Vimentin, like other IFs, functions as scaffolding and signaling platforms for 
signaling molecules. Intermediate filament scaffolding abilities can regulate intra-
cellular distributions of signaling proteins and thereby their abilities to phosphor-
ylate specific targets. On the other hand, IF-associated signaling molecules can 
participate in the regulation of their own scaffold (Ivaska et al., 2007a; Kim and 
Coulombe, 2007). Vimentin, for example, affects Erk-signaling scaffold to activate 
Slug – one of the EMT key proteins (Virtakoivu et al., 2015). Vimentin-deficient 
fibroblasts exhibit slower cell proliferation due to a lower level of DNA synthesis 
(Wang and Stamenović, 2000). Citrullination of vimentin is involved in rheuma-
toid arthritis pathology, and is a candidate for diagnostic testing (Kuna, 2012).
Recently, vimentin has been associated with inflammation and reactive oxy-
gen species (ROS) production. Vimentin downregulates activation of NLRP3 in-
flammasome attenuating pathophysiologic events of acute lung injury (dos Santos 
et al., 2015). Vimentin has been shown to negatively affect bacterial killing and 
ROS production in murine colitis models (Mor-Vaknin et al., 2013). Vimentin 
and GFAP also negatively affect neurogenesis increased endocytosis of Jagged1 in 
astrocytes (Wilhelmsson et al., 2012).
7.1. Vimentin phosphorylation
Recently identified functions of vimentin establish it as an organizer of both 
structural, and signaling-associated proteins. Interactions with different partners 
are highly dynamic and require a fast turnover. Phosphorylation is a key regula-
tor of IF dynamics. Vimentin has a highly complex phosphorylation pattern in 
its N-terminal head and C-terminal tail (Eriksson et al., 1992, 2004a; Kochin et 
al., 2006). Vimentin phosphorylation motifs are highly conserved, and many of 
these sites still lack an identified partner or function. It is presumed that numer-
ous phosphorylation sites of vimentin regulate numerous protein-protein interac-
tions and through them cellular processes, which vimentin participates in (Ivaska 
et al., 2007b). As with other IFs, phosphorylation modulates the organization of 
the vimentin network and the subcellular distribution of vimentin, for example 
by affecting vimentin solubility. Vimentin phosphorylation sites and their corre-
sponding kinases have specific functions in different cellular states, such as mi-
tosis, differentiation, and stress (Omary et al., 2006). In addition to phosphory-
lation, vimentin has been observed to be at least sumoylated, ADP-ribosylated, 
glycosylated, and acetylated (Choudhary et al., 2009; Icenogle et al., 2012; Rho et 
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al., 2009; Wang et al., 2010b). There is far less information regarding the sites and 
effects of these modifications as compared to phosphorylation.
Phosphorylated serine residues in mouse vimentin head 
domain and their in vitro kinases
6 8 9 20 24 25 28 33 38 41 46 50 55 64 65 71 72 82 86
A kinase X X X X X X X X
C kinase X X X X X X X X X X X X
CaM kinase X X
PAK X X X X X
Cdk1 X X
Rho-kinase X X
Aurora-B X X X X X X X X
Plk1 X
Table 3: Mouse vimentin head domain phosphorylation sites and their in vitro ki-
nases. Modified from (Izawa and Inagaki, 2005). The phosphorylation sites involved 
in vivo in mitosis are marked in yellow.
Phosphorylation of vimentin during mitosis causes vimentin disassembly and 
is required for normal mitosis. This process is well studied and includes multiple 
kinases and phosphorylation sites. During mitotic vimentin filament disassembly, 
vimentin serine 55 was observed to be hyperphosphorylated, and p34cdc2-kinase 
was responsible for disassembly (Chou et al., 1990, 1991). Other interphase-specif-
ic high-turnover sites have also been identified, among them serine 38 and serine 
72, which are phosphorylated by PKA in vitro (Inagaki et al., 1987). Phosphory-
lation of these sites causes decelerated filament formation in vivo (Eriksson et al., 
2004a). It has also been shown that vimentin disassembly increases from serine 
56 phosphorylation, which is mediated by PAK (Li et al., 2006). In addition, novel 
functions of vimentin in mitosis, differentiation, and stress are regulated by phos-
phorylation (Chou et al., 1990, 1991; Gard and Lazarides, 1982; Goto et al., 1998, 
2003; Stefanovic et al., 2005; Takai et al., 1996; Yamaguchi et al., 2005).
Vimentin functions as a regulator of 14-3-3. 14-3-3 binds to vimentin phos-
phorylation-dependently. Phosphorylation-dependent binding to 14-3-3 can con-
formationally change the target protein, shut out a specific region, or change the 
subcellular localizations of targets, thereby modulating their functions (Bridges 
and Moorhead, 2005). Head-domain phosphorylation of vimentin has been shown 
to play a crucial role in 14-3-3 binding. In this way, vimentin can scaffold a portion 
of 14-3-3, limiting the ability of 14-3-3 to bind to other target molecules such as 
Raf (Tzivion et al., 2000). Later observation has shown that at least the binding of 
14-3-3 to vimentin inhibits autophagy and promotes Akt-mediated tumorigenesis. 
In this case, 14-3-3 serves as a linker between phosphorylated vimentin and auto-
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phagy-initiating Beclin 1 (Wang et al., 2012).
Phosphorylation of numerous sites of vimentin is usually associated with in-
creased migration (Chang et al., 2012; Eriksson et al., 2004a; Helfand et al., 2011; 
Ivaska et al., 2005a).
Observed vimentin post-translational modifica-
tion sites, their regulators and cellular function. 
N-terminus
S4,6,7,8,9 Phospho-rylation
β1-integrin cycling and cell 
motility regulation
PKC epsilon-mediated 
(Ivaska et al., 2005a)
Phospho-
rylation
Macrophage transendothe-
lial migration regulation
PI3Kgamma-mediated 
(Barberis et al., 2009)
S38 Phospho-rylation Slowing of assembly kinetics
PKA (Eriksson et al., 
2004a) 
Phospho-
rylation
Phosphorylation at the 
cleavage furrow in cytoki-
netic event
Rho-kinase (Goto et al., 
1998)
Phospho-
rylation
Phosphorylation-mediated 
by Rac1 during lamellipodia 
formation
p21 (Helfand et al., 2011)
Phospho-
rylation
Increased breast cancer cell 
motility and invasion, and 
vimentin protection from 
caspases
AKT1 (Zhu et al., 2011)
R44 ADP-ribosyla- (Icenogle et al., 2012)
R49 ADP-ribosyla- (Icenogle et al., 2012)
S50 Phospho-rylation
S55 Phospho-rylation
Filament disassembly in 
early G2/M phase
CDK1 (Chou et al., 2003; 
Tsujimura et al., 1994)
Phospho-
rylation
Reorganization of filaments 
during smooth muscle con-
traction
PAK-1 (Tang et al., 2005)
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Phospho-
rylation
Regulation of the disso-
ciation of Crk-associated 
substrate from vimentin
PAK-1 (Wang et al., 2007)
Phospho-
rylation
GTP-induced secretion in 
neutrophils. Cdk5 (Lee et al., 2012)
Phospho-
rylation
Cdc42GAP activation de-
creases PAK-1 (Li et al., 2009)
S71 Phospho-rylation
Phosphorylation at the 
cleavage furrow in cytoki-
netic event
Rho-kinase (Goto et al., 
1998)
Phospho-
rylation
Filament remodeling in 
neurites
Rho-kinase (Nakamura et 
al., 2000)
Phospho-
rylation
GlcNAc-induced, increase in 
disassembly to tetramers
Rho-kinase (Komura et 
al., 2012)
S72 Phospho-rylation
Decelerated assembly kinet-
ics
PKA (Eriksson et al., 
2004a)
Phospho-
rylation
Phosphorylation at the 
cleavage furrow in cytoki-
netic event
Aurora-B (Goto et al., 
2003; Yasui et al., 2001)
S82 Phospho-rylation
Sequential phosphorylation 
after CDK1 phosphorylation 
on S55 in mitosis. Crucial 
for filament segregation be-
tween daughter cells. Works 
in co-ordination with S72 
phosphorylation by Aurora-
B kinase
Plk-1 (Yamaguchi et al., 
2005)
Phospho-
rylation
Formation of a vimentin 
cage during African Swine 
Fever virus infection.
CamKII (Stefanovic et al., 
2005)
Phospho-
rylation
Memory phosphorylation 
site in astrocytes. Suggested 
to decrease vimentin disas-
sembly threshold after ad-
ditional phosphorylation 
CamKII (Oguri et al., 
2006)
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Phospho-
rylation
Enterovirus 71 VP1 binding 
site in phosphorylated form
CamKII (Haolong et al., 
2013)
Phospho-
rylation
Increase during IbeA+ E. 
Coli K1 invasion CamKII (Chi et al., 2010)
Rod domain
S354 Sumoyla-tion
Inhibits glioma cell migra-
tion
PIAS-mediated (Wang et 
al., 2010b)
C-terminus
S418 Phospho-rylation Unknown function
S429 Phospho-rylation Unknown function
S457 Phospho-rylation Unknown function p37 (Chou et al., 1996)
S458 Phospho-rylation Unknown function p37(Chou et al., 1996)
Phospho-
rylation
Decreases endocytic vesicle 
fusion in mitosis, required 
for integrin trafficking to-
ward cleavage furrow during 
cytokinesis
Plk1 (Ikawa et al., 2014)
Table 4: Post-translational modifications of vimentin and their cellular functions. 
Modified from (Hyder et al., 2008a).
7.2. Vimentin in cell migration, adhesion, and EMT
Vimentin is considered a canonical marker for epithelial-mesenchymal transi-
tion (EMT). EMTis a cellular re-programming process wherein epithelial cells ac-
quire a mesenchymal phenotype that causes them to dramatically alter their shape 
and exhibit increased motility (Gonzalez and Medici, 2014; Thiery, 2002). Epithe-
lial-mesenchymal transition normally occurs during embryonic development and 
wound healing, but it can also appear during pathological processes, most im-
portantly cancer, wherein EMT increases cancer cell invasiveness and metastasis 
(Ivaska, 2011; Lamouille et al., 2014; Moustakas and Heldin, 2007). During EMT, 
epithelial cells which normally express only keratin IFs, start to, express vimen-
tin, fibronectin, N-cadherin, Twist, and Snail and decrease expression of keratins 
and E-cadherin (Gonzalez and Medici, 2014; Ivaska, 2011). There is also a reverse 
process called mesenchymal to epithelial transition (MET), wherein cells begin 
acquiring the epithelial phenotype characterized by reverse expression changes 
compared to EMT and lower motility rates (Chaffer et al., 2006; Yao et al., 2011).
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Intermediate filaments have variable effects on cell migration and can have dif-
ferent effects in different cell models. Keratins have variable, but usually reductive, 
effects on cell migration depending on the context and keratin type, but vimentin 
always stimulates cell migration (Chung et al., 2013; Leduc and Etienne-Manne-
ville, 2015). Vimentin expression has been especially associated with increased mi-
gration of immune and cancer cells, whereas keratin expression usually decreases 
cancer and epithelial cell migration (Eckes et al., 1998; Fortier et al., 2013; Ivaska 
et al., 2007a; Iyer et al., 2013; Nieminen et al., 2006; Rotty and Coulombe, 2012; 
Schoumacher et al., 2010; Seltmann et al., 2013). Intermediate filament type is not 
the only variable for the effects on migration. For example, the expression level of 
IFs and their interaction partners, intracellular organization, and covalent modifi-
cations all affect cell migration (Chung et al., 2013; Leduc and Etienne-Manneville, 
2015). The mechanisms by which vimentin affects cell migration are not complete-
ly known, but some studies have shown that there are multiple mechanisms for 
both structural and signaling functions of vimentin, involving mature network 
and soluble subunits. Vimentin has been shown to affect cell polarity determina-
tion, the formation of adhesions, lamellipodia formation, and cell migration-af-
fecting signaling protein transport and localization (Chernoivanenko et al., 2013; 
Ivaska et al., 2007a).
Vimentin is the main IF present in cell types in which migration is most of-
ten studied: fibroblasts and leukocytes. Leukocyte migration affects leukocyte ex-
travasation when leukocytes home to tissues, and therefore affects immune resis-
tance. Leukocytes can migrate through cell junctions (paracellular route) or have 
the opportunity to migrate directly through endothelial cells (transcellular route) 
(Dejana, 2006). Vimentin affects both of these processes and indeed, in a vimen-
tin-deficient mouse model, both lymphocyte extravasation to tissues and the lym-
phatic system are impaired (Nieminen et al., 2006). Fibroblast migration is a major 
effector of wound healing. Vimentin knockout mice have slower wound healing 
response, and fibroblasts from these mice exhibit less directional migration and 
contraction (Eckes et al., 1998). Vimentin has been observed to retract from fibro-
blast lamellipodia during migration, which allows directional migration response 
(Helfand et al., 2011). Retraction is mediated by actomyosin arcs and plectin cross-
linkers (Jiu et al., 2015). Also, vimentin expression can appear in many cell types 
after wounding, as a major positive contributor to migration in these cases (Eckes 
et al., 2000).
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Figure 4: Important cell migration mechanisms and the major mechanistic roles 
of vimentin in them. Adapted from (Alberts et al., 2007; Helfand et al., 2011; Ivaska 
et al., 2005a).
Vimentin is expressed widely during embryogenesis, but its role in cell mi-
gration in embryogenesis is less studied. Nevertheless, embryogenesis progresses 
almost normally in a vimentin-deficient mouse model, indicating that vimentin 
may not be needed for cell migration during embryogenesis, perhaps due to slow 
speed requirements for cells (Chernoivanenko et al., 2013). However, vimentin 
plays an important role in cancer cell migration (Hendrix et al., 1996; Leduc and 
Etienne-Manneville, 2015; Mendez et al., 2010; Wei et al., 2008).
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Figure 5: Some of the signaling molecules that affect migration through vimentin. 
Modified from (Chung et al., 2013).
An important migration regulator, Rho-associated protein kinase 1 (ROCK1), 
has been shown to phosphorylate serines 38 and 71 in vimentin N-terminus (Goto 
et al., 1998; Kumar et al., 2007; Sin et al., 1998). ROCK1 was shown to interact 
directly with vimentin, most likely on the head domain of vimentin. When RhoA 
was activated, the result was the collapse of the vimentin network in a ROCK1-de-
pendent way, while at the same time, ROCK1 was detached from vimentin and 
traveled to the cell periphery (Sin et al., 1998).
Cell adhesion is a crucial process in cell migration and signal transduction. 
Vimentin regulates cell adhesion mainly via surface adhesion receptors (Ivaska 
et al., 2005b, 2007a). Vimentin-negative endothelium has a reduced number of 
adhesion receptors ICAM-1 and VCAM-1, and lymphocytes have a lower level of 
integrin β1, which also contributes to adhesion. In vimentin negative mice, endo-
thelium is leaky, which reflects defects in cell-cell adhesion and/or cell interactions 
(Nieminen et al., 2006). Vimentin regulates membrane trafficking of integrins via 
PKCepsilon-containing vesicles. PKC-mediated phosphorylation of vimentin ser-
ines 4,6,7,8 and/or 9 regulates vimentin association and disassociation to integrin 
and PKCε-containing vesicles, and allows recycling of integrins back to the plas-
ma membrane in fibroblasts affecting directional migration (Ivaska et al., 2005a). 
This effect is regulated by vimentin binding to filamin A and filamin A binding to 
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PKCε, which allows vimentin phosphorylation by PKCε (Kim et al., 2010). Also, 
PI3Ky-mediated (PI3K protein family member, which relays G-protein binding 
receptor signals to PI3K signaling pathways) phosphorylation of vimentin serines 
4,6,7,8 and/or 9 regulate transcellular migration (Barberis et al., 2009).
Vimentin affects focal adhesions; structures that assemble clearly in cultured 
cells and have less clear counterparts observed in in vivo. In focal adhesions, in-
tegrins bridge the extracellular matrix with the cellular cytoskeleton and recruit 
a complex network of signaling and scaffolding proteins (Geiger et al., 2001). In 
vimentin-mediated matrix adhesion (VAM) vimentin binds directly to α2β1-in-
tegrin in endothelial cells. α2β1-integrin in turn binds laminin and collagen in a 
cell-dependent manner (Kreis et al., 2005; Wallez and Huber, 2008). Vimentin is 
connected to stable hemidesmosome-like structures by α6β4-integrin (Homan et 
al., 1998). Outside focal adhesions on the inside of plasma membrane, vimentin 
filaments link to integrins through IAP (integrin-associated protein, CD47) and 
PLIC-linker proteins (Lindberg et al., 1993; Wang and Frazier, 1998). Vimentin 
also associates with lipid rafts in neutrophils and may mediate integrin trafficking 
in detergent-resistant membrane rafts (DRMs) (Feuk-Lagerstedt et al., 2007). In 
addition to participating in the above-mentioned integrin-mediated cell-matrix 
contacts, vimentin can be part of cell-cell contacts. Endothelial cells have special-
ized desmosome-like junctions, called complexus adherens, which anchor both 
actin and vimentin IFs to VE-cadherin-based plasma membrane domains (Calk-
ins et al., 2003; Green et al., 2005; Kowalczyk et al., 1998). Vimentin has also been 
reported to reside in filopodia and podosomes of adherent macrophages. Non-fil-
amentous vimentin associates with flexible crosslinking protein fimbrin in these 
structures. When observed, this association occurred through the vimentin N-ter-
minus and seemed to be dependent on vimentin phosphorylation (Correia et al., 
1999).
7.3. Vimentin in cell mechanics
Vimentin filaments, among other IFs, are critical regulators of intracellular cell 
mechanics. The vimentin network increases mechanical integrity of the cells and 
localizes and stabilizes intracellular organelles (Buehler, 2013; Gruenbaum and 
Aebi, 2014; Guo et al., 2013). Vimentin filaments also affect cell shape and the 
organization of other cytoskeletal networks (Mendez et al., 2010; Wang and Sta-
menovic, 2002b). The organization of the GFAP network is disrupted in vimen-
tin-deficient astrocytes and later restored when vimentin is transfected back to 
cells (Galou et al., 1996). In vimentin-deficient mice, arterial dilation is impaired, 
and arterial remodeling altered (Henrion et al., 1997). Another role of vimentin 
in cell mechanics is increased mechanosensing of the cells through focal adhe-
sion, anchored to (via plectin) vimentin IFs. Major mechanosensor focal adhesion 
kinase (FAK) has been shown to regulate vimentin targeting to focal adhesions 
(Gregor et al., 2014). Endoplasm, which is an organelle and microtubule-rich re-
gion at the center of the cell, is needed to transport cargos to the cell periphery and 
develop long-range forces. Cells that express polymerization-deficient vimentin 
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variant have deficient endoplasmic spreading and defects in focal adhesion growth 
(Lynch et al., 2013; Tsuruta and Jones, 2003). It has been postulated that endo-
plasmic spreading requires the coalescence of vimentin IFs at force-bearing focal 
adhesions (Lynch et al., 2013).
Vimentin polymer gels show stress-strain relationships, which are highly 
non-linear. Low strain causes very low stiffness, but high strain causes relatively 
much higher stiffness. This non-linear relationship is called strain-stiffening or 
hardening behavior (Janmey et al., 1991). Strain-stiffening occurs in live cells mak-
ing IFs major determinants of cell stiffness cell type-dependently. Cells without 
vimentin are less stiff, and stiffen less than wild-type cells under increasing shear 
stress (Wang and Stamenovic, 2003). In endothelial highly-spread cells, the effect 
is even more prominent. Vimentin network deforms rapidly under physiological 
fluid shear stress (Helmke et al., 2000). Through vimentin network’s connections 
to the nucleus, cell junctions, and other cytoskeletons, vimentin transmits me-
chanical stress and maintains interactions with the other cytoskeletal compo-
nents, the nucleus, and nearby cells (Helmke et al., 2000). Vimentin-deficient cells 
have reduced contractility, and cell-cell interactions are dramatically decreased in 
these cells (Eckes et al., 1998). Vimentin filaments are required for the mechanical 
strength of the cytoskeleton, and protect the structural integrity of the cell. Cells 
without vimentin are more prone to plasma membrane deformation and rupture 
than wild-type cells when cell surface receptors are pulled (Maniotis et al., 1997).
Vimentin IFs provide stabilization for microtubules. Continuous lateral sup-
port from IFs reduces the critical buckling length of microtubules and thus main-
tains their stability during cell contraction (Goldman et al., 1996; Tang et al., 2008). 
In fibroblasts and endothelial cells IF contribution to cell stiffness is about 20-40%, 
but in T lymphocytes rigidity depends mainly on vimentin, whereas microtubules 
play a minor role in T cell rigidity (Brown et al., 2001; Wang and Stamenović, 
2000). Structural alterations in vimentin IFs in circulating T lymphocytes may 
be important in transendothelial migration of these cells (Wang and Stamenovic, 
2002b).
7.4. Vimentin in vesicle and molecule trafficking and organelle posi-
tioning
Vimentin filaments associate with microtubule and actin networks and the 
motor proteins connected to these networks. Via these connections, vimentin fil-
aments can regulate membranous organelle transport (most prominently endo-ly-
sosomal system), the positioning of membranous organelles, and molecule traf-
ficking. Intermediate filaments, vimentin included, have multiple links to vesicular 
membrane transport machinery. Vimentin also affects the function of some cell 
organelles, for example, endosomes and mitochondria (Margiotta and Bucci, 2016; 
Minin and Moldaver, 2008b; Styers et al., 2004).
Vimentin polymers are highly dynamic and exchange subunits between the 
polymer and soluble subunits. Non-filamentous IF precursors, which are short fil-
aments termed “squiggles”, are transported along microtubules with the help of 
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motor proteins kinesin and dynein. Transported IF subunits are hypothesized to 
help transport specific interacting proteins by linking them to microtubule motor 
complexes (Helfand et al., 2002, 2003, 2005). One notable example of this occurs 
during sciatic nerve damage. Damage induces vimentin expression and cleavage 
by calpains. Soluble vimentin fragments link phosphorylated Erk1 and Erk2 kinas-
es to importin β and dynein-mediated transport to nerve cell body. Phosphorylat-
ed Erk kinase can activate signaling that results in neuronal regeneration (Perlson 
et al., 2005). Vimentin also protects active Erks from phosphatases by steric hin-
drance (Perlson et al., 2006). These functions at least partially explain why vimen-
tin is re-expressed upon injuries, and they provide a model of how vimentin can 
function as a long-distance messenger (Ivaska et al., 2007b).
Vimentin is active in vesicle trafficking, mainly through its effects on recep-
tors and interactions with vesicle trafficking components. Vimentin interacts 
with AP-3 adapter protein complexes through its domain consisting of β3A and 
β3B subunits. AP-3 regulates vesicle transport between endosomal and lysosom-
al compartments, and affects transport to hematopoietic granules, melanosomes, 
and synaptic vesicles. AP-3 or vimentin absence in fibroblasts leads to drastic zinc 
ion decrease, especially in vesicles, indicating a role in zinc transport (Minin and 
Moldaver, 2008a; Styers et al., 2004). Zinc also stabilizes vimentin structure via 
vimentin C328 (Pérez-Sala et al., 2015).
Disruption of IF keratin 8 assembly leads to defects in autophagosomal vac-
uole formation in hepatocytes. Vimentin, on the other hand, inhibits autophagy 
through sequestration of Beclin 1 (Blankson et al., 1995; Holen et al., 1992; Parsons 
et al., 2002; Wang et al., 2012). Vimentin binding to AP-3 may also affect autopha-
gosome formation via LAMP-2 (lysosome-bound membrane protein) (Shintani 
and Klionsky, 2004). Regulation of vimentin in membrane trafficking also works 
the opposite way: when membrane traffic is inhibited by mutant forms of ARF1 
(a small GTPase that functions in vesicle budding) or Brefeldin A (which inhibits 
vesicle trafficking from Golgi to the cell surface) vimentin filaments are disrupted, 
and the membrane adaptor complexes AP-1 and AP-3 translocate on vimentin fil-
aments. Microtubules also become more bundled by induced vimentin disruption 
(Perlson et al., 2005; Styers et al., 2006).
Mitochondria localize around IFs in many cell types. Motility of mitochondria 
in cultured fibroblasts is reduced by vimentin (Nekrasova et al., 2011). Vimen-
tin IFs also increase mitochondrial membrane potential (Chernoivanenko et al., 
2015). Vimentin interacts with Golgi apparatus. This interaction is mediated by 
formiminotransferase cyclodeaminase (FTCD), M130, MICAL (molecule inter-
acting with CasL) and GTPase Rab1, which participates in the ER-Golgi transport 
(Gao and Sztul, 2001; Minin and Moldaver, 2008a; Suzuki et al., 2002).
The localizations of the cell nuclei are regulated by IFs and other components of 
the cytoskeleton. Intermediate filaments connect to the nucleus via plectin and the 
protein families KASH and SUN (Starr, 2007). In the case of vimentin, in vimen-
tin-free SW13 cells, nuclear membrane invaginations were observed along with 
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other distortions (Minin and Moldaver, 2008a; Sarria et al., 1994).
7.5. Vimentin in angiogenesis 
Figure 6: Role of vimentin in angiogenesis (adapted from (Dave and Bayless, 
2014a)).
Vimentin also affects the angiogenic processes. Angiogenesis has a critical sig-
nificance in several processes such as pregnancy, ovulation, wound healing, and 
tumor invasion, and vimentin may affect these processes partly through its effects 
on angiogenesis (Carmeliet, 2003; Folkman and D’Amore, 1996). Angiogenesis 
occurs in several steps: basement membrane degradation, sprout initiation, mi-
gration, lumen formation, and stabilization, and vimentin likely affects more than 
one of these processes (Dave and Bayless, 2014a; Iruela-Arispe and Davis, 2009). 
The first possible link between vimentin and angiogenesis was identified when it 
was demonstrated that vimentin silencing resulted in a lag in granulation tissue 
formation (Eckes et al., 1998). Another study indicated that deficiency of vimentin 
causes increased fragility of the retina under stress and impaired angiogenesis un-
der oxygen-induced retinopathy (Lundkvist et al., 2004). Vimentin is a substrate 
of calpain. Calpain cleavage of vimentin produces soluble vimentin. This soluble 
vimentin binds directly to the cytoplasmic tail of MT1-MMP. When calpain or vi-
mentin are silenced, the result is impaired surface localization of MT1-MMP. Less 
MT1-MMP on the cell surface leads to significantly reduced endothelial sprouting 
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responses (Kang et al., 2011; Kwak et al., 2012).
7.6. Vimentin in cancer
Vimentin is overexpressed in various epithelial cancers, including prostate can-
cer, gastrointestinal tumors, CNS tumors, breast cancer, malignant melanoma, and 
lung cancer. Overexpression of vimentin correlates highly with tumor growth, in-
vasion, and poor prognosis (Hendrix et al., 1996; Leduc and Etienne-Manneville, 
2015; Mendez et al., 2010; Wei et al., 2008). Many tumors originating from epithe-
lia start to express vimentin during metastasis (Satelli and Li, 2011a). Vimentin 
expression in cancer cells was shown to correlate with the cells ability to migrate 
and invade surrounding tissue (Gilles et al., 1996; Santini et al., 1996; Sommers et 
al., 1992). The enhancing effect of vimentin on processes such as cell migration 
and invasion, EMT, and perhaps less importantly cell proliferation and angiogen-
esis, at least partially explains why vimentin hastens cancer progression. Howev-
er, many of the detailed mechanisms involved in how vimentin affects cancer are 
still unknown (Chernoivanenko et al., 2013; Dave and Bayless, 2014a; Kidd et al., 
2014; Thiery, 2002). Because knocking out vimentin results in only mild pheno-
type in mice, and because even heavy vimentin aggregation in mice only causes 
cataracts, vimentin is a possible molecular target for slowing tumor progression 
without significant side effects (Bornheim et al., 2008; Colucci-Guyon et al., 1994; 
Müller et al., 2009; Satelli and Li, 2011a). Migration of cancer cells is important for 
metastatic properties. Around 90% of cancer deaths are not caused by a primary 
tumor, but developed metastases (Mehlen and Puisieux, 2006). Vimentin inhibi-
tion could potentially be useful in inhibition of cancer metastases for a variety of 
cancers (Satelli and Li, 2011a).
Withaferin A (WFA) is a bioactive compound isolated from Withania Som-
nifera – a plant from the nightshade family. It has been shown to bind tetrameric 
vimentin in a binding pocket between the pair of head-to-tail α-helical dimers 
(Bargagna-Mohan et al., 2007). Apoptosis caused by WFA is more pronounced in 
cancer cells containing vimentin. This apoptosis promotion was suggested as re-
sulting from vimentin degradation upon binding to WFA (Lahat et al., 2010). WFA 
has also been shown to reduce lung metastatic nodules in breast cancer mouse 
models in low doses (Thaiparambil et al., 2011). WFA was also shown to be rather 
unspecific in inhibiting vimentin, and affected other IF networks as well, meaning 
it may have debilitating organism-wide effects (Grin et al., 2012). Silibinin is a 
flavolignan isolated from milk thistle. Silibinin has strong chemopreventative and 
anticancer properties. Silibinin inhibits cell migration and invasion by downregu-
lation of vimentin and MMP-2 in prostate cancer cells, and upregulation of E-cad-
herin indicating inhibition of EMT in a mouse model (Singh et al., 2008; Wu et al., 
2009). Also, antibiotic salinomycin induces mesenchymal-to-epithellian transition 
(MET, the opposite of EMT) in colorectal cancer cells (Kopp et al., 2014). MicroR-
NAs miR-200 and miR-30 were also shown to cause MET in thyroid carcinomas 
(Braun et al., 2010; Satelli and Li, 2011b).
45
8. Sphingolipids
Sphingolipids are a class of lipids. They are amphipathic in nature. A hydro-
phobic end consists of a sphingoid base linked to a fatty acid, and a hydrophilic 
end consists of hydroxyl groups, phosphates, and sugar residues. Sphingolipids 
are important for the structure of the plasma membrane, as well as in different 
signaling pathways (Gault et al., 2010). They affect many biological processes such 
as adhesion, migration, cell death and survival, proliferation, angiogenesis and 
embryogenesis (Pitson, 2011). Aberrant sphingolipid metabolism, often degrada-
tion and accumulation defect, can cause sphingolipidoses, for example, Tay-Sachs, 
Niemann-Pick, Fabry’s or Gaucher’s diseases, or metachromatic leukodystrophy, 
depending on the specific metabolic defect (Sandhoff, 2013).
Figure 7: De novo sphingolipid synthesis pathways, including potential sphingosyl-
phosphorylcholine (SPC) metabolism and possible reaction into sphingosine-1-phos-
phate (S1P). Adapted from (Bertea et al., 2010; Nixon et al., 2008).
Sphingolipids are divided into different groups. Simple sphingolipids include 
sphingoid bases and ceramides. All sphingolipids derive from ceramide group 
and/or sphingoid bases. Complex sphingolipids include glycosphingolipids and 
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sphingomyelins. Glycosphingolipids contain glucose or the galactose sugar group. 
Glycosphingolipids are divided into cerebrosides, gangliosides, and ceramide oli-
gosaccharides. Molecules in the sphingomyelin group contain phosphorus (D’An-
gelo et al., 2013; Gault et al., 2010; Goñi et al., 2014; Peter Slotte, 2013).
Sphingomyelins are synthesized from ceramide and phosphorylcholine derived 
from phosphatidylcholine. They are the only sphingolipids that contain phos-
phorus. Sphingosine-1-phosphate (S1P) and sphingosylphosphorylcholin (SPC), 
which are of interest in this thesis, belong to sphingomyelin group. Sphingomye-
lins are most abundant in nervous tissue, especially in the myelin sheath of nerves, 
but they also reside in the blood (Goñi and Alonso, 2006; Karlsson, 1998; Merrill 
et al., 1997; Peter Slotte, 2013; Ramstedt and Slotte, 2002; Slotte, 2013).
8.1. Sphingosine-1-phosphate and sphingosylphosphorylcholine
Sphingosylphosphorylcholine (SPC) and sphingosine-1-phosphate (S1P) are 
the two structurally related lysosphingolipids belonging to sphingomyelin group. 
They affect cellular functions through signals transduced by either activation of 
G-protein coupled receptors or possibly by acting intracellularly. S1P has been in-
tensely studied, and SPC is the less studied of these two, although SPC has also 
been the subject of much recent interest. The S1P and the proposed SPC synthesis 
pathway is shown in Fig. 7 (Alewijnse and Michel, 2006; Mendelson et al., 2014; 
Nixon et al., 2008; Pyne et al., 2016; Yue et al., 2015).
Sphingosine-1-phosphate is a major regulator of cellular responses, including 
proliferation, survival, motility, angiogenesis, and inflammation. Angiogenesis, 
cardiogenesis, neurogenesis, and limb development during embryogenesis are all 
affected by S1P (Alewijnse and Michel, 2006; Mendelson et al., 2014; Pyne et al., 
2016). S1P has also an important role in leukocyte trafficking (Aoki et al., 2016a). 
S1P resides in animal cells in relatively small amounts. Insects, yeasts, and plants 
also contain S1P (Mendelson et al., 2014; Pyne et al., 2016). Five different S1P 
receptors (S1PR1-5) activate various signaling routes and different functional out-
comes in cells. Distinct G-protein families partner in particular combinations with 
different S1P receptors. Ras, Rho, and Rac are commonly activated later. Signaling 
molecules further downstream include adenylate cyclase, phospholipase C, PI-3-
kinase, protein kinase C, and calcium (Lee et al., 2001; Mendelson et al., 2014; Ryu 
et al., 2002; Sugimoto et al., 2003). Two sphingosine kinases, SphK1 and SphK2, 
convert sphingosine to S1P, and are essential for S1P metabolism. They are com-
mon in the cytosol and endoplasmic reticulum. They are expressed tissue-specif-
ically in unique cellular locations and have distinct functions (Mendelson et al., 
2014; Pyne et al., 2016).
SPC naturally resides in plasma and, in higher amounts, in serum. SPC is also 
an important constituent of lipoproteins. SPC has cell type-specific functions in 
major tissues, such as in the heart, blood vessels, skin, brain, and immune system. 
As S1P, SPC affects cardiac and blood vessel functions. Also, SPC can act as a 
mitogen in several different cell types and, in certain circumstances, may also be 
a pro-inflammatory mediator (Alewijnse and Michel, 2006; Nixon et al., 2008). 
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The effects of SPC are regulated through a variety of different intracellular signal-
ing cascades, also dependent on cell type. SPC synthesis and breakdown pathways 
are less well understood than S1Ps (Nixon et al., 2008). SPC synthesis increases 
in some pathological conditions, including cancer (Nixon et al., 2008; Yue et al., 
2015). Some of the effects of SPC occur via plasma membrane receptors (e.g. S1P2 
and S1P3) used by S1P. SPC binds to these with significantly lower affinity than 
S1P (An et al., 1997; Liliom et al., 2001; Okamoto et al., 1999). SPC-specific recep-
tor signal transduction mechanisms have not been found, although SPC has some 
novel effects on cells compared to S1P, suggesting that there could be novel SPC 
receptors (Alewijnse and Michel, 2006; Nixon et al., 2008). SPC has been reported 
to increase calcium levels in numerous cell types by cell type-specific mechanisms 
(Afrasiabi et al., 2006; Calcerrada et al., 1999; Orlati et al., 1998). SPC is known to 
often activate mitogen-activated protein kinases (MAPK) and sometimes, like S1P, 
monomeric G-proteins (Nixon et al., 2008). Several effects of SPC are blocked by 
inhibiting RhoA or Rho-kinase (Afrasiabi et al., 2006; Orlati et al., 1998; Todoro-
ki-Ikeda et al., 2000).
S1P has several crucial functions in tissues. Immune cell trafficking, vascular 
development, and the stability of blood vessels are affected by S1P receptor ex-
pression and localization dynamics (Mendelson et al., 2014). Through S1PR1 S1P 
maintains flow-dependent vascular network stability. S1PR1 deletion causes endo-
thelial hypersprouting by increasing VEGFR2 activation and poor vessel function 
via destabilization of VE-cadherin. This results in hypoxia and increased VEGFA 
expression and hypersprouting (Gaengel et al., 2012; Jung et al., 2012; Liu et al., 
2000). S1P also regulates tissue inductive events. S1P regulates mesenchymal and/
or endothelial cell differentiation into pancreatic tissue (Serafimidis et al., 2011). 
In limb development, S1P affects skeletal patterning, vascularization, and digit 
sculpting (Chae et al., 2004a). These effects may function via HIF1α and VEGF 
(Ben Shoham et al., 2012). Neuronal tissue contains S1P receptors in especially 
high levels (Chae et al., 2004b). Mice without Sphk isoenzymes exhibit neuro-
nal cell loss likely through apoptosis and decreased cell division (Mizugishi et al., 
2005). S1P is also a regulator in neural progenitor cell recruitment (Callihan and 
Hooks, 2012; Mendelson et al., 2014). 
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Figure 8: Different sphingosine-1-phosphate (S1P)-induced signaling pathways 
through S1P-receptors (S1PR1-5). The signaling pathway studied in this thesis is de-
noted by red boxes (Rho activation has several possible outcomes). Adapted from 
(Nagahashi et al., 2014).
The functions of SPC in tissues are less known. Based on the results from in 
vitro cell models, SPC may induce differentiation of mesenchymal stem cells to 
smooth muscle cells in vascular development (Jeon et al., 2006; Nixon et al., 2008). 
SPC has pro-inflammatory effects in various contexts (Wirrig et al., 2011). In dis-
rupted endothelial layer, platelets are attracted to the injury site and secrete, among 
other factors, SPC and S1P. In these conditions, SPC can increase inflammation by 
regulating inflammatory cytokine tumor necrosis factor α and ICAM-1 (Imokawa 
et al., 1999; Nixon et al., 2008; Okamoto et al., 2003). SPC can sometimes act as a 
chemoattractant for natural killer cells, potentially contributing to inflammation 
(Jin et al., 2005). In the skin, SPC increases wound healing in in vivo models (Sun 
et al., 1996). SPC increases interleukin-6 expression, which causes an increase in 
fibronectin expression. An increase in fibronectin expression increases collagen 
deposition during wound healing (Gailit and Clark, 1994; Suhr et al., 2003). SPC 
also increases connective tissue growth factor expressions (Zhu et al., 2005). In 
atopic dermatitis epidermal lesions, SPC concentration is four-fold compared to 
the normal epidermis. In neurons, SPC increases calcium levels and can increase 
nerve growth factor synthesis (Furuya et al., 1996; Huang and Chueh, 1996). SPC 
effects in neurons may involve neural cell maintenance and survival. Numerous 
sphingomyelinase gene mutations can cause neurodegenerative Niemann-Pick 
disease types A and B (Simonaro et al., 2002). In A-type disease, SPC levels in 
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the cerebral cortex are increased 50- to 100-fold (Rodriguez-Lafrasse and Vanier, 
1999). SPC may contribute to neurodegeneration by inducing astrocytes to release 
glutamate, which increases calcium in adjacent neurons or via tumor necrosis fac-
tor secretion, which causes inflammation (Chiulli et al., 2007; Nixon et al., 2008).
S1P and SPC have common effects, but also some differences in their effects on 
cells. For example, SPC has been shown to decrease heart rate species-specifically 
in guinea pigs, possibly via the muscarinic receptor-activated K+ channel, but S1P 
causes this effect in both humans and mice (Orlati et al., 1998; Todoroki-Ikeda 
et al., 2000). SPC causes hypertrophic growth in neonatal rat cardiomyocytes in 
vitro, whereas S1P does not (Sekiguchi et al., 1999). SPC and S1P generally cause 
vasoconstriction in individual blood vessels mostly via an increase in calcium and 
activation of the RhoA/Rho-kinase (ROCK) pathway, but the effects of SPC on 
blood vessels can be variable (Nixon et al., 2008). In intact blood vessel endothe-
lium, specifically HDL-binding SPC, like S1P, may prevent cardiovascular disease 
(Kimura et al., 2001; Nofer and Assmann, 2005; Sachinidis et al., 1999). 
S1P and SPC can affect the IF cytoskeleton. SPC can cause reorganization of 
keratin 8 and 18 filaments into perinuclear space, increased keratin phosphor-
ylation, and higher cell elasticity in tumor cells originating from human epithe-
lia. These effects are largely independent of microtubules and F-actin (Beil et al., 
2003). SPC-induced phosphorylation of keratins regulates keratin reorganization 
and cell motility in a substantial manner (Busch et al., 2012; Fois et al., 2013; Park 
et al., 2011). S1P also causes reorganization of vimentin. S1P causes vimentin to 
form complexes with FAK and RACK1 in invading endothelial cells. Complex for-
mation affects focal adhesion formation (Dave et al., 2013; Sin et al., 1998).
8.1.1. S1P and SPC in cell migration
S1P affects cell migration in several concepts through various mechanisms. 
The effects of S1P to migration occur mainly through S1PR1-3. While S1PR1 and 
S1PR3 typically induce migration, when activated, S1PR2 typically inhibits migra-
tion (Adada et al., 2013a).
In vascular sprouting, endothelial cells show collective migration patterns. The 
collective migration patterns are regulated by S1P and S1PR1-3 (Gaengel et al., 
2012; Jung et al., 2012). Also, S1P helps the movement of immune cells from lym-
phatic organs to blood circulation by forming a gradient at the boundary between 
the tissues and the vasculature (Cyster and Schwab, 2012; Pappu et al., 2007). This 
gradient forms with the help of spinster 2 (a sphingosine-1-phosphate transporter), 
cell-surface lipid phosphate phosphatase 3, and sphingosine kinases. Egress-pro-
moting receptors, e.g. S1PR1, together with retention promoting receptors, e.g. 
CCR7, on lymphocytes recognize the gradient and activate a suitable chemotactic 
response (Bréart et al., 2011; Cyster and Schwab, 2012; Fukuhara et al., 2012; Pham 
et al., 2008).
S1P affects cell-cell and cell-matrix adhesion mainly through G-protein cou-
pled S1P-specific S1P1-5 receptors and in much smaller amounts via intracellu-
lar targets, e.g. HDAC1 and 2, TRAF2, and prohibitin (Alvarez et al., 2010; Chun 
50
et al., 2010; Hait et al., 2009; Strub et al., 2011). The adhesion effect can conse-
quently affect cell migration and invasion, cell growth and survival, differentiation 
and cytokine production. S1P receptor 1 activation can induce the formation of 
VE-cadherin-containing adherens junctions in vascular endothelial cells. S1PR1 
also influences adhesion between pericytes and endothelial cells via N-cadher-
in-dependent junctions (Lee et al., 1999; Paik et al., 2004). S1PR1 and 3 can ac-
tivate integrins and focal contact formation in vascular endothelial cells (Paik et 
al., 2001). Microtubule polymerization at the cell cortex is regulated by S1PR1 and 
Rac (Paik et al., 2004).
S1PR2 signaling disrupts adherens junctions via Rho, Rho-kinase (ROCK), 
and PTEN, and inhibits specific growth factor or chemokine-induced cell migra-
tion by inhibiting Rac (Michaud et al., 2010; Sanchez et al., 2005; Sugimoto et al., 
2003). S1P induces actin stress fiber assembly through S1PR2 and Rho GTPase, 
and cortical actin assembly through S1PR1 and Rac GTPase, (Lee et al., 2001; Ryu 
et al., 2002; Sugimoto et al., 2003). S1PR2 signaling typically inhibits cell migration 
through Rho and ROCK signaling or PTEN signaling that leads to inhibition of 
Akt (Adada et al., 2013a). Insulin-like growth factor (IGF) and platelet-derived 
growth factor (PDGF) are known to be affected by S1PR2 and S1P can inhibit 
via S1PR2 chemokines C5a, CCL2, and stromal-derived growth factor 1 (SDF1, 
CXCL12), which all are regulators of cell migration in specific contexts (Michaud 
et al., 2010; Sugimoto et al., 2003).  
During organism development, S1P is crucial for heart cell precursor migra-
tion. In zebrafish, S1PR2 and spinster 2 mutations cause the formation of two 
hearts (Kupperman et al., 2000). This defect may be tracked to observable defects 
in endodermal sheets. S1P affects via S1P2/G13/Rho integrins and fibronectin. 
The effect may cause myocardial precursor cell migration guidance defect (Zhang 
et al., 1999). Prechordal plate migration is regulated by S1P (Kai et al., 2008). S1P 
regulates migration and clustering of pancreatic endocrine precursor cells during 
development (Mendelson et al., 2014). 
8.1.2. S1P and SPC in cancer
S1P plays an important role in inflammatory disease, cancer, and Alzheimer’s 
disease. Recently developed sphingosine analog Fingolimod (FTY720), which af-
fects S1P signaling, has been shown to be effective in treating multiple sclerosis 
and has potential uses in cancer treatment (Aoki et al., 2016b; Patmanathan et al., 
2015; White et al., 2016). Fingolimod becomes phosphorylated to its active form 
in the body. The active form can bind S1P1, 3, 4, and 5 receptors. The binding 
causes inhibition of lymphocyte egress from lymphoid organs (Aoki et al., 2016b). 
SphK1 and SphK2 are predictive markers in inflammatory diseases and cancer. 
Sphingosine kinases are potential targets for cancer treatment. Additionally, there 
is evidence of S1PR and sphingosine kinase 1 interaction, which can amplify can-
cer cell growth (Pyne et al., 2014). The stimulative or inhibitory effect of S1P on 
cancer cells depends on the cell type. The effect may be dependent on S1P receptor 
composition (Adada et al., 2013b; Meyer zu Heringdorf and Jakobs, 2007). Recent-
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ly, SPC has raised interest in cancer research due to high levels of SPC in cancer 
patients’ malicious ascites, and because of SPC’s effect on cancer cell proliferation 
and migration in pancreatic cancer cells and epithelial ovarian carcinoma cells, 
among others (Yue et al., 2015).
9. Rho-associated protein kinase (ROCK)
Rho-associated coiled coil kinase (ROCK) is a major signaling protein relaying 
signals from small GTPase RhoA. ROCK family consists of two isoforms; ROCK1 
and ROCK2. ROCK is a considerable regulator of actin cytoskeleton organization 
and it affects, for example, contraction, adhesion, migration, proliferation, and 
apoptosis. ROCK affects several processes of cancer malignancy, such as tumori-
genicity, tumor growth, metastasis, angiogenesis, tumor cell apoptosis and surviv-
al and chemoresistance, more often by hastening cancer progression, but some-
times in an inhibitory manner (Wei et al., 2016a). ROCK effect on cell migration 
is usually increasing, but sometimes inhibitory, for example, in the case of MCF-7 
breast cancer cells, SW480 and – only in three-dimensional matrix – SW620 colon 
cancer cells (Loirand, 2015; Wei et al., 2016b).
10. Notch signaling
Notch signaling is an important regulator in cell fate determination. Notch 
signaling is activated by direct contact of the signal-sending cell to the signal-re-
ceiving cell (Hori et al., 2013). Differentiation, apoptosis, and proliferation are in-
fluenced by Notch signaling depending heavily on the cellular context. The Notch 
signaling pathway exists in a conserved fashion in most multicellular organisms 
(Artavanis-Tsakonas et al., 1999; Bray, 2006; Kopan and Ilagan, 2009). Many dis-
eases that present changes in cell fate and proliferation, such as cancer, are affected 
by aberrant Notch signaling (Louvi and Artavanis-Tsakonas, 2012).
Notch receptors localize mainly on the cell surface within the plasma mem-
brane in a processed heterodimer form. Furin-dependent cleavage (S1 cleavage) 
occurs in the Notch extracellular domain (NECD), during travel of Notch recep-
tor through the Golgi complex (Logeat et al., 1998). During Notch synthesis and 
secretion, O-linked glycosylation takes place in the NECD. Post-translational 
modifications help  Notch receptors fold correctly and, in the right conformation, 
interact with their ligands DSLs (Delta, Serrate, Lag-2) (Rana and Haltiwanger, 
2011). The glycosylation is regulated by Fringe-gene, which encodes a glycosyl-
transferase. The glycosyltransferase transfers N-acetylglucosamine to fucose on 
Notch epidermal growth factor-like (EGF) repeats (Brückner et al., 2000; Molo-
ney et al., 2000). Notch receptor in the signal-receiving cell binds ligands directly 
onto the signal-sending cell surface. Mammals have four Notch receptors: Notch 
1, Notch 2, Notch 3, and Notch 4, and five ligands: Jagged 1, Jagged 2, Delta-like 
1, Delta-like 3, and Delta-like 4 (Bray, 2006; Hori et al., 2013; Kopan and Ilagan, 
2009). Metalloproteinase ADAM performs second NECD cleavage (S2 cleavage) 
when a receptor binds to a ligand on a signal-sending cell. This event facilitates 
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an S3 cleavage event by presenilin-containing γ-secretase complex within the 
Notch transmembrane domain (Brou et al., 2000; Struhl and Greenwald, 1999). At 
this point, Notch intracellular domain (NICD) is free to move off the membrane, 
and the NECD is trans-endocytosed inside the signal-sending cell still bound to 
its ligand (Gordon et al., 2008). Eventually, NICD travels to the nucleus. Inside 
the nucleus NICD forms a transcriptional complex with Mastermind (Mam), 
DNA-binding protein CSL (CBF1, Lag1, Suppressor of Hairless), and transcrip-
tional co-activators allowing Notch target gene synthesis. Without NICD, CSL 
interacts with several co-repressors, causing transcriptional inhibition of Notch 
target genes (Bray, 2006; Kopan and Ilagan, 2009).
Figure 9: The mechanisms of Notch signaling in human cancers and angiogenesis. 
Notch signaling can lead to several outcomes depending on the context and signaling 
pathway. The angiogenic route is shown in detail.  Adapted from (Zhou et al., 2013).
Notch ligands can bind Notch receptors in the same cell in a cis manner. Cis-in-
teractions inhibit Notch signaling, whereas trans-interactions between cells en-
hance Notch signaling (del Álamo et al., 2011; Sprinzak et al., 2010). The interplay 
between these interactions is a crucial factor for distinguishing the signal-receiv-
ing cell from the signal-sending cell. The ratio of receptor-competent ligands to 
ligand-competent receptors on the cell surface is also a factor that affects cell fate 
determination. Ligand recycling critically regulates Notch signaling activity by 
controlling cell surface ligand accumulation. Trans-endocytosis of the ligands with 
the Notch receptor is considered a prerequisite for fully active Notch signaling. 
Binding of a ligand to a receptor on an adjacent cell and the following endocytosis 
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has been suggested to produce mechanical pulling force. The force causes a con-
formational change that reveals the S2 Notch receptor cleavage site and allows pro-
teolytic cleavage of NICD, which is required for Notch signaling (Meloty-Kapella 
et al., 2012). Notch signaling activity is also regulated in a complex way by endocy-
tosis and endosomal processing during various stages of Notch signaling (Fortini, 
2009; Yamamoto et al., 2010). Endocytic trafficking has been shown to have a role 
in Notch signaling induced by ligands (Coumailleau et al., 2009). Under specific 
circumstances, the receptor can be activated in endocytic compartments without 
ligand activation (Hori et al., 2011; Vaccari et al., 2008, 2009; Wilkin et al., 2008).
10.1. Notch signaling in angiogenesis
Notch signaling is important in angiogenesis in development and pathologi-
cal conditions, as well as for maintaining vascular homeostasis. In development, 
Notch functions in arterial differentiation, lymphatic development, and sprouting- 
and lymphangiogenesis. Notch ligands and receptors express in endothelial and 
perivascular cells (e.g. vascular smooth muscle cells, pericytes, and macrophages), 
and also in tumor endothelial cells. Defective expression of Notch ligands or Notch 
receptors during development causes embryonic lethality due to vascular defects 
(Krebs et al., 2000; Limbourg et al., 2005; Xue et al., 1999).
Notch signaling is critical in sprouting angiogenesis. In sprouting angiogen-
esis, there is communication between two cell types: tip and stalk cells. Tip cells 
protrude filopodia into the surrounding tissue, and stalk cells follow and prolif-
erate to form the trunk of the new vessel sprouts (Patel-Hett and D’Amore, 2011; 
Ribatti and Crivellato, 2012). Notch signaling determines the formation of tip and 
stalk cells (Ribatti and Crivellato, 2012). When cells become stimulated by VEGF, 
cells with a higher VEGFR2 signal upregulate Dll4 and form tip cells (Tung et al., 
2012). Dll4 then activates Notch signaling in adjacent endothelial cells to reduce 
their expression of VEGFR2 and VEGFR3. Reduction in VEGFR2 and VEGFR3 
expression promotes the stalk cell phenotype (Ribatti and Crivellato, 2012; Tung 
et al., 2012). If Notch signaling is depressed, endothelial cells continue to form 
more sprouts in response to VEGF signaling (Benedito et al., 2009; Li et al., 2007; 
Napp et al., 2012; Ridgway et al., 2006; Siekmann and Lawson, 2007; Suchting et 
al., 2007; Thurston et al., 2007). Jagged 1 plays a proangiogenic role in mice by 
antagonizing Dll4-Notch signaling in cells, which express Fringe family glycos-
yltransferases (Benedito et al., 2009). Fringe family of glucosaminyl transferases 
modify Notch receptors in a way that enhances Dll4-signaling but suppresses Jag-
ged1 signaling (Benedito et al., 2009). Notch signaling also regulates the expres-
sions of endothelial growth factor receptors 1, 2, and 3 in a complicated way (Phng 
and Gerhardt, 2009).
Jagged1 and Dll4 have opposing effects on vascular formation, but how this sig-
naling is balanced is widely unknown. Dll4-mediated activation of Notch signaling 
suppresses angiogenesis, and Jagged1 antagonizes Dll4 and promotes angiogenesis 
and sprouting (Benedito et al., 2009; Pedrosa et al., 2015; Trindade et al., 2008; Xue 
et al., 1999). Both Jagged1 and Dll4 regulate tip and stalk cell selection, and the 
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initiation of new branches in the branching endothelium (Benedito et al., 2009; 
Phng and Gerhardt, 2009). Dll1 functions as an inhibitor of angiogenesis when 
expressed by vasculature, but enhances angiogenesis when expressed by surround-
ing tissue. Dll1 maintains VEGF expression later in angiogenesis (Kume, 2009; 
Napp et al., 2012; Sörensen et al., 2009). How ligand-receptor signaling specificity 
is achieved is not clearly known.
If delta-like 4 (Dll4) is blocked, hyperbranching of blood vessels occurs when 
more tip cells are created. These vessels are leaky and less functional. Dll4 overex-
pression causes attenuated vessel formation in developing mouse embryos, and 
haploinsufficiency causes embryonic lethality (Gale et al., 2004; Trindade et al., 
2008). Balanced regulation of ligands is crucial for functional vasculature forma-
tion (Andersson et al., 2011; Artavanis-Tsakonas et al., 1999).
Mice lacking Jagged1 are early embryonic lethal due to hemorrhages (Hans-
son et al., 2010; Xue et al., 1999). Jagged1 deregulation is associated with vascular 
injuries and observed in pulmonary arterial hypertension patients (Lindner et al., 
2001; Yamamura et al., 2014). Jagged1-mediated Notch activation causes increased 
retinal vascular density and vascular smooth muscle recruitment to retinal arteries 
(Kangsamaksin et al., 2014b). Increased glucose causes Jagged1 overactivation and 
pathological angiogenesis, including increased sprouting and vessel destabilization 
(Yoon et al., 2014). The effect may be explained by the downregulation of soluble 
decoy VEGFR1 (antagonist of VEGFR2) expression by Jagged-Notch signaling. 
This leads to an increase in VEGFR2 signaling (Kangsamaksin et al., 2014b).
10.2. Notch signaling in cancer
Notch signaling promotes cell survival, angiogenesis, differentiation, and treat-
ment resistance in many cancer types. Notch signaling also has crosstalk with oth-
er critical cancer-promoting signaling pathways. Notch signaling is, therefore, a 
target candidate for cancer drugs. Today there are several gamma-secretase inhib-
itors in clinical trials, but other Notch signaling molecules may also be potential 
targets (Purow, 2012). Current Notch inhibitors produce considerable side effects, 
rendering them unusable treatments (van Es et al., 2005; Wong et al., 2004; Yan 
et al., 2010). In a recent preclinical article, Notch decoy receptors that selectively 
block Delta-like- or Jagged-Notch signaling inhibited mouse xenograft tumor an-
giogenesis without considerable side effects (Kangsamaksin et al., 2014b).
11. Par-4
Par-4 is a pro-apoptotic protein that is especially active in prostate cancer. Par-4 
can inhibit NF-kappaB and simultaneously activate FasL and Fas. These activa-
tion level changes can induce cancer cell apoptosis and tumor regression. They 
can selectively induce or sensitize cancer cells to apoptosis without affecting nor-
mal cells. Par-4 can induce apoptosis both intracellularly and extracellularly, and 
can be excreted spontaneously. Systemic Par-4 induces apoptosis via cell surface 
GRP78 receptor/caspases pathway (Bhattarai and Rangnekar, 2010; Burikhanov et 
al., 2009; Zhao et al., 2011). The in vivo delivery of Par-4 with adenovirus or nano-
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liposomes to HT29- or PC-3-cell-derived tumor in mice has been shown to cause 
tumor regression or sensitization to therapeutic agents (Chakraborty et al., 2001; 
Kline et al., 2009). Par-4 has been observed to be downregulated in breast cancer, 
lymphoma, and pancreatic and renal carcinoma. The Par-4 gene that resides in 
chromosome 12 can often undergo deletion in gastric and pancreatic cancers, and 
in tumors of male germ cells (Boehrer et al., 2001; Cook et al., 1999; Johnstone et 
al., 1998; Nagai et al., 2010; Schneider et al., 2003). Par-4 is a major factor in breast 
cancer recurrence (Alvarez et al., 2013). Mice without Par-4 develop tumors in 
several tissues spontaneously (García-Cao et al., 2005). Par-4 induces apoptosis 
via its caspase-cleaved form, and by inhibiting survival factors NF-κB, PKCζ, and 
AKT kinase (Diaz-Meco et al., 1999; Díaz-Meco et al., 1996; Lee et al., 2010; Wang 
et al., 2010a). Phosphorylation of different sites of Par-4 can inhibit or activate 
Par-4-mediated apoptosis (Goswami et al., 2005; Gurumurthy et al., 2005).
12. CK2
Casein kinase 2 (CK2) is a serine/threonine protein kinase with amino acid 
consensus motif ‘S/T-X-X-Asp/Glu/pSer’ recognition property. It forms tetramers 
that consist of two subunits with a kinase catalytic domain (α and/or α´ in differ-
ent combinations) and two β-subunits. β-Subunits mediate interactions between 
CK2 catalytic subunits and their substrates (Allende and Allende, 1995; Meggio 
and Pinna, 2003). Casein kinase 2 has global roles in cell growth (increase), cell 
proliferation (increase), and cell death (protect), and also regulates processes such 
as cell cycle control, DNA repair, and circadian rhythm (Volodina and Shtil’, 2012). 
CK2 inhibition is presently under intense study, because CK2 activity and/or ex-
pression is increased in colon, prostate, lung, and head and neck cancers, among 
others (Daya-Makin et al., 1994; Gapany et al., 1995; Münstermann et al., 1990; 
Yenice et al., 1994). Inhibition of CK2 may affect cell growth, proliferation, and 
apoptosis, ubiquitously resulting to toxicity (Trembley et al., 2010). CK2 activity 
increases expression/activity of pro-survival proteins Wnt, NF-κB, and Akt, in-
hibits pro-apoptotic genes by preventing caspase cleavage of them, and inhibits 
mitochondrial apoptotic pathways (Ruzzene and Pinna, 2010; Wang et al., 2006a; 
Yenice et al., 1994). CK2 inhibition can predispose cancer cells to apoptosis, and 
overexpression of CK2 increases cancer cell survival (Desagher et al., 2001; Guo 
et al., 2001; Izeradjene et al., 2005; Ravi and Bedi, 2002; Wang et al., 2005, 2006b).
13. AATF
Apoptosis antagonizing transcription factor (AATF, also known as Che-1) is 
a transcriptional cofactor that is an important cofactor of DNA damage response 
machinery. This signaling network initiates DNA repair and prevents tumorigen-
esis by causing growth arrest or apoptosis when DNA damage occurs. AATF also 
affects various signaling pathways that regulate proliferation and survival in both 
physiological, and pathological conditions (Iezzi and Fanciulli, 2015). AATF is 
ubiquitously expressed in tissues. In cells, AATF usually shows nuclear and nucle-
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olar localization, but a cytoplasmic localization has also been reported in specific 
cells (Iezzi and Fanciulli, 2015). 
AATF is an essential component or an organism, since AATF knockout mice 
are embryonically lethal at the preimplantation state. When AATF in mice is mu-
tated and not completely functional, embryos have reduced number of cells high-
lighting AATFs role in cell proliferation (Thomas et al., 2000). 
The gene that produces AATF is located on chromosome 17. Its protein prod-
uct consists of 558 amino acids and is highly conserved among eukaryotes. AATF 
protein negatively regulates its own coding (Monaco et al., 2003). AATF consists 
of an N-terminal acidic domain, a canonical leucine zipper, and three LXXLL mo-
tifs for nuclear receptor binding. It has one nuclear and two nucleolar localization 
signals (Fanciulli et al., 2000; Lindfors et al., 2000; Scott et al., 2011). 
AATF is part of DNA damage response machinery and is phosphorylated and 
activated after DNA damage by MK2, ATM, and Chk2 checkpoint kinases (Bruno 
et al., 2006; Ciccia and Elledge, 2010; Höpker et al., 2012). After DNA damage, one 
option for AATF function is that MK2 phosphorylates AATF T366, which allows 
AATF to move from the cytoplasm, where it can be sequestered by MRLC3, to 
the nucleus (Höpker et al., 2012). ATM and Chk2-mediated AATF phosphoryla-
tion reduces AATF degradation, causing stabilization and accumulation of AATF 
(Bruno et al., 2006). These modifications also affect AATF interactions and cause 
a different cellular response; AATF effect changes from cell cycle progression to 
cell cycle arrest and survival. ATM-Chk2 phosphorylation moves AATF from 
E2F1-dependent promoters to checkpoint activation gene promoters (for example 
TP53 and p21) inhibiting them and the cell cycle, and promoting AATF interac-
tion with p53 (Bruno et al., 2006; Desantis et al., 2015). ATM and Chk2 phosphor-
ylation of ATF also occurs after DNA-damaging agent exposure (mild DNA dam-
age) and promotes antiapoptotic factor XIAP transcription (Bruno et al., 2008). 
PolyADP-ribosylation of AATF occurs after DNA damage and increases AATF 
stability (Bacalini et al., 2011).
During DNA damage AATF may accumulate into centrosomes. AATF is part 
of the spindle assembly checkpoint: it prevents the formation of multiple centro-
somes and multipolar spindles and enables mitotic arrest and apoptosis after mild-
ly genotoxic treatments (Lara-Gonzalez et al., 2012; Sorino et al., 2013; Zhang et 
al., 2007). In apoptotic DNA damage AATF gets degraded by HIPK2-mediated 
phosphorylation of T144, promoting a conformational change which allows ubiq-
uitination to occur (De Nicola et al., 2007, 2014). AATF promotes p53 transcrip-
tion upon DNA damage. Transcription promotion also happens with mutant p53s, 
which are often found in cancers. If AATF depletes, then mutant p53 is not tran-
scribed inducing apoptosis via tumor suppressor protein p73 (Bruno et al., 2010).
In addition to DNA damage, AATF participates in many types of stresses, in-
cluding ER stress, hypoxia, hyperosmotic stress, and glucose deprivation. ER stress 
induces AATF which activates AKT1 through direct interaction with STAT3 (Ishi-
gaki et al., 2010). AATF has been shown to protect from apoptosis induced by 
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ionizing radiation, hypoxia, or glucose deprivation by inducing autophagy (shown 
to protect from metabolic stress) via inhibition of mTOR (Desantis et al., 2015).
AATF is usually related to antiapoptotic activity (Iezzi and Fanciulli, 2015). 
AATF interacts with and antagonizes proapoptotic Dlk ZIP kinase (Page et al., 
1999). In neural tissue AATF has antiapoptotic effects in physiological and patho-
logical conditions. AATF interacts with neurotrophin receptor-interacting MAGE 
homolog (NRAGE), which functions in neuronal cell death during development 
and counteracts NRAGE’s effect (Di Certo et al., 2007). AATF’s antiapoptotic effect 
also functions in neurodegenerative processes. AATF can counteract neurodegen-
eration by interacting with Par-4, preventing its effect on producing a neurotoxic 
peptide (Guo and Xie, 2004; Xie and Guo, 2004). AATF is also a substrate, and 
interacts with Cdk5, whose activity is deregulated in neurodegenerative diseases 
(Buontempo et al., 2008). In kidney proximal tubule cells AATF has been shown 
to preserve mitochondrial function and reduce oxidative damage, consequently 
counteracting apoptotic cell death (Xie and Guo, 2006). Although AATF is mainly 
a pro-survival protein in several contexts, in this thesis, we describe a pro-apop-
totic function for AATF, which activates after UV damage (Ferraris et al., 2012).
During proliferation, AATF promotes cell cycle progression by inhibiting 
pRb-regulated growth suppression. AATF binds to pRb and removes HDAC1 
from the Rb E2F-complex, which allows transcription and S-phase entry. AATF 
is hyperphosphorylated during G1/S transition (Bruno et al., 2002). AATF also 
localizes to centrosomes during interphase and regulates centrosome duplication 
and spindle formation (Sorino et al., 2013). Therefore, AATF affects cell cycle pro-
gression with more than one mechanism.
Due to AATF’s effects on, for example, cell cycle, cell survival, autophagy, and 
p53, AATF affects tumor cell survival. Cancer cell transformation has been shown 
to be affected by AATF, and increased expression of AATF may be crucial for the 
survival of tumor cells (Iezzi and Fanciulli, 2015). In one screening, mutations of 
AATF were not associated with breast cancer (Haanpää et al., 2009). AATF has 
been found to be upregulated in many leukemia cell lines (Bacalini et al., 2012; 
Kaul and Mehrotra, 2007). In neuroblastoma patients, AATF was overexpressed 
and predicted poor prognosis (Höpker et al., 2012). AATF downregulation leads 
to enhanced cytotoxicity from DNA-damaging chemotherapy, and tumor cells 
with mutant p53 were more likely to induce apoptosis (Bruno et al., 2006, 2008, 
2010; Höpker et al., 2012). A functional AATF inhibitor has not yet been devel-
oped (Iezzi and Fanciulli, 2015). Therefore, AATF is a potential cancer treatment 
target, although this is still mainly theoretical.
AATF interacts with at least several proteins in several contexts. These interac-
tions form the basis of AATF cellular functions. The interactions are often regulat-
ed by post-translational modifications that allow fast and dynamic responses (Iezzi 
and Fanciulli, 2015). It has been shown that AATF interacts with nuclear hormone 
receptors in vitro, and enhances transactivation of several steroid hormone re-
ceptors sometimes cooperating with acetyltransferase p300 (Leister et al., 2003). 
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AATF enhances androgen receptor-mediated transcription, and TSG101 binding 
to AATF regulates this transcription (Burgdorf et al., 2004). AATF interacts with 
pRb, p65, and STAT3 transcription factors (Bruno et al., 2002, 2006; Ishigaki et 
al., 2010). AATF can bind hRBP11 subunit in RNA polymerase II, and rat ortho-
log exhibits transactivation (stimulate transcription by binding to DNA) activity 
(Fanciulli et al., 2000; Page et al., 1999). Since the hRBP11 subunit exists in various 
forms in C-termini of other proteins of this protein family, AATF may have a wid-
er effect via this interaction (Benga et al., 2005; Grandemange et al., 2001).
14. c-Jun
c-Jun is a member of the AP-1 transcription factor family. The AP-1-family 
consists of Jun, ATF, and Fos subfamilies. Different members of families stand out 
with particular DNA-binding specificities, dimerization partners, and posttrans-
lational modifications. AP-1 family members primarily affect cell proliferation, 
survival, and death (Devary et al., 1991; Dhanasekaran and Reddy, 2008; Herrlich 
et al., 2008; Kasibhatla et al., 1998; Le-Niculescu et al., 1999). c-Jun usually acts 
antiapoptotically, but c-Jun deficiency has also been observed to protect fibroblasts 
from UV- or alkylating agents-induced apoptosis (Kolbus et al., 2000; Shaulian et 
al., 2000). Prolonged c-Jun activation has been shown to precede apoptosis (Ka-
sibhatla et al., 1998; Raivich, 2008). Apoptosis occurs when a certain threshold of 
pro-apoptotic signals is reached when c-Jun induces at least TNFα, FasL, and Bim 
(Devary et al., 1991; Dhanasekaran and Reddy, 2008; Herrlich et al., 2008; Kasi-
bhatla et al., 1998; Le-Niculescu et al., 1999). c-Jun is activated by phosphorylation 
induced by c-Jun N-terminal kinases (JNKs) (Johnson and Nakamura, 2007).
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OUTLINE OF THE STUDY
The aim of this research was to study the effects of phosphorylation primarily 
in vimentin structure and function, and also phosphorylation-mediated functions 
of Par-4 and AATF in the apoptosis context.
Earlier, our lab identified several vimentin in vivo serine and threonine phos-
phorylation sites. Most of the functions of these phosphorylation sites are still un-
identified. We aimed to characterize how phosphorylation of most of the vimentin 
serine and threonine in vivo phosphorylation sites affected mainly vimentin net-
work structure with phospho-deficient and phospho-mimicking point mutations.
Sphingolipids S1P and SPC are known regulators of cellular migration and af-
fect keratin 8 and 18 phosphorylation and network, but their effects on the vimen-
tin network are not known. Our aim was to examine how vimentin organization 
and ultimately cell migration via vimentin phosphorylation was affected by sphin-
golipid S1P and SPC signaling in primarily cancer cell models.
There is limited information about the effects of IFs on Notch signaling, even 
though Notch signaling and vimentin share several similar functions in cells. Our 
aim, initially, was to examine how vimentin-influenced Notch signaling from the 
ligand side of the signaling pathway, and ultimately how vimentin affects angio-
genesis via Notch ligand regulation.
Par-4 is a pro-apoptotic protein highly expressed in prostate cancer, which 
preferentially switches on apoptosis in cancer cell lines as compared to normal 
cells. CK2 also regulates apoptosis by inhibiting it, and is an important kinase in 
prostate cancer. Although these proteins affect the same processes in the same tis-
sue, how Par-4 signaling connects to CK2 signaling has not yet been described. 
There were potential conserved sites for CK2 phosphorylation in Par-4. Our aim 
was to describe how CK2 signaling affects Par-4 signaling and ultimately apoptosis 
by direct phosphorylation.
AATF is a transcription factor protein described as promoting proliferation 
and inducing cell cycle arrest. The function of AATF has not been defined widely 
under stress conditions. Our aim was to describe how AATF functions after UV 
stress, and ultimately to describe the mechanism by which AATF induces apopto-
sis after UV stress.
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EXPERIMENTAL PROCEDURES
More detailed information on the materials and methods used can be found 
in the original publications and manuscripts. Publications, where used, in paren-
theses.
1. Cell lines 
MEF vimentin -/- and wild-type (I-III)
MCF7 (I)
HeLa (I)
MDA-MB-435S (II)
C643 (II)
SW13 (II)
293 FLN1 (III)
3T3J (III)
HTC116 (IV)
PC3 (IV)
LnCap (IV)
PNT2C2 (IV)
PrEC (IV)
COS7 (IV)
HEK293 (V)
MEF c-Jun -/- and WT (V)
2. Plasmids
pcDNA4-vimentin (WT, S4A&D, S4,6A&D, S6A&D, S4,6,7,8,9A&D, S7,8,9A&D, 
S419A&D) (I)
pcmv-vimentin (WT, S38A&D, S50A&D, S55A&D, S71,72A&D, S429A&D, 
TS457,T458A&D) (I)
GST-Par-4 (Filhol et al., 2003)we fused its catalytic alpha and regulatory beta 
subunits with green fluorescent protein (GFP (IV)
GFP-CK2α & β (Filhol et al., 2003)we fused its catalytic alpha and regulatory beta 
subunits with green fluorescent protein (GFP (IV)
pcDNA3.1 TOPO GFP-Par-4 (124A223A, 124D,223D, 124A, 124D, 223A, 223D, 
123A), Flag or GFP rat Par-4 Δ124-332 (IV)
pcDNA3.1 Myc-Par-4 (WT, 231A, 231D) (IV)
GFP-AATF (V)
HA-c-Jun (Gal4-cJunwt, Gal4-cJunAA, Gal4-cJun-Δ) (Westermarck et al., 2002; 
Weiss et al., 2003) (V)
3. Antibodies
Vimentin (clone V9, Sigma-Aldrich) (I-III)
Vimentin (clone D21H3, Cell Signaling)  (I-III)
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Vimentin chicken polyclonal (Covance) (I-III)
Alexafluor488-conjugated phalloidin (Invitrogen) (I-II)
β-tubulin rabbit polyclonal (Abcam) (I)
Notch 1 (Cleaved-Val-1754 rabbit, Sigma Aldrich) (III) 
β-actin (rabbit, Cell Signaling Technology) (III)
Cleaved Notch1 (rabbit Val1744, Cell Signaling Technology) (III) 
CD31 (PECAM-1, BD Biosciences) (III)
Notch 1 (C20 rabbit, Santa Cruz Biotechnology) (III)
Jagged1 (rabbit 28H8, Cell Signaling Technology) (III)
Jagged1 (C20, Santa Cruz Biotechnology) (III)
Delta (C20 rabbit, Santa Cruz Biotechnology) (III)
Anti-Dll4 (rabbit) (Sigma-Aldrich) (III)
AATF (mouse, Santa Cruz Biotechnology) (V)
c-Jun (rabbit, Santa Cruz Biotechnology)  (V)
Nucleolin (rabbit, Santa Cruz Biotechnology) (V) 
c-Jun phS73 (rabbit, Cell Signaling Technology) (V)
actin (mouse, Sigma-Aldrich) (V)
phJNK (rabbit, Cell Signaling Technology) (V)
GFP (rabbit, Living Colors, Clontech) (V)
4. siRNAs
siControl 5’-CCUACAUCCCGAUCGAUGAUG(dTdT)-3’ (Högel et al., 2011) 
(II)
siS1P2 5’-CUACAAAGCCCACUACUUU(dTdT)-3’ (Högel et al., 2011) (II)
siCK2T (Thermo Fisher Scientific) (IV)
siPar-4T (Thermo Fisher Scientific) (IV)
siCK2AB (Ambion, Life Technologies) (IV)
siPar-4T (Thermo Fisher Scientific) (IV)
siPar-4sc (Santa Cruz, Tebu-Bio) (IV)
Scr siRNA fluorescently labeled with FAM (Santa Cruz) (IV)
AATF siRNA, scrambled siRNA (Qiagen) (V)
5. Complete methods list
Cell culture and treatments (I-V)
Plasmid constructs, molecular cloning and antibodies (I-V)
Transient transfections (I-V)
Microscopic analyses (I-V)
Immunofluorescence labeling (I-V)
Immunohistochemistry (III)
Confocal microscopy (I-V)
Colocalization analysis (III) 
Correlative electron microscopy (CLEM) and electron microscopy (I)
Fluorescence recovery after photobleaching (FRAP) analysis (II)
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Vesicle tracking (III)
Cell shape measurements (II)
Vimentin distribution analysis (I)
Fingerprint assay (III)
SDS-PAGE and western blotting (I-V)
Recombinant protein purification (IV)
Immunoprecipitation (IV-V)
Apoptosis assays (IV-V)
Caspase cleavage assay (IV)
Measure of CK2 activity (IV)
Measure of apoptosis and caspase-3 activity (IV)
UV irradiation and cell death analysis (V)
Phosphorylation assays (II, IV)
Tryptic digestion, two-dimensional separation and Edman degradation (IV)
In vitro kinase assay (IV)
Mass Spectrometry (II)
Intermediate filament solubility assays (I-II)
Sequential centrifugation (II)
Assay of vimentin subunit composition (I)
Crosslinking assay (I)
Triton X-100 extraction (I)
Migration assays (II)
Chemotactic migration with Boyden chambers (II)
Wound healing with Incucyte ZOOM (II)
Wound healing, single-cell motility imaging, and analysis with Cell-IQ (II)
Angiogenesis assays (III)
Aortic ring protocols (III) 
Aortic ring assay (III)
Vimentin Null Aortic Rings with Notch Ligands (III)
Quantification of Aortic Ring Sprouting Responses (III)
Immunostaining of Aortic Rings (III)
Chorion-allantois membrane (CAM) angiogenic assay (III)
3D Matrigel angiogenesis assay (III)
Surface protein detection by biotinylation (III)
Recycling assay (III)
Luciferase reporter assays (III-IV)
Activation of Notch signaling by immobilized recombinant Notch ligands (III)
Receptor binding and ligand trans-endocytosis (III)
Quantitative real-time PCR (III-IV)
6. Selected methods 
Some methods were used in more than one publication with slightly different 
protocols, but only one protocol is shown here. Methods that the author of this 
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thesis performed himself are preferentially shown here.
Methods that the author of this thesis performed himself for the publications:
I) Everything, except part of the cloning, epon block cutting, EM imaging and 
Suppl. Fig. 1B.
II) Fig. 2B, C (Cell shape measurements), Suppl. Fig. 2 (FRAP), Suppl. Movies 1,2 
(FRAP).
III) Fig. 5A, B, C (Vesicle tracking), Fig. 6A, B (Fingerprint assay), Suppl. Fig. 6A, 
B, C (Colocalization analysis), Suppl. Fig. 8 (tissue mRNA databank correla-
tion analysis).
IV) Fluorescence microscopy with Par-4 GFP constructs (with CK2a and TRAIL). 
Not in the publication.
V) Fig. 4D, E (Immunofluorescence).
6.1. Transient transfections (I-V)
Transient transfections for wild-type MEF and vimentin -/- MEF, MCF7, 
and HeLa cells were done with Lipofectamine LTX (Cat# 15338-100, Invitrogen, 
UK) according to the manufacturer’s instructions for MCF7, HeLa, and MEF cell 
lines. For solubility assay MEF vim-/- cells were transfected by electroporation in 
Optimem I (Cat# 31985-047, Invitrogen, UK). Electroporation settings were 300 
volts, 1,07 mF in a 400 µl cuvette with Gene Pulser II (Bio-Rad, UK).
6.2. Immunofluorescence (I-V)
I) Cells were grown on glass coverslips. Adhered cells were transfected as de-
scribed. Cells were fixed two days after transfection for five minutes with 3% PFA 
in PBS. Cells were stained with one of the following protocols: Protocol 1: cells 
were permeabilized with 0.1% Triton X-100 in PBS for five minutes at room tem-
perature (RT), blocked with 1% BSA in PBS for one hour at RT. Then, coverslips 
were incubated with primary antibody in 1% BSA in PBS for one hour, washed 
three times, for five minutes each in PBS, incubated for one hour at RT with sec-
ondary antibody, washed three times, for five minutes each in PBS, rinsed in dis-
tilled H2O and mounted with Mowiol mounting media. Protocol 2: Cells were 
incubated for five minutes in 100 mM glycine in PBS at RT, blocked with blocking 
buffer: 10% fecal calf serum (FCS), 0.2% saponin, 0.5% fish skin gelatin in PBS 
for one hour at RT, incubated with primary antibody in blocking buffer, rinsed 
three times in washing buffer (blocking buffer without serum), incubated with sec-
ondary antibody for 45 minutes in blocking buffer, rinsed three times in washing 
buffer and once in distilled H2O, finally and mounted on microscope slides with 
Mowiol mounting media.
6.3. Confocal microscopy (I-V)
Cells were imaged with Leica SP5 laser scanning confocal microscope (Leica; 
Wetzlar, Germany) using 60X /1.4 plan-apochromat oil immersion objective or 
Zeiss LSM510 META laser scanning microscope (Oberkochen, Germany). Cor-
relative electron microscopy samples were imaged with Zeiss LSM510 META laser 
scanning confocal microscope using 100X /1.4 plan-apochromat oil immersion 
objective. The widefield mCherry transfection images were acquired with Leica 
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DMRE 20x magnification objective.
6.4. SDS-PAGE and western blotting (I-V)
I, II) Cells were scraped from the cell culture plate with a rubber scraper or 
treated otherwise, as described earlier. All the samples were dissolved in laem-
mli buffer (4% SDS, 20% glycerol, 120 mM pH 6.8 Tris-HCl, 0.02% bromophenol 
blue) containing 3% mercaptoethanol. Samples were treated for five minutes at 
95 °C. Proteins were resolved by SDS–PAGE, and transferred to a nitrocellulose 
membrane (Protran nitrocellulose; Schleicher & Schuell, Dassel, Germany) using 
a wet transfer apparatus (GE Healthcare, USA). Membranes were blocked with 5% 
nonfat milk in PBS containing 0.3% Tween-20 for one hour at RT, and incubated 
overnight at 4 °C with primary antibody: vimentin (Cat# 5741, clone D21H3, Cell 
Signaling, USA). After washed three times, for five minutes each with PBS/0.3% 
Tween-20, membranes were probed with horseradish peroxidase–conjugated sec-
ondary antibodies purchased from Promega, Southern Biotechnology, and GE 
Healthcare. Proteins were visualized using the ECL detection kit (GE Healthcare, 
Amersham, Buckinghamshire, UK).
6.5. Correlative electron microscopy (CLEM) and electron micros-
copy (I)
Transiently transfected cells that were grown on plates with gridded glass bot-
tom (Cat# P35G-2-14-C-GRID, MatTek Corporation, Massachusetts, USA) were 
fixed in PBS with 3% PFA. Plates were washed briefly two times with PBS. Cells 
were immunostained corresponding to immunostaining protocol described above. 
After confocal microscope imaging and noting cell positions, cells were fixed in 
2.5% glutaraldehyde in cacodylate buffer (50 mM sodium cacodylate, 50 mM KCl, 
2.5 mM MgCl, pH 7.8). Then, plates were rinsed in cacodylate buffer and osmicat-
ed for one hour in cacodylate buffer with 1% OsO4. Plates were washed twice for 
three minutes each time in cacodylate buffer, and afterwards three times for five 
minutes each in distilled water. Then, samples were treated for one hour at 4°C 
with 1 % uranyl acetate, 0.3 M sucrose in distilled water. The plates were washed 
three times for three minutes each in distilled water. The plates were dehydrated 
in a 70 %, 96 %, and two times absolute ethanol series for one minute each. After 
this, almost all ethanol was removed, and some epon was dropped immediately 
onto the sample and the epon capsule put on top of the marked cells. Coverslips 
were incubated for two hours at room temperature and then baked for 14 hours 
at 60°C. Samples were transferred directly from oven to hot plate, and coverslips 
removed carefully. Samples were cut with a diamond microtome and previously 
confocal microscope imaged cells were imaged with an FEI Tecnai 12 transmission 
electron microscope. For pure electron microscopy samples, coverslips were used, 
and sample preparation was conducted as described for CLEM, with the exception 
of no immunostaining and confocal imaging done, and with sample preparation 
initiated from glutaraldehyde fixation. The dehydration step included a rinse in 
acetone at the end, and epon treatment was done on an aluminium planchette.
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6.6. Colocalization analysis (III)
For colocalization analysis MEF WT and vim-/- cells were seeded on 24-well 
plates with glass coverslips and transfected with Rab4-GFP or Rab11 constructs 
with Lipofectamine LTX according to the manufacturer’s instructions. Two days 
after transfection, cells were fixed and labeled according to immunofluorescence 
protocol. Samples were imaged with a Leica SP5 laser scanning confocal micro-
scope (Wetzlar, Germany) using 60X /1.4 plan-apochromat oil immersion objec-
tive. Colocalization analysis of jagged1 and Rab4 or Rab11 was done using the 
Fiji ImageJ software and associated plugins. 3072x3072 resolution images with 80 
nm pixel size were used for the analysis. The subtract background function was 
used with 200-pixel rolling ball radius for each image. Images showing colocal-
ization and Manders colocalization coefficients were calculated with Colocaliza-
tion Threshold. Pseudocolor images showing colocalization amounts were created 
from Colocalization Threshold colocalization images by removing green and red, 
transforming the image into grayscale and changing the look-up table to rainbow. 
Zero-zero pixels were not included in the threshold calculation. Pearsons colocal-
ization coefficients were calculated using the Colocalization Test.
6.7. Fluorescence recovery after photobleaching (FRAP) analysis (II)
II) FRAP was carried out with Zeiss 780 confocal microscope (Carl Zeiss AG; 
Jena, Germany) with 60x water immersion objective. 50,000 MDA-MB-435S cells 
were plated on each 35 mm glass-bottomed dish (MatTek Corporation; Ashland, 
MA, USA). Cells were transfected with the mCherry-vimentin WT construct the 
following day with Lipofectamine LTX (Life Technologies) according to the man-
ufacturer’s instructions. The next day, the cells were lipid-starved O/N. FRAP im-
aging was performed 48 hours post-transfection. Bar-shaped 2 µm wide regions 
were bleached, and recovery was imaged for 15 minutes at 30-second intervals. The 
FRAP-images were analyzed afterward with ImageJ (measurement of the intensity 
of the bleached spot and control area) followed by FCalc (fitting of the recovery 
curve and calculation of half-recovery and mobile fraction values). The analysis 
was done only for spots where individual filaments could be followed from start 
to finish, and the analysis region was moved over time, if cell or the analyzed in-
tracellular region moved uniformly. One function fit and correction for bleaching 
were used for FRAP calculation. The data for the recovery curves were normalized 
(deduction of background noise, normalization of all experiments to 0-1 scale). 
GraphPad Prism was used for the fitting of the exponential one-phase association 
recovery curve.
6.8. Vesicle tracking (III)
Immunofluorescence tracking of vesicles was performed on WT and KO 
MEFs. Cells were cultured in DMEM (Sigma-Aldrich, St Louis, MO). The media 
was supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine and 100 
units/ml both penicillin and streptomycin (all from Life Technologies, Carlsbad, 
CA). Jagged1 was over expressed in both cell types. 50,000 cells were plated onto 
35 mm glass-bottomed plates and transfected with Jagged1 after 24 hours using 
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Lipofectamine LTX according to the manufacturer’s instructions. Before labeling, 
human Alexa 488 secondary antibody was incubated with rN1ECD as described 
above, and the cells were simultaneously blocked with DMEM containing 10% 
goat serum and 1% BSA for 45 minutes at +37°C. Next, the cells were incubated for 
two hours at 37°C with medium containing the rN1ECD-Alexa 488 complex, to 
allow internalization. Culture media with the label was extracted and DMEM with 
supplements was added onto the cells. Alexa 488 signal from the brighter Jagged1 
overexpressing cells were imaged with Leica SP5 confocal microscope with 63x 
oil objective. Images taken were in 512x512 resolution at 600 ms time intervals. 
Images were analyzed with CellProfiler software with an LAP tracking algorithm. 
Statistics were further analyzed, and movement track-images were produced with 
R statistics software.
6.9. Cell shape measurements (II)
The C643 cells were labeled with CFSE CellTracker dye according to the manu-
facturer’s instructions prior to sphingolipid treatments. Cells were fixed, mounted, 
and entire cells were imaged with Leica SP5 or Zeiss LSM 780 confocal microscope 
with 20x air objective. For cell volume analysis with BioImageXD (Kankaanpää et 
al., 2012), images were converted to 512x512 resolution and stacks were segment-
ed, in order to identify individual cells and measure volumes. Objects with less 
than 500 voxels were removed from the analysis. To measure cell perimeter, 3D 
image stacks were made into maximum projections and cell perimeter was ana-
lyzed with CellProfiler (Carpenter et al., 2006).
6.10. Vimentin distribution analysis (I)
Image quantitation for filament mixing experiment in Fig. 3 was conducted 
with imageJ software. Cell areas where vimentin intensity in the cell was mea-
sured were labeled manually. Quantitation was initiated by turning images into 
8-bit grayscale images and auto thresholding them. Results for pseudocolor im-
ages were obtained using the following formula: P=(X/2+127)-(Y/2) where P is 
pixel intensity, X is green channel intensity (both vimentins), and Y is red channel 
intensity (human mutant vimentin). Results for histogram quantitation were cal-
culated from areas after auto thresholding with corresponding formula P=Y/X.
6.11. Fingerprint assay (III)
The 96-well glass-bottom microplates (Sensoplate, #655892, Greiner bio-one, 
Austria, Kremsmünster) were coated overnight at RT with 50 µg/ml protein G in 
PBS. Wells were washed three times with RT PBS. After this, the wells were blocked 
with 10 mg/ml BSA in PBS for one hour at RT. The wells were washed three times 
with PBS at RT. After this, the wells were incubated with 1 µg/ml NotchECD-FC 
in 0.1 % BSA in PBS for two hours at RT. Then, the wells were washed three times 
with PBS at RT. The wells were washed once in the cell culture medium. 10,000 
MEF WT of MEF vim-/- cells per well were plated. Cells were allowed to attach 
overnight. During the following day, the wells were washed three times in HBSS 
with magnesium and calcium. The wells were incubated with 3.3-dithio-bis-suc-
cinimidylproprionate at 37°C for 30 minutes in HBSS. The crosslinking reaction 
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was quenched with 50 mM Tris-HCl (pH 7.5) for 10 minutes. Cells were extracted 
with 0.1 % (w/v) SDS in PBS for five minutes at RT. The wells were washed with 
PBS. The wells were briefly rinsed with acetone, and then fixed for five minutes in 
acetone at RT. Then, the wells were washed three times in PBS at RT, and this was 
followed by immunofluorescence staining of jagged1 and NotchECD.
6.12. Assay of vimentin subunit composition (I)
The 150 mm plates of MEF vim-/- cells was transfected with vimentin mutants 
with electroporation. After two days, cells were scraped off into 200 µl IF fraction-
ation buffer per plate (pH 7.5, 25 mM HEPES, 100 mM NaCl, 5 mM MgCl2, 5 mM 
EGTA, 0.5% Triton X-100 with protease inhibitors). Lysis was continued on ice for 
30 minutes. Lysate fraction was collected, and the rest of the lysate was centrifuged 
in 15,000xG for 45 minutes at 4°C. Supernatant from centrifugation product is 
fractionated filament-fraction and pellet pellet-fraction (Eriksson et al., 2004b). 
Part of the fractionated filaments-fraction was further centrifuged in 200,000xG 
for 30 minutes at 4°C. Produced supernatant is soluble fraction, with only truly 
soluble vimentin subunits. Samples were analyzed by western blotting.
6.13. Statistical analyses (I-III)
Results are expressed as means±S.E.M. from at least three independent exper-
iments. Values were analyzed using the Student’s t-test, or one- or two-way ANO-
VA. Or, where appropriate, either Dunnett’s or Bonferroni’s post hoc tests were 
used for statistical analysis. All P-values were obtained using the two-tailed tests, 
and error bars in the graphs represent 95% confidence intervals. Quantitative data 
was analyzed using the GraphPad Prism program (La Jolla, CA, USA). Blots were 
treated by Photoshop (San Jose, CA, USA) and quantified by ImageJ (Bethesda, 
MD, USA). Statistical significance, P<0.05 and P<0.01, is denoted with single and 
double asterisks (* and **), respectively.
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RESULTS AND DISCUSSION
1. Vimentin phosphomutants (I)
Phosphorylation is the most important post-translational modification regu-
lating intermediate filament function. Our lab previously identified several serine 
and threonine phosphorylation interphase in vivo sites in vimentin. In the pre-
vious study, the in vivo sites were identified in baby hamster kidney (BHK-21) 
cells during interphase under Calyculin A (serine/threonine phosphatase inhibi-
tor) treatment. It was observed that the phosphorylation-induced disassembly did 
not affect which sites were phosphorylated, but only the extent of phosphoryla-
tion of all the sites. Hamster vimentin sequence is very close to human vimentin 
(Eriksson et al., 2004a; Kochin et al., 2006). Our goal, which had already been set 
before the author arrived at the laboratory, was to create phospho-mimicking and 
phospho-deficient point mutations of these sites, and to study the structural and 
functional effects of blocked or constantly activated phosphorylation of single sites 
or small phosphorylation clusters.
Fig. 10: Created phospho-deficient and phospho-mimicking mutants of vimentin 
(blue) and observed vimentin in vivo serine/threonine phosphorylation sites (red).
In this technique, phosphorylated amino acid residues (serine or threonine in 
this case) are mutated to similar residues that do not become phosphorylated in 
live cells (e.g. serine to alanine), or to residues that mimic the phosphorylated state 
of a phosphorylated residue most closely (e.g., serine to aspartic acid or glutamic 
acid). Generally, mutated proteins in which the phosphorylation of certain resi-
dues is blocked function similarly as wild-type protein with the unphosphorylated 
state of this residue. However, mutations that mimick phosphorylated state of a 
residue can in some cases function similarly as the wild-type with the phosphor-
ylated state of this residue, but in some cases very differently. The reason for this 
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is, specifically, the different charge of aspartic or glutamic acid compared to phos-
phorylated serine or threonine (-1 versus -2), and slightly different structure. Also, 
many phosphorylation sites typically have a low amount of phosphorylation in 
cells, so having a mutant where a certain residue in every molecule is in the phos-
phorylated state may yield different results than normal quantities of phosphoryla-
tion (Dephoure et al., 2013; Paleologou et al., 2008). Also, the mutation of multiple 
adjacent sites together with some mutants in this study increases the probability 
that phosphomimicking or phosphodeficient mutants do not produce the same 
effects as the real mimicked structures and produces a some doubt to reliability of 
many of the findings.
The problem for functional studies with our created vectors was that the ex-
pression levels were very variable and typically low, even after transfection optimi-
zation in vimentin negative MEF and MCF7 cell lines. The expression problems 
made a functional comparison of vimentin phosphomutants difficult. Overexpres-
sion screening in mammalian cells in the cell lines, which are not the most easily 
transfectable, have been done with virus vectors (Arnoldo et al., 2014; Škalamera 
et al., 2011). Virus vector choice was, however, rejected. Because of the expression 
problems, analysis of the vimentin phosphomutants was mostly limited to meth-
ods, where the whole cell population was not analyzed.
1.1. Vimentin N-terminal serines 7, 8, and 9, and serines 71 and 72 
are the key phosphorylation sites affecting vimentin organization
We did an immunofluorescence analysis of vimentin phosphomutants trans-
fected to endogenously vimentin negative MCF7 breast cancer cells. Of all the 
phosphorylation site mutations observed, the most dramatic effects on vimentin 
structure were caused by phospho-mimicking and phospho-deficient mutations 
of vimentin N-terminal serine cluster and phospho-deficient mutations of ser-
ines S71 and 72. No clear changes in vimentin phenotype with vimentin S38, S55, 
S419, S429, and TS457,458 alanine and aspartate and S71,72 aspartate mutations 
were observed (not shown). However, vimentin S38D, S55D, and S71,72D mutants 
exhibited a rare (under 1% of transfected cells) phenotype with some aggregates 
and network disruption (not shown). We observed that vimentin S4,6,7,8,9A and 
S4,6,7,8,9D mutants completely and S71,72A partially disassembled vimentin net-
work (and later described partial mutations of these sites usually had similar ef-
fects), indicating that these are the phosphorylation sites with the strongest effect 
on vimentin structure. The large majority of other sites did not have observable 
structural effects (I Fig. 2).
Vimentin S4,6,7,8,9D mutant had only soluble vimentin in about 60% of the 
transfected cells (quantitated later), while the other transfected cells also had 
round aggregates from small to massive, and often radially distributed (I Fig. 2, 
3C). 3D-projection showed soluble vimentin distribution better (I Fig. 3B).
Vimentin S4,6,7,8,9A produced smaller, brightly stained, round aggregates 
nearer to the center of the cell. Some cells had thick, sparse, filamentous structures 
instead (I Fig. 2). With stimulated emission depletion (STED) imaging, which al-
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lows immunofluorescence imaging up to 50 nm resolution with the microscope 
we used, we discovered that some cells had some normal-looking filaments con-
nected to aggregates (I Fig. 3A).
Vimentin S71,72A mutant disassembled vimentin completely into aggregates 
in some cells, and some had an almost intact filamentous network. Aggregates 
produced by S71,72A mutant were more indeterminate in shape, varied in size, 
and usually filled the entire cytoplasm (I Fig. 2, 3A).
We did partial mutations of N-terminal serine cluster and observed that S7,8,9A 
and D exhibited corresponding phenotypes as S4,6,7,8,9A and D. Vimentin 
S4A&D, S6A&D and S4,6A&D had normal vimentin networks, but with vimentin 
S6D and S4,6D part of the transfected cells had aggregates in addition to the fila-
mentous network (I Fig. 2, 3C). We quantitated the amount of aggregate-contain-
ing cells in transfected cells and discovered that vimentin S7,8,9D and S4,6,7,8,9D 
had both aggregates in about 40% of transfected cells, while S6D and S4,6D had 
aggregates in about 10% (I Fig. 3C). Results indicate that phosphorylation state 
of vimentin S7, 8 and/or 9 have (at least when taken together) a significant effect 
on vimentin structure, while S6 alone has a minor effect, and phosphorylation of 
S4 has no observable effect. The intracellular expression level of a protein is likely 
to increase aggregation when the protein is expressed over its natural expression 
level (Tartaglia et al., 2007). Transfected plasmid amount had a significant effect 
on aggregate formation frequency, suggesting that higher expression level inside 
the cells produces aggregates more frequently (I Fig. 3 D). This may indicate that 
in normal expression levels and phosphorylation amounts phosphorylation of vi-
mentin S4,6,7,8,9D is likely to produce fewer aggregates or may not produce ag-
gregates at all and that there is likely a threshold of vimentin concentration, above 
which aggregates start to form.
We transfected the mutants with phenotypic changes to HeLa cells to deter-
mine if the effects were dominant. When we imaged fluorescently labeled mutants 
in HeLa cells with existing endogenous vimentin, we observed major vimentin 
network disruptions with vimentin S4,6,7,8,9A and D, and S71,72A mutants, in-
dicating the effects were dominant. Produced phenotypes were similar to mutant 
phenotypes observed in MCF7 cells. Most of the endogenous vimentin collapsed 
in cells in which aggregates were observed (I Fig. 3E). Endogenous vimentin col-
lapse suggests that only a fraction of vimentin with certain phosphorylation state 
in these dominant sites may affect the whole network. Vimentin S6D mutant did 
not show aggregates and did not have a dominant effect (not shown).
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Vimentin 
mutant
Aggregates in 
% transfected 
Filament 
disruption
Phenotype 
dominance
Normal 
phenotype
S4A No X
S4D No X
S6A No X
S6D 10 No No
S4,6A No X
S4,6D 10  No  No
S7,8,9A 100 Complete Partial
S7,8,9D 40 Complete Partial
S4,6,7,8,9A 100 Complete Partial
S4,6,7,8,9D 40 Complete Partial
S38A No X
S38D  <1 No  No
S50A No X
S50D No X
S55A No X
S55D  <1 No No
S71,72A 30 Partial Partial
S71,72D  <1 No  No
S419A No X
S419D No X
S429A No X
S429D No X
TS457,458AA No X
TS457,458DD No X
Table 5: Observed vimentin phosphomutant phenotypes.
The most striking phosphomutant phenotypes were produced by mutations of 
vimentin S7, 8 and 9. Vimentin S8 and 9 belong to nonapeptide motif SSYRRIF-
GG of vimentin (amino acids 8-16). This motif is critical for tetramer assembly 
into higher vimentin structures. Desmin has a similar motif (Gohara et al., 2008; 
Herrmann et al., 1992). Many of the residues in this motif are crucial for filament 
formation. The end serines can be removed without breaking filaments, but the 
role of phosphorylation of the serines is still unclear (Beuttenmüller et al., 1994; 
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Gohara et al., 2008; Herrmann et al., 1992). Desmin S13, which corresponds to 
vimentin S9 in the conserved nonapeptide sequence, has been observed to accu-
mulate desmin and cause desmin myopathy when mutated to F. Since vimentin 
S7,8,9D accumulates similarly, vimentin S9 would be a good candidate to be a 
major effector in our observed vimentin phosphomutant phenotypes (Pica et al., 
2008; van Tintelen et al., 2009). Serine 9 has been observed to be partially phos-
phorylated in interphase and highly phosphorylated by PKC in vitro, and S6 and 8 
are also PKC targets (Eriksson et al., 2004, Geisler et al., 1989; Inagaki et al., 1997). 
Vimentin serine 9 A and D mutants and possibly antibody against phosphorylated 
vimentin serine 9 (there is already phospho-vimentin S6 available) would provide 
good tools to study the mechanisms of phosphorylation of this cluster further, if 
deemed important enough.
In vitro vimentin can assemble without post-translational modifications (Ip et 
al., 1985). Our results indicate that in vivo phosphorylation (or other modifica-
tions) at vimentin S7,8,9 may be needed to stabilize vimentin in cell models. This 
observation is very likely not caused by the structural difference between serine 
and alanine, but likely by lack of phosphorylation, since phenotype corresponding 
to vimentin S7,8,9A had been observed with wild-type vimentin with PKC inhi-
bition and vimentin S4,6,7,8,9A (Ivaska et al., 2005a). We also observed vimen-
tin S4,6,7,8,9A to have a few complete filaments, although most of the vimentin 
were collapsed, suggesting that vimentin S4,6,7,8,9A mutant is capable of forming 
filaments. If in vitro assembly of vimentin S4,6,7,8,9A were comparable to WT, 
this would provide even stronger proof that in cells, for extensive vimentin net-
works to form, some phosphorylation of vimentin S4,6,7,8,9 is needed. Because 
S4,6,7,8,9 are not very highly phosphorylated during interphase (Eriksson et al., 
2004a; Kochin et al., 2006; Snider and Omary, 2014a), only a fraction of S7,8,9 may 
have to be phosphorylated in order to stabilize vimentin structure. Earlier zinc 
ions have been observed to stabilize vimentin structure through vimentin C328 in 
living cells (Pérez-Sala et al., 2015).
Vimentin residues 40-95 or 25-38 are not needed for filament formation, and 
the middle section of the vimentin head has been hypothesized as forming a pro-
truding loop (Shoeman et al., 2002). Therefore, changed interaction to a stabilizing 
protein, and not to the filament structure itself, may explain our observation of 
filament disruption by S71,72A mutant and is an interesting open question.
1.2. Vimentin phosphorylation does not affect vimentin distribution 
within endogenous network
We tested if mutant vimentins distribute differently than endogenous vimentin. 
We conducted the test using untagged human constructs in MEF cells by staining 
with an antibody that stains only human vimentin, and an antibody that stains 
both human and mouse vimentins, and then used image analysis to calculate the 
signal ratios of different antibodies in various parts of the cell. No clear changes 
in vimentin phenotype with vimentin WT, S38, S55, S419, S429 or TS457,458 ala-
nine or aspartate or with S71,72 aspartate mutations were observed (I Fig. 4A, not 
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shown). The observed minor changes in mutant versus EG&mutant signal ratios 
(for example WT pseudocolor image in I Fig. 4A) are reasonably explained by the 
lack of sensitivity of the method. We discovered that aggregates of vimentin S4, 6, 
7, 8, 9D or vimentin S71, 72A contained comparably more human vimentin than 
vimentin S4, 6, 7, 8, 9A mutant. This may indicate a weaker interaction between 
mutant and wild-type vimentin. Otherwise, there were no clear differences in the 
network distribution between endogenous and mutant vimentins in any of the 
mutants (I Fig. 4A, B, not shown). Quantitation of more cells per sample would 
bring more confidence to the result, since only a few cells (5 spots/cell) were quan-
titated. Our results indicate that phosphorylation of individual sites does not cre-
ate preferences for vimentin localization inside the cells (other than solubility) or 
affect vimentin distribution inside the existing vimentin network.
1.3. Aberrant vimentin phosphorylation may lead to aggregation
To determine what the observed structures were, we conducted correlative 
light electron microscopy (CLEM) with assembly-disrupting mutations. We found 
out that the abnormal structures caused by vimentin S4,6,7,8,9A and D, S71,72A 
and S6D mutants were aggregates of slightly different morphology (I Fig. 6A, B). 
We quantitated the textures of the aggregates. We discovered that, for example, the 
SumAverage texture measure was significantly different in vimentin S4,6,7,8,9D 
aggregates than in aggregates caused by other mutants. The SumAverage measure 
is not directly transferable to human perception, but coarseness of the texture, for 
example, has an effect on the value (Haralick et al., 1973). The result highlights the 
major effect of the phosphorylated form of vimentin S4,6,7,8,9 has on vimentin 
structure compared to the unphosphorylated form. When we saw the large vesicu-
lar-like structures, our initial thought was that they were vesicles. It appeared likely 
that vimentin antibody did not penetrate larger aggregates, and only the surface 
was stained. We found structures colocalizing with various endosomal Rab-GFP 
markers, but CLEM confirmed that GFP in the endosomal constructs was accu-
mulating inside aggregates (not shown). The result nevertheless indicates that the 
aggregates do not consist solely of vimentin.
Aberrant phosphorylation of IFs are related to aggregate formation, but which 
of these is the causative factor is not clear (Dale and Garcia, 2012; Negron and 
Eckert, 2000; Snider and Omary, 2014a). Heavy vimentin aggregation has been 
shown to cause cataracts and aggregated vimentin has been observed for example 
in giant axonal neuropathy patients cells (Bornheim et al., 2008; Bousquet et al., 
1996; Müller et al., 2009; Schietke et al., 2006). Our results indicate that aberrant 
phosphorylation of vimentin at specific sites may be able to cause aggregation, but 
an open question does these situations arise in live cells. 
1.4. Phosphorylation of vimentin N-terminal serine cluster affects vi-
mentin cytoskeletal associations
Since aggregate localizations of described vimentin phosphomutants were 
different, we conducted immunofluorescence analysis to determine if their as-
sociations with other cytoskeletal components – actin and microtubules – were 
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different. Actin and microtubules, along with IFs, are the main proteins affecting 
localization of molecules and structures inside cells. Vimentin S4,6,7,8,9D mu-
tant aggregates colocalized more with actin (on the cell edges) and microtubules 
(around larger aggregates) than with vimentin S4,6,7,8,9A mutant, indicating that 
phosphorylation of these sites may have effects on vimentin cytoskeletal interac-
tions (I Fig. 5A, B). This observation would have also benefited from quantitati-
on, since only some of the vimentin S4,6,7,8,9D aggregates were clearly covered 
with microtubules and only some of the vimentin S4,6,7,8,9D in the cell edges was 
clearly colocalizing with actin.
Vimentin links to myosin 10, kinesin, and dynein, of which, for example, myo-
sin 10 has also been associated with integrin trafficking and migration, similarly 
as vimentin S4,6,7,8,9 phosphorylation (Barberis et al., 2009; Helfand et al., 2002; 
Ivaska et al., 2005a; Menko et al., 2014; Prahlad et al., 1998; Zhang et al., 2004). 
Unstructured vimentin is localized via microtubule networks, and soluble vimen-
tin affects the transport of, for example, phosphorylated ERK and the transport of 
vesicles via multiple connections (Helfand et al., 2002; Margiotta and Bucci, 2016; 
Menko et al., 2014; Prahlad et al., 1998). The localization differences and observed 
effects of vimentin S4,6,7,8,9A and D on microtubule and actin association may 
be related to solubilized vimentin transport via microtubule and actin networks, 
and changed associations to cytoskeleton-associated motor proteins. Myosin 10 
and 9 interaction of vimentin S4,6,7,8,9D was also suggested by our preliminary 
mass-spectrometry identification, which however could not be confirmed.
1.5. Vimentin serines 6,7,8,9 controls vimentin solubility with thresh-
old mechanism
Since we observed unstructured, likely soluble, vimentin with vimentin 
S4,6,7,8,9D and S7,8,9D mutants in immunofluorescence images (I Fig. 2, 3B), we 
performed solubility assays to prove the increased solubility. We did Triton X-100 
extraction and solubility assays to test detergent solubility. We noted that aggre-
gates formed by mutants were not detergent-soluble, but S6D mutant produced 
more a fragmented network than WT, indicating increased solubility (I Fig. 7A). 
To obtain more quantitative results, we performed solubility assay with centrifu-
gal fractionation, separating lysates into fractions containing vimentin in different 
forms: soluble (supernatant from 200000*g centrifugation), fragmented filaments 
and soluble subunits (supernatant from 15000*g centrifugation), and full filaments 
(pellet from 15000*g centrifugation). Results indicate that vimentin S4,6,7,8,9D 
mutant caused a major solubility increase compared to wild-type, and S6D caused 
a minor solubility increase. Vimentin S4,6,7,8,9A had less fragmented filaments 
than WT (I Fig. 7B). We conducted crosslinking assay with glutaraldehyde from 
the vimentin S4,6,7,8,9D soluble fraction. It proved identical to control, which had 
vimentin solubilized mainly to tetrameric form with calyculin A-treatment from 
HeLa cells (I Fig. 7C). Observations indicate that vimentin S4,6,7,8,9D soluble 
fraction is mainly in tetrameric formation.
Formation of higher than soluble tetramer vimentin structures needs vimentin 
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head domain interaction with helix 2B at the carboxyl end of the rod domain. 
Phosphorylation of vimentin (by PKA) can disrupt this interaction (Gohara et 
al., 2001). Vimentin head also interacts with rod domain helix 1A (Aziz et al., 
2009). Interacting locations in the head domain are not known, but nonapeptide 
motif has been hypothesized to interact with one of these sites likely by having 
anionic rod domain parts binding to cationic arginines in vimentin (Gohara et al., 
2008). Phosphorylation of vimentin does not affect head-rod 1A interaction (Aziz 
et al., 2009). Logically, combined with our observation, it is likely that phosphor-
ylationof vimentin S7,8,9, by introducing repelling anionic molecules, breaks the 
head domain interaction with rod domain 2B, although direct interaction studies 
would be needed to confirm this. Also, it is an open question if the disassembly of 
vimentin by S7,8,9A-mutant could be caused by lack of binding dynamics or too 
tight binding to 2B-domain. A hypothesised model of vimentin N-terminal serine 
cluster phosphorylation function is proposed in Fig. 11.
Phosphorylation of vimentin S4,6,7,8,9 increases integrin recycling (via endo-
some regulation), which is active in directional motility, and transmigration (Bar-
beris et al., 2009; Ivaska et al., 2005a). Serine 6 was more enriched in vimentin 
pool dissociating from PKCε-containing vesicles, and therefore was speculated to 
have an effect on vimentin disassembly (Ivaska et al., 2005a). In this previous study 
conducted by Ivaska et al., vimentin S4,6,7,8,9D was observed to have normal, fil-
amentous, phenotype, vimentin S4,6,7,8,9A had a similar phenotype to our study 
and no solubility differences with vimentin S4,6,7,8,9A or D were observed (Ivaska 
et al., 2005a). These observations were from PKCε-reconstituted MEFs (our from 
MCF7s without endogenous vimentin). The results may indicate that endogenous 
vimentin negates the solubility difference, and PKCε-overexpression may rescue 
vimentin S4,6,7,8,9D aggregate-phenotype or, for example, expression levels were 
lower and cells with aggregate-phenotypes were not shown due to lower amounts 
of these. 
In an earlier article from our lab, we noticed that PKA phosphorylation of 
vimentin at serines 38 and 72 increases vimentin solubility by transforming vi-
mentin tetramers to higher off-rate in association with filamentous network, and 
predisposes further vimentin phosphorylation at S4,6,7,8,9. Also, part of vimentin 
had high phosphorylation at S4,6,7,8,9, and these serines had complex phosphor-
ylation patterns (Eriksson et al., 2004a). Our results show that vimentin S(6,)7,8,9 
are likely more critical to solubility than than S38 and 72 based on observed phe-
notypes. S38 and 72 phosphorylation may allow more S4,6,7,8,9 to be phosphor-
ylated possibly by making easier for nonapeptide motif to detach from the rod 
domain and allowing kinases to act on it leading to further solubility. Vimentin 
S7,8,9 have not been identified as mitotic phosphorylation sites (Matsuyama et al., 
2013), indicating that S7,8,9 are not critical for the solubilization of vimentin, at 
least during mitosis.
Serine and threonine phosphorylation sites are often found in clusters and these 
often interact with each other. Also, one kinase often phosphorylates more than one 
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clustered phosphorylation sites and the phosphorylation sites often interact with 
each other (Schweiger and Linial, 2010). Phosphorylation clusters tend to exhibit 
threshold-like behaviour instead of switch-like. In threshold-like behaviour  above 
certain threshold of phosphorylation effect may switch to completely active or more 
often increase gradually  (Gunawardena, 2005). Based on our results, vimentin 
N-terminal serine cluster seems to exhibit gradual threshold-like behaviour, since 
at least two phosphorylation sites regulate solubility (and produce aggregation). 
On the other hand, phosphorylation of S7,8, and 9 seems to produce switch-like 
behaviour (although this may be caused by threshold-like behaviour of the three 
phosphorylation sites) with complete filament breakdown and scattered phenotype 
and molecules, which spend large majority of time not connected to the network. 
Fig 11. Hypothesized model for vimentin solubilization by phosphorylation, based 
on previous knowledge and our results. Some phosphorylation of vimentin S(6,)7,8,9 
head domain may be needed for filament stabilization, but in higher amounts 
S(6,)7,8,9 phosphorylation may disturb intermolecular vimentin head-rod 2B do-
main interaction, heavily limiting vimentin mostly to tetrameric state. Phosphoryla-
tion sites further in the head domain have a lesser solubilization effect.
In summary, our results of human vimentin mutant phenotypes suggest that 
at least in MCF7 and MEF cells: 1) Vimentin S71 and/or S72, vimentin S6, and 
most critically vimentin S7, S8 and/or S9 are the only phosphorylation sites in 
which phosphorylation state observably affects vimentin structure; 2) Some phos-
phorylation of vimentin S7,8 and/or 9, and less critically of S71 and/or 72 may 
be needed for normal assembly of vimentin in live cells; 3) Phosphorylation of 
vimentin S6,7,8 and/or 9 may be a major regulator of vimentin solubility with 
gradual threshold mechanism of multiple sites, and, based on earlier research also, 
is hypothesized to disrupt vimentin head connection to the rod domain helix 2B; 
4) Aberrant phosphorylation of vimentin S6,7,8 and/or 9, and S71 and/or 72 may 
cause vimentin aggregation; 5) Vimentin S4,6,7,8,9 D-mutant aggregates colocal-
ize more than corresponding A-mutant with actin and microtubules in specific lo-
cations, suggesting that phosphorylation of these sites may also affect associations 
with other cytoskeleton.
The results suggest that phosphorylation of vimentin serines 6,7,8,9 may be a 
critical regulator of vimentin structure in interphase cells and would be interesting 
to study further, for example, during major restructuring events in interphase or, 
possibly, as a vimentin population with separate functions.
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2. Sphingolipids regulate vimentin assembly and migra-
tory properties (II)
2.1. Sphingolipids regulate vimentin organization
The initial result for this project occurred when another lab in our department 
accidentally noticed a change in vimentin solubility with sphingolipid treatment. 
Sequential fractionation confirmed this, and immunofluorescence images showed 
a vimentin restructuring into the perinuclear space (II Fig. 2A). FRAP analysis 
showed a decrease in the vimentin subunit exchange rate with S1P treatment (not 
shown).
This phenomenon was tested in three cell lines and was consistent in all of 
them. Only the time frame for vimentin restructuring was different. We continued 
to use C643 thyroid carcinoma cell line and MDA-MB-435S breast cancer cell line. 
Typical physiological concentrations of S1P and SPC are 10-100 nM. Concentra-
tions we used were optimized for the lowest concentrations showing the effect. We 
also observed cell shape changes with both cell lines after SPC and S1P treatment 
(II Fig. 2A, B, not shown). C643 cell volume and circumference both decreased 
after S1P and SPC treatment (II Fig. 2B, C).
2.2. S1P and SPC inhibit migration through vimentin serine 71 phos-
phorylation
We conducted mass spectrometry to identify which sites of vimentin become 
phosphorylated with S1P and SPC treatment. Results showed that vimentin ser-
ines 38, 41, and 71 became phosphorylated (II Fig. 1D, not shown). From these, we 
tested 38 and 71, since we had phosphorylation-specific antibodies for those sites. 
We were able to confirm an increase in serine 71 phosphorylation most clearly 
with an increase by approximately three times with S1P, and 1.5 times with SPC 
treatment (II Fig. 1E&F). We concentrated on the S71 phosphorylation site.
Sphingolipids and vimentin are both regulators of migration. First, we tested 
to determine if SPC and S1P affect C643 and MDA-MB-435S migration. We ob-
served 80-90% inhibition in migration with both cell lines with both treatments (II 
Fig. 1A&B). We also tested to determine whether migration effect of SPC and S1P 
occurs via vimentin in vimentin wild-type and vimentin knockout MEFs. SPC and 
S1P both had a non-significant effect on vimentin KO MEF migration, while WT 
MEF migration was significantly inhibited (II Fig. 6B).
We hypothesized regarding whether the phosphorylation of vimentin serine 
71 contributes to migration defect. We used mCherry-tagged vimentin S71A mu-
tant and vimentin WT and empty vector (EV) in the same backbone as controls. 
Filament formation of mCherry-vimentin was normal with endogenous vimentin 
background (not shown). We were able to rescue the SPC- and S1P-induced mi-
gration defect partially with vimentin S71A in Boyden chamber assay using MDA-
MB-435S cells (II Fig. 6D). The result indicates that vimentin serine 71 phosphor-
ylation regulates chemotactic migration. The reason for rescue being only partial 
may indicate that endogenous wild-type vimentin in the cells caused some migra-
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tory inhibition via S71 phosphorylation. Vimentin S71A somewhat increased cell 
migration without treatment when compared to WT vimentin. S1P and SPC treat-
ment also tend to round cells. Vimentin S71A mutant did not prevent this round-
ing in MDA-MB-435S cells (II Fig. 6F) indicating that vimentin S71 phosphoryla-
tion does not cause cell rounding. Also, WT MEF treatment caused vimentin S71 
phosphorylation, but not cell rounding. We also attempted wound healing assay 
with C643 cells and vimentin S71A mutation. The vimentin S71A mutant did not 
affect cell motility, and it did not rescue migration defect during S1P or SPC treat-
ments (not shown). In Boyden chamber, there is a serum gradient that induces 
chemotactic migration. The chemotactic gradient is not present in wound healing 
assay. The absence of the gradient may explain the difference, and suggests that 
vimentin phosphorylation affects chemotactic sensing in C643 cells. Adhesion re-
ceptor localization on the cell surface is known to be regulated by vimentin (Ivaska 
et al., 2007b). Our findings indicate that the organization of other receptors on the 
cell surface, especially those involved in chemotactic signaling, may be affected by 
vimentin phosphorylation. Single-cell motility analysis provided results that show 
a substantial decrease in cell movement caused by S1P and SPC (II Fig. 4D&E).
An earlier study indicates that keratin is a crucial component in cell round-
ing, which is induced by SPC (Beil et al., 2003). Sphingolipids, however, regulate 
many pathways that regulate actin polymerization and actomyosin contractility. 
Therefore, we used myosin IIA and IIB inhibitor blebbistatin to prevent actomy-
osin contractility. Blebbistatin rescued cell rounding effect induced by S1P and 
SPC (not shown). The rescue indicates that in our cell models, which are devoid of 
keratins, cell motility defects caused by S1P and SPC are dependent on both actin 
and vimentin.
2.3. S1P and SPC affect vimentin through the S1P2 receptor
Sphingolipids signal predominantly through G-coupled receptors S1PR1-5. 
S1PR2 is the most highly expressing receptor of these in MDA-MB-435S and C643 
cells (Balthasar et al., 2006). While, for example, S1PR1 and S1PR3 typically in-
duce migration, signaling via S1PR2 has been associated with migration inhibition 
(Adada et al., 2013b; Lepley et al., 2005). Therefore, we tested if S1PR2 inhibitor 
JTE013 would rescue sphingolipid-induced effects on migration, vimentin organi-
zation, and cell morphology. S1PR2 inhibition rescued cell velocities back to con-
trol levels (II Fig. 4D&E). Rac is a downstream signaling molecule of S1PR2 and is a 
major regulator of cell motility (Okamoto et al., 2000; Steffen et al., 2013; Sugimoto 
et al., 2003). S1PR2 has been shown to cause inhibition of Rac activation, explain-
ing the effect. S1PR2 inhibition also rescued vimentin morphology changes, cell 
rounding effect, and vimentin serine 71 phosphorylation (II Fig. 4A&B&C). These 
effects were also, importantly, rescued with S1PR2 downregulation. We conclude 
that S1P and SPC signal through S1PR2 to phosphorylate vimentin serine 71 in 
C643 and MDA-MB-435S cells.
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2.4. Vimentin serine 71 phosphorylation and sphingolipid effects on 
migration are prevented by Rho-associated kinase (ROCK)
ROCK has been shown to phosphorylate vimentin serine 71 in vitro. Also, in 
COS-7 cells, ROCK activation induces vimentin serine 71 phosphorylation (Goto 
et al., 1998). RhoA-ROCK-cascade is also known to be activated by sphingolipids, 
and is a regulator of cell migration (Lepley et al., 2005). We tested if sphingolipid 
affects vimentin serine 71 phosphorylation, cell morphology, and migration signals 
via ROCK, using ROCK inhibitor Y27632. Rock inhibitor rescued effects caused 
by S1P and SPC in all three cases (II Fig. 5A&B&C). ROCK has been associated in 
several studies as the only kinase that affects vimentin serine 71 phosphorylation. 
In one study, ROCK and vimentin have been shown to colocalize with vimentin, 
but when vimentin structure is disrupted, ROCK travels to the cell periphery. In 
this study, S1P was used as a ROCK activator, and it caused vimentin collapse and 
ROCK translocation to the cell periphery, although this was not studied in further 
detail (Sin et al., 1998).
Kinases, which phosphorylate certain amino acids, interact at least transiently 
with these sites. Therefore, in order to provide more evidence that ROCK would 
directly phosphorylate vimentin serine 71, we tried to analyze whether ROCK 
associates or interacts with vimentin. With immunofluorescence colocalization 
analysis we disovered that both SPC and S1P cause increased colocalization of 
ROCK with vimentin in C643 cells, particularly at the 30-minute time point. We 
checked if this was caused by cells shrinking and molecules coming closer to each 
other. After taking into account that cell volume does not decrease with SPC treat-
ment but decreases with S1P treatment, only one timepoint with SPC treatment 
seemed to reliably indicate increased colocalization (data not shown). We tried co-
IP, dot-blot assay, and proximity ligation assay to confirm the interaction, but with 
no success. Difficulties caused by vimentin becoming too insoluble after S1P and 
SPC treatment for immunoprecipitation, and perhaps interaction being too tran-
sient may have caused negative results. With a few attempts at proximity ligation 
assay, we were unable to eliminate the background signal sufficiently (not shown).
We did not examine how vimentin S71 phosphorylation inhibits migration. 
ROCK inhibits or induces migration context-dependently. The tissue-specific 
downstream signaling events of ROCK migration inhibition are not known (Wei 
et al., 2016c). Our results suggest that vimentin S71 phosphorylation is a key play-
er in downstream in ROCK inhibition of chemotactic migration. Vimentin is as-
sociated with chemotactic regulation (Eckes et al., 1998). It has been proposed 
that vimentin maintains the directionality of the migrating cell (Chernoivanenko 
et al., 2013). Vimentin disassembly can induce membrane ruffling and change of 
migration direction (Mendez et al., 2010). Our results propose that vimentin S71 
phosphorylation may be important for chemotactic migration.
Sphingolipids have varied signaling roles and usually pro-oncogenic effects. 
These effects signal mostly via five different G-protein-coupled S1P receptors. 
Among the identified downstream participants of S1P and SPC treatments are vi-
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mentin and keratin IFs, both of which dramatically reorganize after sphingolipid 
treatment. Sphingolipid-induced keratin network reorganization is crucially me-
diated by keratin phosphorylation (Beil et al., 2003; Busch et al., 2012; Park et al., 
2011). C643 and MDA-MB-435S cells do not express keratins and express desmin 
only weakly (not shown, (Alix-Panabières et al., 2009; Iyer et al., 2013; Sellappan 
et al., 2004)). Therefore, the observed effects of S1P and SPC through vimentin are 
not influenced by other IFs. Because both S1P and vimentin affect migration, we 
tested to determine if sphingolipid migration effect occurs via vimentin. We found 
that S1P and SPC have an effect on C643, and MDA-MB-435S cancer cell migra-
tion takes place in the following order: via an S1P2 receptor, ROCK activation, and 
finally phosphorylation of vimentin serine 71. Another effect of S1P and SPC was 
actin-dependent cell rounding, which may have an effect on migration. There are 
many missing details about the mechanisms by which vimentin affect migration. 
This study highlights one particular signaling pathway, where extracellular signal-
ing can affect IF organization and cell motility.
3. Vimentin regulates Notch signaling dynamics and de-
velopment of the embryonic vasculature (III)
Vimentin effect on Notch signaling is not known. Vimentin-deficient mice 
have a mild phenotype, but vimentin deficiency has been connected to defects in 
the modulation of vascular tuning and integrity, endothelial sprouting, flow-in-
duced arterial remodeling, wound healing, and fibroblast migration (Dave and 
Bayless, 2014b; Ivaska et al., 2007a). Similar phenotypes are linked to aberrant 
Notch signaling. Jagged1 (one of the ligands that can activate Notch) deficiency 
causes early mice embryos to die from hemorrhages. Notch antisense mice (which 
have, as a consequence, reduced levels of Notch) have delayed wound healing. 
Also, Jagged-ligand deregulation leads to a predisposition to vascular injuries and 
vascular remodeling in patients and mice with pulmonary hypertension (Hansson 
et al., 2010; Krebs et al., 2000; Limbourg et al., 2005; Lindner et al., 2001; Xue et 
al., 1999; Yamamura et al., 2014). Vimentin is a known regulator of focal adhesions 
and affects recycling of integrins. Vimentin is already known to regulate several 
surface molecules (Kidd et al., 2014; dos Santos et al., 2015; Virtakoivu et al., 2015; 
Vuoriluoto et al., 2011). Based on these studies, we hypothesized that vimentin 
also may have some effect on Notch signaling.
3.1. Vimentin affects Jagged1 localization, expression, and signaling
When we blotted for Notch ligands in vimentin positive and negative SW13 
adrenal carcinoma cells, we found that vimentin negative SW13s had manyfold 
expression of Jagged1 protein compared to vimentin positive cells (not shown). 
In vimentin-depleted HUVEC cells, Jagged1, and Notch1 intracellular domain 
(N1ICD), and less significantly Dll4, expression was elevated (III Fig. 2A). We dis-
covered that Jagged1 had accumulated on the surface of vimentin negative cells. 
Expression levels of Jagged1 were about equal in vimentin negative and positive 
satellite cells, and in MEFs, but in both vimentin negative SW13 and MEF cells we 
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observed Jagged1 surface accumulation (III Fig. 6A). Jagged1 mRNA levels were 
reduced in vimentin-deficient MEF cells (not shown).
We used Jagged1 fingerprint assay to test if Jagged1 was still binding to Notch 
receptors. In this assay, coverslips were coated with Notch1 extracellular domain 
(ECD) or control, cells were grown on the coated coverslips, and crosslinking 
agent was used to link Notch1 ECD to ligands. Cells were extracted with SDS de-
tergent, and the Jagged1 that was left on the coverslips was stained. Results showed 
that the Jagged1 levels bound to Notch1EC (III Fig. 6B&C) were somewhat similar 
to the surface levels of Jagged1 in vimentin negative versus positive MEFs (III Fig. 
6A). The ratio indicated that Jagged1 binding to Notch1EC was not significantly 
affected by the absence of vimentin.
3.2. Vimentin decreases Notch signaling activity
Next, we tested if vimentin-deficient cells have a distinct Notch signal-sending 
potential to adjacent cells. 293 HEK-cells with luciferase reporter system for quan-
titation of Notch signaling were co-cultured with vimentin positive or negative 
SW13 cells. Both short- and long-term Notch signaling potential was higher in vi-
mentin negative cells. However, when this higher signaling potential is compared 
to higher Jagged1-levels on the cell surface in vimentin negative cells, it is clear 
that only a fraction of Jagged1 is in active signaling state (III Fig. 7B). Jagged-me-
diated pulling force/Jagged1 surface expression ratio also indicated that Jagged1 
signaling is more efficient in vimentin-containing MEF cells (III Fig. 7C).
Next, we measured Notch1EC internalization. Extracellular Notch is usually 
internalized in the signal-sending cell. Soluble Notch1EC was conjugated to a fluo-
rophore and Notch1EC uptake was measured by FACS. In vimentin negative cells, 
we observed increased internalization of Notch1EC compared to wild-type cells 
(III Fig. 4 A). The comparably mild increase of internalization suggests that Not-
ch1EC ligand binding and internalization are not radically affected, despite the fact 
that Jagged1 levels on the surface are radically higher. Internalized Notch1EC-ves-
icles had a different distribution in vimentin negative cells. When Notch1EC was 
attached to beads in order to mimic mechanical strain caused by Notch1EC bind-
ing described as pulling force, no differences in Notch1EC internalization were 
detected, despite higher surface levels of Jagged1 in vimentin negative cells (not 
shown).
We analyzed the movement of Notch1ECD inside cells. We fed fluorophore-la-
beled Notch1ECD into vimentin WT and KO MEFs and imaged internalized 
Notch1ECD in live cells with a confocal microscope. The Notch1ECD-containing 
vesicle tracks were analyzed. We found that the linearity of the vesicle tracks was 
lower in vimentin KO cells, but the vesicle speeds were unchanged (III Fig. 5 E&F).
We tested recycling amount of Jagged1 with surface biotin labeling and strip-
ping. The small and similar amount of Jagged1 recycled in WT and vimentin KO 
MEFs, but Jagged1 recycling was faster in KO cells, indicating that vimentin may 
balance Jagged1 levels on the cell membrane. We did immunofluorescence colo-
calization analysis of Jagged1 with Rab4 and Rab11 recycling endosome GFP con-
82
structs and found that Jagged1 colocalizes less with both markers in vimentin KO 
cells (not shown). Lower colocalization indicates that Jagged1 may spend less time 
in recycling endosomes in KO cells and therefore recycles faster.
3.3. Vimentin phosphorylation potentiates Jagged-mediated Notch 
signaling activation
Phosphorylation of vimentin by PKC has been known to regulate intracellular 
trafficking. We observed that Jagged1 levels were decreased during PKC inhibition 
by BIM-I and increased during PKC activation by PMA in Jagged1 overexpressing 
3T3 mouse fibroblast cells (III Fig. 8A). This experiment could also be conducted 
with WT and vimentin KO cells to obtain stronger evidence of the vimentin-spec-
ificity of the effect. Pretreatment of 3T3J cells with PMA also increased Notch sig-
naling potential when 3T3J cells were co-cultured with 293FLN1 cells containing 
Notch activation luciferase reporter (III Fig. 8B). We used phospho-mimicking 
vimentin S4,6,7,8,9A and D mutants to determine the effects of these phosphor-
ylation sites on Notch signaling. We discovered that endocytosis of Notch1EC is 
enhanced in cells that contain the phospho-mimetic mutant, and both mutants 
slightly enhanced Notch activation in adjacent cells (III Fig. 8C&D).
Fringe is a significant regulator of Notch signaling. Fringe increases Dll-me-
diated signaling and decreases Jagged signaling to adjacent cells. We found that 
vimentin deficiency increased Fringe expression (not shown). The expression 
change indicates that vimentin-deficient cells favor Delta-like-mediated signaling 
instead of Jagged-mediated, possibly because of the effects vimentin has on Fringe 
expression.
Since Notch is a known angiogenic regulator and because vimentin has been 
associated with endothelial sprouting, we tested how vimentin and Notch inhi-
bition interact in the chorion allantois membrane (CAM) model (not shown). 
Vimentin inhibitor withaferin A (WFA) caused inhibition of new branching, but 
gamma-secretase inhibitor DAPT (which inhibits Notch signaling) caused new 
branches to form. Next, we tested the effects of Notch ligands and vimentin inhi-
bition in HUVEC sprouting assay (not shown). Bead-immobilized Notch ligands 
can activate Notch signaling. WFA inhibited tube sprouting substantially, but 
adding immobilized Jagged1- or Dll1-ligand rescued this effect (III Fig. 3B, not 
shown). This provides more evidence that vimentin mainly affects Notch signaling 
through Jagged1- or Dll1-ligands.
3.4. Deletion of vimentin delays angiogenesis in mice
Next, we tested if vimentin negative mice embryos and yolk-sac embody chang-
es in their vasculature. We used whole-mount immunostaining for PECAM-1. We 
found that vimentin negative embryos and surrounding yolk sacs at E11.5 have 
disturbed vascular patterning. Embryos had smaller blood vessels and less branch-
ing (III Fig 1A&B). This regression of vascular formation is similar to what has 
been reported in mice expressing non-functional Jagged1 ligands.
To further test the effect of vimentin on angiogenesis in mouse tissues, we did 
aortic rings assay with vim-/- and WT mice aortic rings embedded in a growth 
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factor-containing collagen matrix, which was optimized to induce sprouting. En-
dothelial sprouting response of aortic rings to VEGF was significantly weaker in 
vim-/- aortic rings than in WT (III Fig 1C). The number and length of sprouts 
were reduced, and sprouts were negative to endothelial cell markers PECAM-1 
and VE-cadherin (III Fig. 1c and not shown).
Vimentin is known to affect endothelial sprout initiation via MT1-MMP (Kwak 
et al., 2012), and also regulates growth factor-dependent endothelial cell invasion 
via FAK (known to be important in angiogenesis) activity by forming complexes 
with RACK1 and FAK (Dave et al., 2013; Tavora et al., 2010). Our results show that 
another way that vimentin affects angiogenesis is by balancing Notch signaling in 
sprouting angiogenesis.
Notch is known to interact with LAMP-1, and Notch receptor cleavage is fa-
cilitated on late endosomal/lysosomal membranes by their acidity (Sjöqvist et al., 
2014). Vimentin interacts with AP-3, a protein that regulates sorting of LAMP-1 
and -2 positive vesicles, and vimentin-influenced endosome/lysosome acidity (Po-
tokar et al., 2010; Styers et al., 2004). Therefore, vimentin depletion may enhance 
Notch processing in endo-lysosomal compartments. Protein trafficking is an im-
portant regulator of Notch signaling. Vimentin has multiple contacts to endocytic 
machinery, and the vimentin network may function as a passageway or barrier for 
vesicles. Our results show that Notch ligand endocytosis, recycling, routing, and 
movement is altered in vimentin-deficient cells. In summary, vimentin may func-
tion in Notch quality control in vesicles and/or the vimentin network may affect 
vesicle movements by steric hindrance. Jagged-mediated transactivation potential 
was impaired in vimentin-deficient cell. This may be caused by changes in actin 
polymerization-requiring pulling force. Pulling force may be affected by vimentin, 
since vimentin has been shown to be involved in cytoskeletal tension and integ-
rin-mediated mechanotransduction (Gregor et al., 2014). Vimentin is known to 
interact with membrane proteins through PDZ-domains (Phua et al., 2009) and 
Jagged1, Dll1, and Dll4 have possibly signaling-affecting PDZ-domains (Ascano et 
al., 2003; Kolev et al., 2005). However, we have not been able to confirm interac-
tion of vimentin with Notch ligands.
In summary, our results show that vimentin suppresses Notch signaling in en-
dothelial cells and enhances angiogenesis. Vimentin suppresses Dll4/Notch signal-
ing and enhances Jagged1/Notch transactivation potential. Jagged is an important 
regulator in angiogenesis, cancer, and regenerative processes in the brain. Our re-
sults show an important role for vimentin in Jagged modulation in angiogenesis 
and vascular integrity, highlighting Jagged as a potential therapeutic target in re-
generative and cancer settings.
4. Casein kinase 2 (CK2) regulation of prostate apoptosis 
response-4 (Par-4) pro-apoptotic functions (IV)
4.1. Par-4 is a substrate for CK2
Par-4 and CK2 regulate the same cellular function, apoptosis, but have op-
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posing effects on it. For both proteins, these effects are particularly prominent in 
prostate cancer. With the phosphorylation motif search program (http://scansite3.
mit.edu/) we discovered that Par-4 contains potential CK2 phosphorylation sites, 
which are evolutionarily conserved, and we hypothesized that CK2 may phos-
phorylate Par-4 in living cells.
Therefore, we studied whether Par-4 is a target for CK2. We did immunoprecip-
itation by co-transfecting GFP-tagged rat Par-4 and hemagglutinin (HA)-tagged 
CK2 subunits (CK2α and/or CK2β of human origin) to COS cells. Immunopre-
cipitation was done both ways by pulling GFP or HA tag from the solution. We 
found that Par-4 interacted specifically with CK2α subunit but not with CK2β (IV 
Fig. 1A&B). Similar interaction often occurs with CK2 substrates (Allende and 
Allende, 1995). With purified proteins, we determined that the interaction was 
direct (not shown).
Next, we determined whether CK2 could phosphorylate Par-4 in vitro. We did 
in vitro kinase assay with immunoprecipitated GFP-tag CK2α and CK2β subunits. 
or recombinant CK2 with human GFP-Par-4. We found that Par-4 is indeed a CK2 
kinase target (IV Fig. 1C). Catalytically inactive CK2β subunit was also (like with 
the majority of CK2 targets) required for Par-4 phosphorylation. Protein phos-
phatase 1 (PP1) is known to dephosphorylate some CK2 substrates (Popescu et al., 
2009). We tested whether PP1 can dephosphorylate CK2-phosphorylated Par-4 in 
vitro by using recombinant PP1 and phosphatase inhibitors, and found this was 
the case (not shown).
We wanted to identify the serine/threonine residues in Par-4, which CK2 can 
phosphorylate. To do this, we produced a tryptic phosphopeptide map of rat 
Par-4-GST, which was in vitro-phosphorylated beforehand by CK2. Three major 
CK2-specific 32P-labeled spots were identified from the analysis of a thin layer 
chromatography plate, wherein tryptic peptides were separated into two dimen-
sions (IV Fig. 2A). Matrix-assisted laser desorption/ionization-time-of-flight-
mass spectrometry (MALDI-TOF-MS) analysis of these spots, and later manual 
Edman degradation were performed to identify phosphorylated peptides. The re-
sults revealed that serines 124 and 223 are the target sites of CK2 phosphorylation 
in Par-4 (IV Table 1).
To determine whether Par-4 serines 124 and 223 have any functional relevance, 
we constructed phospho-deficient and phospho-mimicking GFP-tagged mutants 
of the following sites: GFP-Par-4 S124,223A, GFP-Par-4 S124,223D, and the cor-
responding single mutants of these sites. In vitro CK2 phosphorylation assay with 
GFP-Par-4 S124,223A revealed that the mutant Par-4 was not phosphorylated, in-
dicating that these sites were indeed CK2 targets. S124D and S223D single mutants 
both had decreased phosphorylation compared to Par-4 wild-type, indicating that 
these sites are both targeted by CK2 (IV Fig. 2B).
4.2. CK2 phosphorylation of Par-4 inhibits its pro-apoptotic func-
tions
Par-4 and CK2 are both regulators of anti-apoptotic NF-κB and pro-apoptotic 
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caspases, albeit in opposite ways (Chakraborty et al., 2001; Desagher et al., 2001; 
Nalca et al., 1999; Wang et al., 2006a). Therefore, we studied if Par-4 phosphomu-
tants had altered effects on these processes. We studied how Par-4 pro-apoptotic 
functions changed with these mutations in PC-3 cells. With luciferase reporter as-
say, which indicated NF-κB transcriptional activity, we found that Par-4 wild-type 
and S124,223A had an inhibitory effect on NF-κB transcriptional activity, while 
S124,223D had no effect (not shown).
Next, we studied how Par-4 S124,223D mutant performs when apoptosis is in-
duced in PC-3 prostate cancer cells with death ligand TRAIL or with chemother-
apeutic drug Paclitaxel. We found that the cells transfected with Par-4 S124,223D 
mutant were resistant to apoptosis while wild-type or S124,223A mutant sensitized 
the cells to apoptosis (IV Fig. 3A). Par-4 S124,223D mutant caused absence of 50-
kDa cleaved form of Par-4 (IV Fig. 3C). This cleaved form exists in human cells 
during apoptosis induced by cisplatin or Fas (Chaudhry et al., 2012; Leroy et al., 
2005). The results indicate that phosphorylation of CK2 phosphorylation sites on 
Par-4 protects from apoptosis. This suggests that CK2 may inhibit the pro-apop-
totic function of Par-4.
4.3. CK2 rat Par-4 S124 phosphorylation prevents Par-4 caspase 
cleavage and protects from apoptosis
In the pro-apoptotic functions of Par-4, Par-4 cleavage by caspases is a critical 
step. In humans, caspases cleave Par-4 to a fragment containing amino acids 132-
340, and in rats to Par-4 124-332. Cleaved forms have full pro-apoptotic functions. 
Included SAC (selective for apoptosis in cancer cells, amino acids 137-195) core 
domain is crucial for the pro-apoptotic functions. Par-4 S124 is close to D123, an 
ortholog of human Par-4 D131, which is a caspase cleavage site (Chaudhry et al., 
2012). Therefore, we tested whether rodent Par-4 S124 phosphorylation protects 
from caspase cleavage. We first confirmed that rodent Par-4 was also cleaved by 
caspases (IV Fig. 4A). Then, we used zVAD-FMK, a pan-inhibitor of caspases, to 
confirm that caspases caused the cleavage: there was no cleavage product with 
caspase inhibition (not shown). We then confirmed that Par-4 D123A (a potential 
rat caspase site) was not cleaved by caspases, and that this mutant also impaired 
Par-4 pro-apoptotic function like human equivalent Par-4 D131A had earlier been 
reported as doing (not shown).
Then, we tested whether CK2-mediated S124 phosphorylation regulates rat Par-
4 cleavage by in vitro caspase assay using recombinant caspases and Par-4 wild-
type and mutants. The assay showed that Par-4 wild-type, S124A, and S124,223A 
were cleaved by caspase-3 and caspase-8, but Par-4 S124D and S124,223D mutants 
were not. The results indicate that caspase cleavage is inhibited by S124 phosphor-
ylation (IV Fig. 4A&B). We confirmed the result using in vitro CK2-phosphorylat-
ed recombinant rat Par-4-GFP in in vitro caspase 3-assay and observed that CK2 
phosphorylated Par-4 was not cleaved (Fig. 4C). This effect was limited to rodent 
Par-4, because when we repeated the same assay with human Par-4, the Par-4 was 
cleaved.
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We observed that rat Par-4 S124D and D123A mutants both had the same ef-
fects on Par-4 pro-apoptotic function, indicating that in rat phosphorylation of 
Par-4 S124 inhibits Par-4 pro-apoptotic function by preventing caspase-mediated 
Par-4 cleavage (not shown). CK2 phosphorylation of Par-4 D131 does not affect 
Par-4 proteolytic cleavage in humans. Phosphorylation of Par-4 by CK2, therefore, 
seems to have different effects in different species. CK2 phosphorylation has also 
been shown to inhibit proteolytic cleavage of caspase-9 in rodent cells (McDon-
nell et al., 2008). Max, Bid, or caspase recruitment domain-containing apoptosis 
repressors are also targets of CK2 phosphorylation in both species. In these cases, 
CK2 phosphorylation also inhibits caspase cleavage, and with Bid prevents the 
creation of a pro-apoptotic cleaved product (Desagher et al., 2001; Krippner-Heid-
enreich et al., 2001). Therefore, the role of CK2 in inhibition of its substrates across 
species has different mechanisms, and these mechanisms are dependent on the 
species.
Par-4 caspase-cleaved form is known to have pro-apoptotic abilities (Chaudhry 
et al., 2012). Therefore, we tested if the caspase-cleaved fragment retained Par-4 
apoptotic properties. We observed that rat Par-4 (124-332) cleaved form caused 
cells to be even more sensitive to apoptosis induced by TRAIL than the full-length 
wild-type Par-4 (IV Fig. 4D).
Both normal and cancer cells can secrete Par-4 in cell cultures. Like intracellu-
lar Par-4, secreted Par-4 can also induce apoptosis in the surrounding cells by ac-
tivating caspases (Burikhanov et al., 2009). For this reason, we tested whether the 
cleaved form of Par-4 could be secreted. We transfected COS cells with GFP, GFP-
Par-4 wild-type, or Par-4 (124-332), and analyzed the cell media with western blot-
ting. We detected both wild-type Par-4 and Par-4 (124-332), but not GFP alone 
in the culture media (not shown). To study the function of the secreted forms, we 
added the concentrated media containing secreted Par-4 wild-type or Par-4 (124-
332) onto PC-3 cells in a culture medium for a 24 hour duration. We quantitat-
ed apoptosis and noticed that Par-4 (124-332) had a stronger apoptosis-inducing 
effect than wild-type Par-4 (not shown). According to our results, pro-apoptotic 
functions of rodent Par-4 are inhibited by CK2 through phosphorylation of Par-
4 S124. The mechanism for this effect is the prevention of the caspase cleavage. 
The apoptotic process may further be amplified by secreted caspase-cleaved Par-4, 
which produces a “bystander” effect that increases apoptosis of the nearby cells.
4.4. Human Par-4 S231 phosphorylation by CK2 protects prostate 
cancer cells from apoptosis
Sequence comparison between human and rodent Par-4 showed that in hu-
mans, S231 corresponds to the S223 phosphorylation site in rodents, but S124 did 
not have an ortholog. The S231/S223 site is conserved across species. In leukemia 
cell lines this site was detected in earlier mass spectrometry studies, suggesting 
that this site may have functional significance (www.phosphosite.com).
We performed in vitro kinase assay of CK2 with human Par-4 wild-type and 
Par-4 S231D. Par-4 S231D had less phosphorylation than wild-type, indicating 
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Par-4 S231 is a target site of CK2 (IV Fig. 5B).
We produced an antibody that recognizes the phosphorylated form of human 
Par-4 serine 231 to help characterize the function of the phosphorylation site. In 
western blot, prostate cancer PC-3 cell lysate displayed a band corresponding to 
phosphorylated Par-4 (IV Fig. 6A). When a blocking peptide was added, this band 
was not detected, indicating the specificity of the antibody. When PC-3 cells were 
treated with TRAIL, we detected an increase in the Par-4 S231 phosphorylation 
(IV Fig. 5C). We tested the effect of Par-4 S231 phosphorylation on apoptosis by 
transfecting HCT116 cells (which allow higher transfection efficiency than PC-3s) 
with Par-4 S231A or S231D, and used TRAIL to induce apoptosis. We observed 
that with the S231A mutant, the cells were sensitized to TRAIL, but with S231D 
mutant the cells were less sensitive to TRAIL. Apoptosis induction was detected 
with caspase-8, PARP-cleavage, and DAPI staining (IV Fig. 5D-F). The results in-
dicate that phosphorylation of Par-4 S231 by CK2 strongly (even more so than rat 
Par-4 S223 phosphorylation) reduces Par-4 apoptosis-inducing properties.
Increased CK2 activity has been observed in prostate cancer cells (Yenice et al., 
1994). Therefore, we tried to find a correlation between Par-4 phosphorylation and 
CK2 activity and expression in normal PrEC and PNT2C2 cells, and in PC-3 and 
LNCaP prostate cancer cells. We learned that the cancer cells had a higher Par-4 
phosphorylation at CK2 site Par-4 S231, and that cancer cells also had a higher 
CK2 activity (IV Fig. 6A). We used CK2 siRNA to study if CK2 depletion reduc-
es Par-4 S231 phosphorylation, and found that this was the case (Fig. 6B). Both 
the CK2 expression levels and the Par-4 S231 phosphorylation were about 50% 
reduced, suggesting a coordinated regulation. When CK2 inhibitor 4,5,6-tetrabro-
mobenzotriazole was used instead of siRNA, the results were similar (Ruzzene et 
al., 2002; Sarno et al., 2001). We did not describe the mechanism by which CK2 
phosphorylation of Par-4 S231 regulates apoptosis in this article. S231 is in the 
C-terminal domain of Par-4. Par-4 C-terminal domain is known to regulate inter-
actions between Par-4 and its partners, e.g. NF-κB and PKCζ. We hypothesize that 
phosphorylation of Par-4 S231 may affect these interactions.
Cells without CK2 are more prone to apoptosis (Di Maira et al., 2007; Izer-
adjene et al., 2004; Slaton et al., 2004; Wang et al., 2005). We tested whether the 
PC-3 cells become more apoptotic during TRAIL treatment when CK2 siRNAs 
are transfected to them. When both Par-4 and CK2 were downregulated, the PC-3 
cells again became more resistant to TRAIL-induced apoptosis (IV Fig. 7A-D). The 
results show that the phosphorylation of Par-4 and the inhibition of its pro-apop-
totic properties reside downstream from CK2 antiapoptotic signaling.
Our results indicate that in human prostate cancer cells Par-4 S231 has consid-
erably more phosphorylation than in normal prostate cells, suggesting that CK2 
phosphorylated Par-4 is potentially a biomarker for prostate cancer. The results 
also show that in prostate cancer cells CK2 has an antiapoptotic role via direct 
phosphorylation of Par-4, providing new significance for Par-4 as a key target for 
cancer therapeutics in prostate cancer.
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5. Nucleolar AATF regulates c-Jun-mediated apoptosis
5.1. AATF upregulates UV-mediated cell death
AATF has been shown to affect cell growth and proliferation by interacting 
directly with the survival machinery components (Bruno et al., 2006; Fanciulli et 
al., 2000). We investigated whether AATF produces a response when the cells are 
under stress. We tested whether AATF overexpression affects MEFs and HEK293 
(human embryonic kidney-derived cell line) cell response to UV irradiation. We 
found that AATF overexpression produces more detached and dead cells in re-
sponse to UV irradiation (IV Fig. 1A). To make these findings more convincing, 
we quantitated active caspase-3 in AATF-GFP or GFP-expressing cells with flow 
cytometry. AATF-GFP-expressing cells contained more active caspase-3, indicat-
ing that more apoptotic cells were present (V Fig. 1B). We also measured apoptosis 
with annexin-V and propidium iodide (PI) staining, which stain cells in the early 
and later stages of apoptosis. In AATF overexpressing cells, with PI staining we 
observed an increased amount of cells with lower than G1-phase DNA content 
(IV Fig. 1C). The western blotting analysis of active caspase-3 and cleaved PARP-
1 (caspase-3 substrate) showed the same results, indicating that AATF promotes 
UV-induced apoptosis (V Fig. 1D, not shown).
5.2. AATF activates c-Jun
Apoptosis can be induced through different signaling pathways. c-Jun has 
been identified as a critical mediator of UV-induced apoptosis (Kasibhatla et al., 
1998; Kolbus et al., 2000; Shaulian et al., 2000). Therefore, we studied whether 
AATF activates c-Jun. GFP/GFP-AATF-expressing cells were predisposed to UV 
irradiation, harvested, and active c-Jun (indicated by phosphorylation at serine 
73 (Pulverer et al., 1991)) was measured. The results showed that UV irradiation 
increased c-Jun activity, and AATF overexpression increased this even further, 
indicating that AATF regulates c-Jun activity (IV Fig. 2A). We also tested other 
separate AP-1 transcription family member ATF-2 activity, which also mediates 
UV-induced apoptosis. We found that AATF did not further increase ATF-2 ac-
tivity, suggesting that the effect was a c-Jun-specific (not shown). AATF-specific 
siRNA also downregulated c-Jun activity (V Fig. 2D).
The length of the c-Jun activation also matters. More transient activation of 
c-Jun often results in cell cycle arrest and suppression of apoptosis under UV stress, 
while more persistent c-Jun activation more likely results to apoptosis (Devary et 
al., 1991; Shaulian and Karin, 1999, 2001; Shaulian et al., 2000). We tested whether 
AATF overexpression could activate c-Jun for a longer period by following c-Jun 
activation after UV exposure. The results showed that AATF overexpression can 
maintain high c-Jun activity at least for two days (V Fig. 2C). AATF downregula-
tion, on the other hand, greatly reduced c-Jun activation (V Fig. 2D). Our results 
show that c-Jun AATF activity is increased (indicated by serine 73 phosphoryla-
tion) after UV stress. This increase is long-term, and likely causes AATF to partic-
ipate in the c-Jun-regulated cellular processes, e.g. apoptosis.
c-Jun can dimerize and bind DNA. Therefore, we examined whether AATF-me-
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diated activation of c-Jun is dependent on these properties by using constructs 
with c-Jun DNA-binding domain replaced by yeast Gal4-transcription factor. 
Gal4-transcription factor activates luciferase reporter expression. These constructs 
are functional and independent of c-Jun dimerization or DNA-binding (Weiss et 
al., 2003). We observed that AATF could activate transfected Gal4-c-Jun (control 
Gal4 DNA-binding domain) (V Fig. 2E). Therefore, AATF affect c-Jun activation 
functions by stimulating c-Jun transactivation capacity.
To eliminate the possibility that AATF effects c-Jun via p53, we tested AATF-me-
diated c-Jun activation in p53 negative PC3 and K562 cell lines. We found that 
c-Jun activation by AATF was normal, and therefore does not require p53 and is 
not specific to cell type (not shown).
We tested whether AATF can activate c-Jun under other stresses than UV. We 
used TNFα and serum withdrawal to induce c-Jun activation. In both cases, AATF 
overexpression strongly increased c-Jun activation, suggesting there is a much 
wider relevance for this signaling pathway (not shown).
We tested whether c-Jun-activation is noticeable in the c-Jun target gene ex-
pression with semi-quantitative RT-PCR. c-Jun target genes TNFα and FasL 
mRNA levels were both strongly upregulated in AATF-GFP-transfected UV-treat-
ed cells and downregulated in AATF siRNA-transfected UV-treated cells, indicat-
ing a consequently changed c-Jun transcriptional activity (V Fig. 2F&G).
To determine whether c-Jun target genes were induced c-Jun-dependent-
ly, we used wild-type and c-Jun KO MEFs. AATF-GFP overexpression without 
stress stimuli was enough to produce increased TNFα expression, but this was not 
seen in c-Jun KO MEFs. When c-Jun was reintroduced with AATF into c-Jun KO 
MEFs, TNFα expression was induced, but AATF or c-Jun transfection alone did 
not induce TNFα, indicating further confirmation that AATF induces TNFα via 
c-Jun (V Fig. 2H&I).
5.3. AATF induces apoptosis in a c-Jun-dependent manner
Next, we tested whether apoptosis induced by AATF functioned c-Jun-de-
pendently. We overexpressed AATF in WT and c-Jun KO MEFs with UV irradi-
ation. Only in WT MEFs did AATF produce a remarkable increase in apoptosis, 
indicating that AATF-mediated apoptosis functions in a c-Jun-dependent manner 
(V Fig. 3A&B).
Since AATF regulated c-Jun after UV treatment, we questioned whether AATF 
interacts with c-Jun after UV treatment. In HEK293 cells, we performed immu-
noprecipitation in both ways. We found that there was a low-stoichiometry in-
teraction between AATF and c-Jun without UV treatment, and this dramatically 
increased after UV treatment (V Fig. 4A&B).
Previously, it has been observed that UV-mediated c-Jun activation can induce 
transcription of pro-apoptotic TNFα and FasL, among others (Dhanasekaran and 
Reddy, 2008; Herr et al., 2000; Kasibhatla et al., 1998; Le-Niculescu et al., 1999). 
Our results show that AATF directly activates the transcriptional activity of c-Jun, 
and that AATF is the first-identified regulator of c-Jun necessary for c-Jun-mediat-
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ed apoptosis. Our results demonstrate that the amount of AATF in the cytoplasm 
positively correlates with c-Jun-mediated apoptosis induction. 
c-Jun is important when cells try to adapt to environmental changes (Jochum et 
al., 2001; Wisdom, 1999). c-Jun also facilitates oncogenic transformation (Behrens 
et al., 2000). Different responses from c-Jun activity to different signals are often 
based on various protein complexes formed around c-Jun. The different complexes 
allow highly flexible responses for c-Jun target gene regulation. AATF interaction 
with c-Jun after UV stress seems to precede c-Jun phosphorylation. This may indi-
cate that AATF tags the amount of c-Jun that can be activated for apoptosis induc-
tion and, therefore, functions as a permissive or limiting factor.
5.4. UV irradiation promotes AATF translocation from the nucleus 
to the nucleolus
One of the regulatory mechanisms of signaling pathways and forming signaling 
complexes includes subcellular localization of signaling molecules. The nucleolus 
acts as a safe to store molecules, which can be released to different compartments 
(e.g. to the nucleoplasm) to initiate different cellular functions. The nucleolus also 
works as an organelle, which often responds to stress (Mayer and Grummt, 2005; 
Pederson and Tsai, 2009; Stark and Taliansky, 2009). AATF mostly localizes to the 
cell nuclei, but has also been found in the cytoplasm and the nucleolus (Andersen 
et al., 2002, 2005; Fanciulli et al., 2000; Thomas et al., 2000). Therefore, we used 
immunofluorescence to image AATF localization before and after UV treatment. 
Our observation was that AATF localized to the nucleolus in the non-treated cells, 
but after the UV treatment completely moved to the nucleoplasm over time (V Fig. 
4D). We also stained c-Jun to see whether it is the same compartment as AATF 
after UV treatment. We found that c-Jun remained in the nucleoplasm (but not in 
the nucleolus) both before and after UV treatment, and could be in contact with 
AATF in the nucleoplasm after UV treatment (V Fig. 4E). After UV treatment, 
AATF and c-Jun could also be seen in nuclear dot-like structures (V Fig. 4E). Our 
results suggest that AATF promotes UV-induced apoptosis by direct interaction 
with c-Jun and by promotion of c-Jun’s transcriptional activity.
Protein sequestration is a common regulatory mechanism controlling protein 
signal-specific activity. Relocalization of several proteins to the subnuclear struc-
tures have been observed during stress (Boulon et al., 2010; Carmo-Fonseca et al., 
2000; Pederson and Tsai, 2009; Stark and Taliansky, 2009). This translocation also 
occurs specifically during stress from the nucleolus to nucleoplasm (Mayer et al., 
2005; Szymański et al., 2009; Westermarck et al., 2002; Wu et al., 2002; Yang et al., 
2008). Nucleolar sequestration and its release under UV stress seem to be the main 
mechanism to determine the amount of AATF available to target c-Jun.
5.5. Identification of AATF domains regulating AATF localization, 
c-Jun activity, and apoptosis
To discover a more detailed mechanism of this phenomenon we created AATF 
deletion mutants 1-198, 1-494, 199-526 and Δ125-246. By performing co-immu-
noprecipitation analysis, we discovered that the c-Jun binding region of AATF is 
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within amino acids 199-454 (V Fig. 5A). Next, we examined which parts of AATF 
are necessary to activate c-Jun. We used luciferase-based AP-1 reporter assay in 
HEK 293 cells. For stimulation of c-Jun transcriptional activity, C-terminal amino 
acids 456-526 of AATF were necessary. We also found a potential inhibitory do-
main within amino acids 125-246 (V Fig. 5B). When we examined with confocal 
microscopy localization of these mutants within cells, we found that C-terminal 
fragment 456-526 was needed for nucleolar localization. AATF 1-198 fragment 
localized to the cytoplasm, but the 1-454 fragment localized to the nucleus. Still, 
according to our results, 1-454 fragment did not stimulate c-Jun (V Fig. 5D).
We tested what effects deletion mutants had on apoptosis induction in WT 
and c-Jun KO MEFs with AATF deletion mutants using PI/annexin-V staining. 
199-526 and Δ125-246 mutants had the strongest positive effect on apoptosis in-
duction. This happened only in the WT MEFs, not in the c-Jun KO MEFs. 1-198 
and 1-454 mutants did not further stimulate apoptosis (V Fig. 5C). These results 
indicate that AATF enhances apoptosis induced by UV through its interaction be-
tween AATF’s C-terminal tail and c-Jun. Relocalization of AATF to nucleoplasm 
allows this interaction.
Our results strongly indicate that c-Jun promotes apoptosis when nucleolar 
cofactors associate with c-Jun after stress stimulus and form a c-Jun-containing 
functional signaling complex. Since AATF also binds another master regulator 
besides c-Jun, p53, we can hypothesize that AATF, p53, and c-Jun could form a 
complex together under stress stimuli, and modulate promoter binding affinities 
of each other.
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CONCLUDING REMARKS
Phosphorylation is so far the most studied post-translational modification and 
essential for cell signaling circuitry.
This thesis describes new phosphorylation-mediated mechanisms in cell mi-
gration, angiogenesis, and apoptosis contexts. Intermediate filament vimentin is 
involved in three of the articles having, at least, a partial phosphorylation theme. 
Also, two other articles describe two new apoptosis signaling mechanisms in 
which phosphorylation plays a key role or is involved. The main molecules studied 
in this thesis affect many cellular processes. They each have connections to cancer, 
and they are currently, at least in theory, potential targets for cancer treatments. 
The articles also examine more details of these molecules’ effects on processes rel-
evant for cancer: cell differentiation in angiogenesis, cell migration, and cell death.
Interest in vimentin research has recently increased because it regulates nu-
merous cellular processes in subtle ways that may be observed when an organism 
is stressed. Vimentin is a marker of EMT and has a major impact on increasing 
cell migration and invasion, and also increases angiogenesis and proliferation. It 
is likely that due to these facts, vimentin is overexpressed in many epithelial can-
cers. Due to its filamentous structure, vimentin offers a large surface area for other 
molecules to interact with and affect cellular processes with various mechanisms. 
Many these interactions are likely regulated by post-translational modifications, 
of which phosphorylation is the most, but still largely incompletely, studied. This 
thesis includes a systematic charting of almost all the in vivo-identified serine/
threonine interphase phosphorylation site phospho-deficient and -mimicking 
mutants and their effects on vimentin filamentous structure. The analysis shows 
that only a few sites have critical and notable effects on vimentin filament network 
structure including, most importantly, serines 6, 7, 8 and 9. Phosphorylation of 
these residues is potentially important for vimentin solubilization in interphase, 
and some phosphorylation of these sites may be needed for network stabilization. 
Two other articles show among their results how vimentin effect to angiogenesis, 
that is barely researched, in development can be seen in vimentin negative mouse 
embryos that have a weakened vascular phenotype, and describe mechanisms by 
which individual phosphorylation site regulate longer known and more researched 
vimentin migration effect. The articles describe two new signaling pathways affect-
ing (S1P/SPC and S1PR2) or affected by (signaling from Notch ligands) vimentin, 
and describe critical phosphorylation sites for these effects in vimentin. Our re-
sults strengthen the view of vimentin as a multifunctional signaling scaffold, and 
provide information of phosphorylation sites regulating some of these functions. 
AATF, Par-4, and CK2 are proteins that are all primarily involved in regulation 
of cell survival or apoptosis. AATF has been known for its role as a transcriptional 
cofactor, for promoting cell cycle progression, for functioning as an antiapoptotic 
factor and for its role in DNA damage response. We show that AATF can also 
function pro-apoptotically by activating c-Jun, and demonstrate this role after UV 
93
stress. This mechanism includes previously unknown AATF relocalization from 
the nucleolus to the nucleus, which allows fast and efficient signaling triggered by 
intracellular signals. Par-4 and CK2 have been known to be important especially 
for prostate cancer. We demonstrate that their pathways connect: CK2 can phos-
phorylate Par-4, inhibiting its pro-apoptotic effect in species-dependent mecha-
nisms. We demonstrate that CK2 antiapoptotic effect functions largely through 
Par-4 and is active in prostate cancer, further indicating Par-4 as a potential target 
for prostate cancer therapies.
Knowing the functions and mechanisms of individual phosphorylation sites 
may, eventually, lead to, for example, applications in diagnostics with phosphor-
ylation state-specific antibodies or therapeutics by alteration of phosphorylation.
Figure 12 (next page): Summary of the findings in this thesis. Background colors 
according to an article in which corresponding results are described (purple: I, green: 
II, blue: III, red: IV, yellow: V).
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